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adjOR   Adjusted odds ratio 
ADHD Attention-deficit/hyperactivity disorder  
AD    Atopic dermatitis 
ASRS  Adult ADHD Self-Report Scale  
ASPD  Antisocial personality disorder 
ATC  Anatomical Therapeutic Chemical (Classification System codes) 
BMI  Body mass index 
CI  Confidence interval 
DSM   (American Psychiatric Association’s) Diagnostic and Statistical Manual  
O  of Mental Disorders  
MBRN   Medical Birth Registry of Norway  
ICD    International Statistical Classification of Diseases and Related Health  
O   Problems 
ICPC   International Classification of Primary Care 
MDD   Major depressive disorder 
M.I.N.I. Plus Mini International Neuropsychiatric Interview Plus 
MS    Multiple sclerosis 
NorPD   Norwegian Prescription Database  
NICE   The National Institute for Health and Care Excellence 
NPR  Norwegian Patient Registry 
OR    Odds ratio 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
RA  Rheumatoid arthritis  
SLE  Systemic lupus erythematosus 
TCI  Temperament and Character Inventory 
T1DM Type 1 diabetes mellitus  
T2DM Type 2 diabetes mellitus 
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Background: Attention-deficit/hyperactivity disorder (ADHD) comprises cognitive 
and behavioural traits present from childhood. During lifespan, people with ADHD are 
more prone to develop psychiatric- and somatic comorbidities compared to those 
without ADHD. Knowledge about possible risk factors, personality traits and 
comorbidities may increase the understanding of underlying mechanisms for ADHD. 
Aims: The main aim of this thesis was therefore to explore clinical features and 
potential causal factors in ADHD: 1) Explore personality traits and their relationship 
to psychiatric comorbidities in adults with ADHD; 2) Investigate maternal 
inflammatory and immune system diseases as prenatal risk factors for offspring 
ADHD; 3) Explore possible sex-specific associations between ADHD and autoimmune 
diseases; 4) Describe the current knowledge on somatic comorbidity in adult ADHD.  
Materials and methods: 1) Personality traits were assessed by a self-report 
questionnaire and psychiatric comorbidity by an interview in a group of persons with 
adult ADHD and a comparison group; 2) and 3) Prenatal risk factors and comorbidity 
were assessed by linking data from Norwegian population-based registries such as the 
Medical Birth Registry and the Norwegian Prescription Database; 4) Knowledge on 
adult ADHD and somatic comorbidity was described in a systematic literature review. 
Results: 1) The personality dimensions Novelty Seeking and Harm Avoidance were 
highly associated with ADHD. However, these associations were dependent on 
common life-time psychiatric comorbidities in ADHD; 2) Maternal multiple sclerosis, 
rheumatoid arthritis, diabetes mellitus type 1, asthma and hypothyroidism significantly 
increased the risk of offspring ADHD; 3) ADHD was associated with psoriasis in both 
sexes, and with Crohn`s disease and ulcerative colitis in females; 4) Obesity, sleep 
disorders and asthma were well-documented comorbidities in adult ADHD. 
Conclusions and consequences: Our findings add to the evidence that ADHD has 
many facets. Associations with immune-related diseases both as prenatal risk factors 
and somatic comorbidities may inform further aetiological research. Clinicians need to 
acknowledge personality traits and comorbidities in order to provide individuals with 
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  Attention-deficit/hyperactivity disorder 
Attention-deficit/hyperactivity disorder (ADHD) is a disorder characterised by 
symptoms of hyperactivity-impulsivity and/or inattention interfering with a person’s 
normal development or functioning. The clinical presentation of ADHD is varied and 
may seriously affect life quality. The diagnosis is associated with social impairment, 
poor academic performance, low occupational status, less job stability and increased 
mortality rates1,2. Further, ADHD patients often suffer from psychiatric and somatic 
comorbidities1. The aetiology behind the disorder is diverse and complex, and specific 
underlying pathophysiological pathways are yet to be identified3.  
 ADHD diagnostic criteria 
The core symptoms comprising ADHD have been described in the literature throughout 
history, portraying people with restless and impulsive behaviour4-6. Throughout the 19th 
and 20th centuries the modern conceptualization of ADHD developed, describing such 
behaviour in a medical context. The term ADHD was introduced in 1987 in the revision 
of the third American Psychiatric Association’s Diagnostic and Statistical Manual of 
Mental Disorders (DSM)7. In DSM-IV (1994), three subtypes were specified: 
predominantly Inattentive, predominantly Hyperactive-Impulsive, and Combined8. 
According to these criteria the symptoms have to be present since before the age of 7. 
ADHD was until the end of the 20th century mainly viewed as a condition in children 
and in Norway, adults with ADHD were not allowed to receive specific 
pharmacological treatment for this disorder before 19979.  
Published in 2013, DSM-5 is used as an international standard for defining ADHD in 
research worldwide10. ADHD is here categorized as a neurodevelopmental disorder10, 
characterised by impairment in neurological functioning affecting behaviour, cognition 
and motor skills11. According to DSM-5, six of nine symptoms from either symptom 
dimension (inattention or hyperactivity-impulsivity) have to be present prior to 12 




criteria are listed in Appendix I. Three clinical presentations are specified, 
corresponding to the sub-types in DSM-IV. DSM-5 also describes associated features 
common in ADHD which may dominate the clinical appearance of ADHD, such as 
mood lability and emotional dysregulation.  
In Norway, the present official diagnostic system is the World Health Organization’s 
International Statistical Classification of Diseases ICD 10th revision (ICD-10), 
published in 199212. The diagnostic group corresponding to ADHD in ICD-10 is 
termed Hyperkinetic disorders13. The Hyperkinetic disorders share the same core 
symptoms as ADHD, but the impairment criteria of daily life function are stricter. As 
opposed to DSM, ICD-10 requires symptoms of both inattention and 
hyperactivity/impulsivity to be present and impairing on several life domains before 7 
years of age. Nevertheless, and as described in the Norwegian national guidelines, the 
term ADHD, as well as the criteria from DSM, are commonly used when diagnosing 
the disorder13.  
The diagnosis is based solely on the clinical presentation of symptoms, and impairment 
as a direct consequence of these symptoms. Thus, ADHD can be a challenge to assess, 
both due to the lack of pathognomonic symptoms, the heterogeneity of symptom 
presentation, including the associated features and comorbid disorders that often co-
occur. To diagnose ADHD, symptoms also have to interfere with or reduce the quality 
of daily life functioning. This judgement can be difficult since the distinction from 
normal behaviour is not always clear. Social and cultural factors may also influence to 
which extent the symptoms lead to impairment14.  
Another obstacle when diagnosing ADHD, is that the symptoms of ADHD and other 
psychiatric diagnoses overlap15,16. One example is ADHD and borderline personality 
disorder, sharing clinical features such as impulsivity and emotional dysregulation16,17. 
Further, symptoms of mood disorders such as restlessness, concentration problems and 
irritability can also be present in ADHD16,18. Clinicians’ experience may also influence 




treating patients with depression, an ADHD patient with depressive symptoms may end 
up being diagnosed with depression, and the ADHD not recognized18.  
 Prevalence, sex distribution and treatment 
The world-wide pooled prevalence estimates of childhood ADHD vary from 3.4%-
7.2%, reported in meta-analyses19,20. The prevalence of diagnosed ADHD in children 
has increased the last decades, in the US from 6.1% in 1997-1998 to 10.2% in 2015-
201621. However, this seemingly increase in prevalence may not be true when 
standardized diagnostic procedures are followed22. The estimated prevalence in adults 
(mainly up to 45 years) ranges from 1.4%-3.6%23,24 across studies. The reported 
prevalence is higher in high-income countries compared to low-income countries24.  
The ADHD prevalence also varies by sex. Among children, 2-3 times more boys than 
girls are diagnosed with ADHD25,26. In adults, the distribution is less skewed, with a 
male/female ratio approaching 1:123. 
The National Institute for Health and Care Excellence (NICE) guideline for ADHD 
emphasizes the importance of a multimodal and broad approach when treating 
ADHD27. This may involve a range of different psychological and pharmacological 
treatments, psychoeducation and psycho-social interventions13.  
In Norway, pharmacological treatment of ADHD is strictly regulated and only 
prescribed after thorough diagnostic assessment in specialist health services28(p.14). The 
pharmacological treatment is generally divided into two groups, psychostimulant and 
non-stimulant medication. Psychostimulants include methylphenidate and different 
formulations of amphetamines, and such treatment is the first pharmacological choice 
in both children and adults13,27,29,30. Psychostimulants are essentially used only in 
ADHD treatment, except also for the sleep disorder narcolepsy. However, stimulants 
used for narcolepsy comprises only about 0.1% of all prescribed stimulants in 
Norway31. Non-stimulant treatment is usually offered when psychostimulants are 
contraindicated, the side-effects intolerable or the effect not satisfactory27,28(p.18), and 




 Aetiology and risk factors 
 Genes, environement and their interactions 
Although several risk factors contributing to ADHD have been established, the definite 
causes remain unknown33. The aetiology behind ADHD is considered to be 
multifactorial, with both genetic and non-genetic factors contributing to altered 
neurodevelopment1. Heritability is a term used to describe the proportion of variance 
in a specific trait that is attributable to genetic factors at a population level34. Twin 
studies of ADHD have consistently yielded high heritability estimates at about 74%35. 
The heritability is mainly due to the combination of many gene variants, each having 
small effects, and where, in most cases, none of these variants are considered sufficient 
or necessary to cause ADHD. An exception is ADHD in individuals with specific 
syndromes such as Klinefelter syndrome and velo-cardio-facial syndrome35. Numerous 
environmental factors have been associated with ADHD. These are often classified by 
their time of influence as pre, peri- and postnatal (i.e. during intrauterine life, the 
immediate time around birth and during infancy and childhood, respectively). 
Examples of prenatal risk factors are maternal smoking, alcohol consumption, thyroid 
levels and urinary tract infections during pregnancy49-55, while maternal epilepsy can 
influence the foetus by prenatal exposure to medication, hypoxia during maternal 
seizures and/or genetic factors36. Examples of perinatal factors are low birth weight 
and prematurity37-39, while traumatic brain injury and emotional trauma during 
childhood40-43 are examples of postnatal factors. Psychosocial factors, e.g. young 
maternal age, low family income, parental education and beginning school at an early 
age have also repeatedly been associated with ADHD38,44-47. The heritability estimates 
in twin studies being less than 100% supports the fact that the environment also plays 
a role in ADHD aetiology35. It may, however, be difficult to disentangle the potential 
genetic and/or environmental mechanisms, and also causal versus non-causal 
associations underlying these primarily environmentally termed risk factors1. Instead 
of trying to separate genetic from environmental mechanisms, they can be seen as 
complementary explanations48. Gene−environment interactions may account for a 




with genetic factors through epigenetic mechanisms49. Epigenetic mechanisms refer to 
changes in the gene expression that are not caused by alterations in the genetic code 
itself, but rather by modifications of the gene expression50. Further, genetic or other 
factors shared within families may account for the observed association between the 
environmental risk factor and ADHD, so-called familial confounding51. Familial 
confounding will be discussed in section 5.3.2. 
 Maternal immune activation 
There is a growing recognition that maternal immune activation during pregnancy 
impacts foetal brain development, and this is suggested to play a role in the 
development of neurodevelopmental disorders52,53. Such maternal immune activation 
may be due to maternal infection or other causes of inflammation such as autoimmune 
disease or allergy53. The immune activation may weaken the foetal blood-brain barrier, 
making the foetal brain vulnerable to influence by immune components from outside 
the central nervous system54. The precise mechanisms of how this immune activation 
alters brain development in the foetus is not known. Complex pathways involving the 
release of interleukins, signalling molecules generated during immune activation, have 
been proposed, based on findings from rodent models55,56. A hypothetical model 
showing how maternal immune activation can impact the foetal brain development is 
shown in Figure 155. This model was originally made to explain altered brain 
development in autism, but the principal ideas can be used as a model also in other 
neurodevelopmental disorders such as ADHD. Maternal immune activation increases 
the level of interleukin-6, leading to the activation of T helper 17 cells. These produce 
interleukin-17 (IL-17) to be present in the mother´s blood. By passing the placenta 
barrier, IL-17 can alter the in utero environment leading to increased expression of the 
IL-17 receptor and further to increased IL-17 signalling in the foetal brain. Exact how 
the altered level of IL-17 influences foetal brain development is, however, unknown. 
Mechanisms including glial activation may also play a role in the altered brain 
development54. Glial cells are immunocompetent cells in the central nervous system. 
In addition to responding to injury and inflammation, they are involved in synaptic 




of brain neuronal networks54. Interestingly, rodent models have shown that sex 
hormones impact the function of the glial cells, thus glial cells are involved in the 
sexual differentiation of the brain57,58. 
Based on the existing knowledge concerning maternal immune activation and foetal 
brain development when Paper II was planned, we hypothesized that chronic maternal 
inflammatory and immune system diseases could be prenatal risk factors for offspring 
ADHD. Investigating such risk factors is important both to inform research on ADHD 
aetiology and also to improve ADHD treatment35,48.  
Figure 1. Hypothetical model showing how maternal immune activation can impact foetal 
brain development.  














From Estes ML, McAllister AK. IMMUNOLOGY. Maternal TH17 cells take a toll on baby's brain55. Reprinted 




 Personality and personality traits 
 The trait theory of personality 
Personality can be described as the total sum of mental and behavioural characteristics 
unique to an individual59. There are different theories on personality. The 
psychodynamic theory developed by S. Freud emphasizes unconscious thoughts, 
memories and feelings as important factors to understand human behaviour60(p.544). 
Another personality theory, the behavioural theory, emphasizes that personality is 
developed through interaction between the individual and the environment61.  
Today, one major theory for explaining personality is the trait theory62. According to 
this theory, it is the combination of personality traits that forms each individual´s 
personality62. B. Roberts has described personality traits as “the relatively enduring 
patterns of thoughts, feelings, and behaviors that reflect the tendency to respond in 
certain ways under certain circumstances”63. Trait theory emphasizes the ability to 
describe and measure personality traits, focusing on differences between individuals62. 
In the trait theory, personality traits are quantitatively assessed64(p.160) and are regarded 
as continuously, not categorically, distributed65. This means that a specific personality 
trait is not a quality that an individual has or has not, but rather has more or less, 
expressed somewhere along the line between the extremities of that trait. Assessment 
of personality traits is useful to predict a person´s behaviour and function66. As 
personality traits can be overthrown by strong factors in a specific situation, they are 
most useful to predict long-term behaviour patterns60(p.533). In addition, investigating 
personality traits may be beneficial to increase our understanding of the structure, 
behaviour, heterogeneity and development of a disorder67-69.  
A number of models based on the trait theory have been developed, with different 
definitions and names of personality traits. One way to develop a trait model was based 
on English words used to describe personality in lay people, applying statistical 
analyses to find underlying clusters or factors of traits by doing factor analyses. This 
model was the basis for developing the Five-Factor model, the most dominating trait 




individual personality70. The version of P. Costa’s and R. McCrae’s is presently the 
best-known and most frequently used60(p.529). This model was developed to describe 
traits in normal life, with no aetiological or neurobiological assumptions behind70,71. 
Now widely accepted used to describe the structure of both normal and abnormal 
personality, it has also proven useful in addressing psychiatric disorders72-74. The five 
traits comprising this model are called Openness, Conscientiousness, Extroversion, 
Agreeableness and Neuroticism75,76(p.6-7). The different traits reflect the individual´s 
tendency to be curious, creative and appreciate variation in experiences (Openness); to 
be self-disciplined, responsible and work towards a goal (Conscientiousness); to be 
optimistic, energetic, sociable and talkative (Extraversion); to be cooperative, 
trustworthy and compassionate towards others (Agreeableness); and to be anxious, 
angry, depressed and emotional unstable (Neuroticism).  
 A psychobiological model of temperament and character  
The Five-Factor model has been criticized for not being based on any underlying 
personality theory, and for not capturing all traits of personality, such as aspects of 
maturity, traditional moral values, individual autonomy and religiosity71,77. The 
psychobiological model of temperament and character developed by C.R. Cloninger, 
one of the most commonly used personality models in ADHD research, aims also to 
cover these issues67,71. As opposed to the Five-Factor model, it is based on seven 
personality dimensions and emphasises the difference between temperament and 
character. For the purpose of this thesis, the psychobiological model of temperament 
and character will be named “the psychobiological model”. 
Temperament and character 
According to the psychobiological model, personality can be divided into two different 
domains; “temperament” and “character”78. Temperament can be perceived as the 
innate tendency to behave or react to the environment in a particular way, such as 
quality and lability of mood, attitudes and coping strategies78-80. These response 
patterns are considered to be moderately heritable and relatively consistent throughout 
life81(p.9). Character relates to the self-regulation of attention and emotions in order to 




the voluntary choices of an individual and moderates the influence of the temperament 
71,84. On the other hand, character is largely influenced by temperament traits, 
sociocultural environment and life events78,85. As opposed to temperament traits, 
character traits develop and mature by age78.       
The seven personality dimensions 
The psychobiological model consists of seven different putatively independent 
personality dimensions, four dimensions of temperament and three dimensions of 
character. The temperament dimensions are called Harm Avoidance, Novelty Seeking, 
Reward Dependence and Persistence. The character dimensions are named Self-
Directedness, Cooperativeness and Self-Transcendence. Each dimension is further 
divided into 3-5 subscales. (The subscales will not be specifically described in this 
thesis, as they are not a part of the results in Paper I). Characterisations of individuals 
with high and low scores on the temperament and character scales are described in 
Table 185. The dimensions are measured by the Temperament and Character Inventory 
(TCI). See sections 3.2.1 and 5.2.1 for description and discussion of strengths and 
limitations of the TCI.  
The specific emotional style of a person as described by the temperament dimensions 
is not either socially desirable or undesirable. Having high or low scores on the 
temperament dimensions are associated with both advantages and disadvantages83. 
Taking Harm Avoidance as an example, individuals with high Harm Avoidance tend 
to be cautious, nervous and pessimistic81(p.20). This can be a disadvantage in social 
situations, but an advantage in dangerous situations were caution is needed83. Contrary, 
persons with low Harm Avoidance tend to be relaxed, optimistic, risk-taking and 
confident when facing danger, but can also behave foolhardily81(p.20).  
As opposed to the temperament dimensions scores, high scores on the character 
dimensions are more socially advantageous compared to low scores83. This can be 
illustrated by using Self-Directedness as an example. Individuals with low scores on 
Self-Directedness are often described as immature by clinicians, and tend to be 




Table 1. Description of the Temperament and Character dimensions, showing                                                                                                     
personality traits in individuals with high and low scores on the specific dimensions.  
I. Temperament scales  High scorer Low scorer 
Harm Avoidance   
Worry and pessimism Pessimistic Optimistic 
Fear of uncertainty Fearful Daring 
Shyness Shy Outgoing 
Fatigability Fatigable Energetic 
   
Novelty Seeking   
Exploratory excitability Exploratory Reserved 
Impulsiveness Impulsive Deliberate 
Extravagance Extravagant Thrifty 
Disorderliness Irritable Stoical 
   
Reward Dependence   
Sentimentality Sentimental Detached 
Openness to communication Open Reserved 
Attachment Warm Cold 
Dependence Appreciative Independent 
   
Persistence   
Eagerness of effort Industrious Inert 
Work hardened Determined Spoiled 
Ambitiousness Enthusiastic Underachiever 
Perfectionism Perfectionistic Pragmatic 
   
II. Character scales and subscales High scorer Low scorer 
Self-Directedness   
Responsibility Responsible Blaming 
Purposefulness Purposeful Aimless 
Resourcefulness Resourceful Inept 
Self-acceptance Self-accepted Vain 
Congruent second nature Disciplined Undisciplined 
   
Cooperativeness   
Social acceptance Tenderhearted Intolerant 
Empathy Empathic Insensitive 
Helpfulness Helpful Hostile 
Compassion Compassionate Revengeful 
Purehearted Principled Opportunistic 
   
Self-transcendence   
Self-forgetful Intuitive Contrived 
Transpersonal identification Acquiescent Controlling 
Spiritual acceptance Spiritual Materialistic 
 
From Svrakic DM, Draganic S, Hill K, Bayon C, Przybeck TR, Cloninger CR. Temperament, character, and 
personality disorders: etiologic, diagnostic, treatment issues85. Content reused with permission from John Wiley 




have high self-esteem, are responsible, mature and reliable. They have the ability to 
adapt their behaviour to achieve their own individual chosen goals81(p.24).  
Strengths and limitations  
The psychobiological model has been used across countries and in different cultures 
worldwide86-88. A study by Miettunen et al. (2008) pooled results from 16 papers with 
information on the temperament dimensions from non-clinical populations with sample 
sizes of at least 100 individuals89. This study supported the validity and reliability of 
the psychobiological model across countries, i.e. the model actually captures what is 
meant to be measured and findings are reproducible90,91(p.57). However, the studies 
included mainly European and East Asian samples89. Thus, the external validity, i.e. 
whether the model is valid in other parts of the world, is limited. A more detailed 
explanation of the terms validity and reliability will follow in section 5.1.1.  
The notion of seven dimensions was corroborated in the previously described study by 
Miettunen et al.89. The correlations between the temperament dimensions were small, 
with the exception of a negative correlation between Harm Avoidance and Novelty 
Seeking. However, a Swedish community-based study by Maitland et al. (2009), failed 
to confirm these seven factors in a confirmatory factor analysis92.  
A study by Josefsson et al. (2013) investigating ~1500 individuals from a Finnish 
population-based sample with 4-10 years follow-up time, showed that character traits 
changed more by age compared to temperament traits93. This is in line with the notion 
that character traits, as opposed to temperament traits, mature through life. 
As opposed to the Five-Factor model, the psychobiological model was based on a 
synthesis of information from neurobehavioural and neuropharmacological studies, 
and family- and twin studies to investigate genetics, and psychometric dimensions of 
personality in individuals and twin pairs71. The model assumptions have partially been 
corroborated with findings from factor-analyses. Contrary to the Five-Factor model, 
the psychobiological model was developed for the assessment of psychopathology94. 
Further, it emphasised the neurobiological basis of personality traits85. Originally, 




temperament traits. However, this model has been criticized to be simple and 
reductionistic, as the function of neurotransmitters is very complex and affect different 
brain functions95. Another critique towards the model is that the distinction between 
temperament and character may not be valid, as research has shown that heritability is 
important not only to explain the variability in temperament traits, but also in character 
traits96-99. Cloninger has recently acknowledged these limitations, and although he and 
his co-authors still argue for the distinction between temperament and character, they 
accept the complex biopsychological structures with different molecular mechanisms 
underlying temperament versus character100.  
The psychobiological model has shown to overlap considerably with the Five-Factor 
Model in both clinical and non-clinical samples101-105. To give an example replicated 
in several studies, Harm Avoidance has been shown to be positively correlated with 
Neuroticism and negatively correlated with Extraversion. This makes sense, as being 
anxious and pessimistic are traits common in both Harm Avoidance and Neuroticism. 
Further, the opposite of the trait Extraversion is introversion – a feature related to 
“shyness” of Harm Avoidance.  
Temperament and character dimensions associated with ADHD and 
comorbid psychiatric disorders    
Distinct psychiatric disorders have been associated with specific personality traits as 
measured by the TCI84,106-109. In a meta-analysis by Gomez et al. (2017) including 20 
studies (clinical and community based, children and adults) on the relation between 
ADHD and personality dimensions, ADHD or ADHD symptoms were associated with 
high scores on Harm Avoidance and Novelty Seeking, and low scores on the other 
dimensions. The exception was Self-Transcendence, which showed no significant 
association84. The associations between high Harm Avoidance and Novelty Seeking 
with ADHD or ADHD symptoms are corroborated by results from other clinical and 
community based samples110-112. Albeit representing a broad base of investigation, due 
to their cross-sectional design they are not suitable to investigate potential causality.  
Similar to ADHD, depressive- and anxiety disorders have been associated with high 




(ASPD), personality dimensions as measured by the TCI appear to be little studied. 
However, in a small Turkish case-control study by Basoglu et al. (2011), ASPD was 
associated with high scores on Harm Avoidance and Novelty Seeking, and with low 
scores on Self-Directedness106. According to these findings, high Harm Avoidance and 
low Self-Directedness are associated with several psychiatric disorders.  
This exemplifies that one personality trait can be common in different psychiatric 
disorders. Such information can be used to elucidate patterns of comorbidity between 
the disorders113. Whether personality traits associated with ADHD are also associated 
with personality traits in common comorbidities in ADHD, is poorly studied. 
 Comorbidity  
Comorbidity may be defined as“any distinct additional clinical entity that has existed 
or that may occur during the clinical course of a patient who has the index disease 
under study”( A. Feinstein)114,(cited in 115). The index condition is the condition which is 
the subject of the study, and comorbidities are diseases coexisting in the participant(s) 
in addition to the index condition116. However, synchronous occurrence of the 
conditions is not always the case, and it is also of interest to study conditions which 
occur at different time periods115. Whether the term ‘comorbid conditions’ should be 
used only for diseases that are causally related to each other, has been discussed, 
without any consensus115,117,118.  
For the purpose of this thesis, a comorbid disorder is understood as a disorder or disease 
occurring during the lifetime of a person once diagnosed with ADHD, where ADHD 
is the index disorder. None of the diagnoses are given priority, and a causal relationship 
is not required. For some purposes, as in Paper III, a disorder can be regarded as a 
comorbid disorder to ADHD even if the person no longer meets the ADHD criteria 
(e.g. psoriasis in an adult diagnosed with ADHD in childhood, but who no longer fulfils 
the ADHD criteria). Further, the specific terms psychiatric comorbidity and somatic 
comorbidity are used when a person with ADHD suffers from another psychiatric 




To study comorbidity is important for many reasons, such as to gain knowledge of 
common risk factors and aetiological factors underlying both the index and the 
comorbid disorders, understand the impact comorbidity may have on the clinical course 
of the index disorder and contribute to holistic care of this disorder114,119-122. 
 Psychiatric comorbidity in ADHD 
Psychiatric comorbidity in ADHD is common in all age groups. Results from both 
population-based and clinical studies on children and adolescents show that 52%-
66%123,124 of those with ADHD suffer from comorbid psychiatric disorders. For adults, 
about 50%-85% have had at least one lifetime psychiatric comorbidity31,125-128, 
indicating that the risk of comorbidity increases by age. Thus, psychiatric comorbidity 
is an important clinical dimension of ADHD heterogeneity29.  
The comorbidity profile alters throughout life3. In childhood, the most frequent 
psychiatric comorbidities are behavioural problems such as conduct disorder and 
oppositional defiant disorder; neurodevelopmental disorders such as autism spectrum 
disorders, learning disability, intellectual disability and tic disorder; and depression and 
anxiety disorders10,33,123,124,129. In adolescence substance use disorders become more 
common, continuing into adulthood1,130. Major depressive disorder (MDD) is highly 
comorbid in adults with ADHD, 25%-65% experience this disorder during their 
lifetime125-128. Other common comorbidities are bipolar, - anxiety, - eating, - and 
personality disorders (in particular antisocial and borderline personality 
disorders)31,125,126,130-133.  
 Somatic comorbidity in ADHD 
Compared to psychiatric comorbidity, somatic comorbidity in ADHD has been 
investigated to a lesser degree, and mainly focused on children. At the time when paper 
IV was written, there was a need for a systematic review to describe what was known 
about somatic comorbidity in adults with ADHD, not only to get an overview over the 
current knowledge, but to gather information about fields warranting further attention. 
Since then, the importance of somatic comorbidity in adults with ADHD has been 




somatic diseases are poorly documented in psychiatric journals, indicating that 
information on somatic comorbidity currently is lacking in psychiatric care134. Studies 
on somatic comorbidity in ADHD have now documented increased risk of eczema, 
asthma, obesity, sleep disorders, migraine, epilepsy and enuresis119,121,135-146. Similarly 
to psychiatric comorbidities, the pattern of somatic comorbidities changes throughout 
life, such as obesity normally appearing later than enuresis3. This underscores the 
importance of studying comorbid somatic diseases both in children and adults.  
Immune system diseases are of special interest, as activation of the immune system can 
be involved in triggering psychiatric disorders147. One example is the possible 
disruption of neuronal “pruning” in schizophrenia, involving brain-based immune cells 
called microglia148. Pruning is the process of shearing away unwanted or non-effective 
connections between neurons149. The immune system also plays a role in brain 
development, indicating that brain-immune interactions may be causally related to 
psychopathology in children (see section 1.2.2.)52.  
One particular focus of interest has been the relation between psychiatric disorders and 
autoimmune diseases. Autoimmune diseases are a heterogeneous group of conditions, 
their common feature being an immune-mediated attack on the body’s own tissues or 
products of own tissues150,151. Today, studies have reported ADHD to be associated 
with different autoimmune diseases such as autoimmune thyroiditis, celiac disease, 
type 1 diabetes mellitus (T1DM), juvenile arthritis and psoriasis152-155. Genetic 
correlations have been found between ADHD and rheumatoid arthritis (RA) and 
psoriasis, possibly implying an inherited immune abnormality behind both ADHD and 
the autoimmune diseases156,157. Moreover, stress related to having ADHD may trigger 
outbreak of autoimmune disease, such as the role of stress in triggering psoriasis158,159.  
However, at the time when Paper III was written, a possible increased risk for 
autoimmune diseases in ADHD had hardly been studied. Immune related diseases and 
ADHD was therefore an understudied area of significant interest, both as possible risk 
factors for the exposed foetus whose mother has immune related diseases, and as 




 Sex differences in ADHD comorbidity 
The ADHD prevalence differs by sex (see section 1.1.2), and this pattern is also present 
in the prevalence of ADHD comorbidities. In persons with ADHD, both anxiety, 
bulimia, depression and asthma have been shown to be more prevalent during lifetime 
in women than in males, whereas substance use disorder, ASPD and hypertension were 
most prevalent in males31,131,160. Knowledge of sex differences in risk of comorbid 
diseases in individuals with ADHD is important for early and correct diagnosis and for 
deciding treatment and prevention strategies31,161. Such knowledge is also important to 
inform further research on aetiological pathways, which may differ by sex. There is a 
large knowledge gap with regards to sex differences in ADHD and comorbid diseases, 
especially for somatic comorbidity. This was the rationale for planning our third study, 
where we aimed at studying sex differences in the associations between ADHD and 
autoimmune diseases. Autoimmune diseases include diseases with evident sex 
differences, where most of these diseases are more common in females. Thus, studying 
sex differences in the association with ADHD was highly relevant.  
   






The overall aims of this thesis were to explore clinical features and potential causal 
factors in ADHD.  
More specifically, our aims were as follows: 
I) To assess personality traits in adult ADHD patients and a comparison group, and 
explore how these traits are associated with anxiety, depression and antisocial 
personality disorder.  
II) To investigate chronic maternal inflammatory and immune system diseases as 
prenatal risk factors for offspring ADHD.  
III) To compare the prevalence of autoimmune diseases in individuals with and 
without ADHD, and evaluate whether possible associations vary by sex.  
IV) To summarise the current knowledge regarding associations between ADHD and 


































3. Material and methods 
An overview of methods and samples used in Papers I-IV is presented in Table 2.    
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All individuals born in 
Norway 1967-2008, alive 
at record linkage 2012  




Controls: all remaining 
individuals 
(n=2,274,713) 
























All individuals born in 
Norway 1967-2011, alive 
and residing in Norway 
at record linkage 2015  






















 Adult ADHD 
(above 18 years) 
Somatic diseases 
aTCI = the Temperament and Character Inventory. bMBRN = Medical Birth Registry of Norway. cNorPD = Norwegian 
Prescription Database. dMS= Multiple sclerosis. eRA= Rheumatoid arthritis. fT1DM= Type 1 diabetes mellitus. 
gT2DM=Type 2 diabetes mellitus. hSLE= Systemic lupus erythematosus. ithe direction between independent and 




 Study designs 
 Clinical sample (Paper I) 
The ongoing project “ADHD in adults in Norway; from clinical characterization to 
molecular mechanisms” was initiated at the University of Bergen (UoB) in 2004, 
aiming to recruit a naturalistic sample of adult ADHD patients and controls. As of 2018, 
855 ADHD patients and 913 controls were participating in the study. Information on 
ADHD symptoms, medication, psychiatric and somatic comorbid disorders, genetics, 
imaging and neuropsychological data as well as information about family members 
have been collected on all or subgroups of participants. The ADHD sample has been 
collected in different ways. The first group was recruited from people 18 years or older 
who had received central stimulant treatment due to ADHD during 1997-2005. To 
receive central stimulant treatment in this specific period, the ADHD diagnosis had to 
be evaluated by a regional Expert Committee of Hyperkinetic Disorder/ADHD. Based 
on information from the clinicians, the committee decided if the diagnostic assessment 
was of good quality, whether proper follow-up was available, and absence of potential 
contra-indications for therapy. If approved, medical treatment was allowed. Since 
referral of patients to these committees was mandatory, they composed a national 
cohort of medically treated adults with ADHD (n=3397). Between 2005-2007, 1700 
individuals from this cohort were invited to participate, of whom 338 (20%) responded. 
Secondly, clinicians from all parts of Norway were encouraged to recruit adults 
(persons ≥18 years) with an ADHD diagnosis according to DSM-IV or ICD-10. No 
formal exclusion criteria were applied. The majority of controls (79%) were recruited 
through the Medical Birth Registry of Norway (MBRN), by random selection of 
individuals with similar age (18-40 years) and geographic regions as the ADHD 
patients. A total of 2963 individuals were invited from the MBRN, of whom 720 (24%) 
responded with complete questionnaires and biological samples and were included in 
the study. Finally, some participants were recruited as students from the UoB, friends 
of the patients or through advertisement at the local hospital. No formal exclusion 
criteria were applied, neither in the ADHD group nor in the control group. 




Norway” project who lived in proximity to the UoB, were invited to undergo a clinical 
interview conducted by two psychiatrists and two medical doctors specializing in 
psychiatry (including the author of this thesis). At the same time, the participants also 
filled out a questionnaire assessing personality traits. Of total cases, 17 were recruited 
from the Expert Committees of Hyperkinetic Disorder/ADHD and 49 from clinicians. 
The 69 participants in the comparison group were included from these sources: MBRN 
(n=53 (77%)), students (n=13), friends of patients (n=2), advertisement at the local 
hospital (n=1). The use of this sample in Paper 1 is discussed in section 5.2.1. 
 Norwegian population-based registries (Papers I, II and III)  
Papers II and III were based on data from several Norwegian population-based 
registries. Data from the registries were linked by using each individual’s unique 
national identification number. At record linkage, data were available for years up to 
(and including) 2012 (Paper II), and 2015 (Paper III), respectively.  
In Paper II, we examined the possible relationship between maternal inflammatory and 
immune system diseases and offspring ADHD. The study population included those 
registered in the MBRN as born during 1967-2008 and alive at record linkage in 2012. 
Based on information from the Norwegian Prescription Database (NorPD) on 
dispensed specific ADHD medication, we defined an ADHD case group (n=47,944). 
The rest of the population served as a control group (n=2,274,713). Data on maternal 
inflammatory and immune system diseases were collected from the MBRN. In Paper 
III, we explored possible associations between ADHD and autoimmune diseases and 
whether these differed by sex. The study population included those registered in the 
MBRN as born during 1967-2011 and alive at record linkage in 2015. As in Paper II, 
an ADHD case group (n=63,721) was defined as those being dispensed specific ADHD 
medication, and the remaining population served as a control group (n=2,436,397). 
Strengths and limitations of using data from population-based registries, focusing on 
the MBRN and NorPD, are discussed in sections 5.2.1 and 5.3.1. 
The Medical Birth Registry of Norway (Papers I, II og III) 
The MBRN was established in 1967 and includes information on all births in Norway 




based on compulsory notification and prospectively collects data during pregnancy on 
maternal health both before and during pregnancy and complications or interventions 
during pregnancy and delivery. Birth outcomes comprising vital status of the child and 
neonatal diagnoses are registered. The notification form was almost unchanged until 
1998, but was changed in 1999 to include more information, such as maternal smoking 
habits and ultrasound-based estimation of gestational age (Appendix III). Electronic 
birth notification was gradually implemented from 2006, and information on further 
variables have been added during later years. In Paper I, 77% of the comparison group 
were randomly recruited from the MBRN. In Papers II and III, individuals registered 
in the MBRN and born 1967-2008 (Paper II), and 1967-2011 (Paper III), all alive at 
record linkage (2012 and 2015, respectively), constituted the source population for the 
studies. Information on maternal diseases was collected from MBRN (Paper II), based 
on free text descriptions and, from 1999, also check boxes. Free text is coded at the 
registry using ICD; version 8 until 1998 and version 10 from 1999. 
The Norwegian Prescription Database (Papers II and III) 
The Norwegian Prescription Database (NorPD) was established in 2004 and provides 
information on prescription drugs dispensed from all Norwegian pharmacies. The 
registry includes information on the patient (encrypted), the prescriber and the drug, 
including the Anatomical Therapeutic Chemical (ATC) Classification System codes. 
From 2008, the NorPD has recorded information on specific diagnostic codes as 
indications for reimbursed medication (chronic diseases), by using the International 
Classification of Primary Care (ICPC) or ICD-10. Information on medication received 
while in hospital/institution is only available as aggregate data. Information from the 
NorPD was used to define the ADHD cases and controls/comparisons in Papers II 
(2004-2012) and III (2004-2015), and to define autoimmune diseases in Paper III.  
The Norwegian Patient Registry (Paper II) 
The Norwegian Patient Registry (NPR) was established in 1997, registering 
information on patients waiting for or having received treatment in specialist health 
care (hospitals and out-patient clinics). From 2008, the NPR includes the national 




diagnostic codes based on the ICD-10 and procedure codes based on The Nordic 
Medico-Statistical Committee classifications. In a sensitivity analysis (Paper II), we 
added patients registered with an ADHD diagnosis in the NPR, but without being 
dispensed ADHD medication, to the ADHD case population (n=2040). 
The National Registry and The National Education Database (Papers II 
and III) 
The National Registry provides each individual residing in Norway (on a permanent 
basis), their unique national identification number, and further includes information on 
e.g. date of birth, death, immigration and emigration. This registry is routinely linked 
with the MBRN, and provided information on emigration and dates of death used in 
Papers II and III. In the National Education Database, the educational level of all 
Norwegian citizens from the age of 16 years has been registered since 1970. Maternal 
educational level was used as a measure for socioeconomic status in Papers II and III. 
 Systematic literature review (Paper IV) 
Paper IV is a systematic literature review, based on research results from studies on 
ADHD and somatic comorbidities in adults published in international peer-reviewed 
journals and identified by a systematic search. The results from this review will be 
discussed in sections 5.4.1 and 5.4.2. 
 Measurements (Paper I) and methods (Paper IV) 
 Scales (Paper I) 
The Temperament and Character Inventory  
The Temperament and Character Inventory (TCI) is a self-administered questionnaire 
measuring the seven basic personality dimensions in the psychobiological model of 
temperament and character (see section 1.3.2 for description of this model)71. These 
personality dimensions composed the main outcomes of Paper I. The participants filled 
out the 240 items long TCI version 9 with true–false responses, taking about 30 minutes 
to complete162. The results are continuous, given as a sum of the total points for each 




developed for measuring personality dimensions in adults. Although not validated in 
Norway, validation of the Swedish version showed similar psychometric properties 
when compared to the original American version162, and the same was true when 
validating the Norwegian version of the Junior TCI designed for adolescents66. The 
psychobiological model was at the time of initiation of the ADHD project one of the 
most commonly used personality models in ADHD research, in addition to the Five-
Factor model67. As the psychobiological model focuses on the neurobiological basis 
for personality traits, it was judged to be the most suitable for this study, as well as for 
the main project “ADHD in adults in Norway”. See section 5.2.1 for a discussion of 
the measurement properties and use of the TCI. 
Adult ADHD Self-Report Scale  
The Adult ADHD Self-Report Scale (ASRS) is an 18 item long questionnaire covering 
ADHD symptoms present for the last six months163. The ASRS was used in a 
subanalysis in Paper I to divide the ADHD group into subtypes. 
 Interview (Paper I) 
The Mini International Neuropsychiatric Interview Plus version 
The Mini International Neuropsychiatric Interview Plus (M.I.N.I. Plus) version 5.0.0 
is a semi-structured interview covering major axis 1 psychiatric disorders in DSM-IV, 
and is also applicable for comparable disorders classified in ICD-108,12,164. This 
interview includes substance-related-, psychotic-, mood- and anxiety disorders, among 
others. ASPD, which we were interested in studying, is also covered. Although not 
validated in Norway, we decided to use this instrument as it is extensively used in 
clinical practice and freely available at the Norwegian Electronic Health Library, 
Norwegian Institute of Public Health165. The Norwegian national ADHD guideline 
further recommends M.I.N.I Plus in the assessment of psychiatric diagnoses in adults13. 
The M.I.N.I Plus is an extended version of the The Mini International Neuropsychiatric 
Interview, which has shown good validity and reliability properties164,166.  
In Paper I, we collected information from the following modules: major depressive 
episode, panic disorder, agoraphobia, generalized anxiety disorder, alcohol dependence 




the following modules into one category called ‘lifetime anxiety and/or depressive 
disorder’: Panic disorder, with or without agoraphobia, generalized anxiety disorder 
and/or MDD, both current and lifetime. See section 5.2.1 for a discussion of strengths 
and limitations of the M.I.N.I Plus and the use of this interview in Paper I. 
 Variables based on the registries (Paper II and III) 
Papers II and III were based on linked registry data. In both these studies, ADHD cases 
were defined by information from the NorPD as individuals being dispensed 
reimbursed ADHD medication (ATC N06BA or specific subgroups) after excluding 
individuals where stimulant drugs were dispensed for narcolepsy (Papers II and III) or 
other sleep disturbances (Paper III). In Paper III, data from the NorPD was also used 
to define different autoimmune diseases by using diagnostic codes (ICD-10 or ICPC) 
for reimbursed medication or ATC-codes for disease-specific medication. The 
information on maternal diseases in Paper II was based on data from the MBRN, where 
data on maternal diseases before and during pregnancy is registered. See section 5.3.1 
for a critical evaluation of these variables. 
 Study selection, data extraction, summarising the results 
(Paper IV) 
After defining the research question, the first step in a systematic literature review is to 
perform a systematic literature search attempting to find all studies covering the 
research question167. A transparent search strategy is developed, making it possible for 
others to replicate the search168. It includes searching in different databases, ensuring 
the results to be comprehensive and not limited to specific journals. Using predefined 
inclusion criteria, the papers found in the search are systematically investigated to 
select those that will be included in the final review. First, the titles and abstracts are 
screened to see if the papers are relevant. If so, the whole papers are read to make a 
final decision of which papers to include. This process of study selection should be 
visible for others, commonly illustrated by using a flow chart such as the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram169.  
In Paper IV, our aim was to write a systematic literature review on the topic adult 




and Medline were explored in collaboration with a university librarian at the UoB, with 
expertise in performing systematic searches. (See Paper IV, Supplementary 1 for more 
detailed information). In total, we identified 4091 records in this systematic search. As 
illustrated in the flow diagram (Figure 1, Paper IV), we performed a study selection 
based on the findings from the systematic literature search and an additional 63 records 
identified through manual search. After removing duplicates, 2774 records were 
screened on the subject ‘adult ADHD and somatic comorbidity’. Of these records, 208 
full text papers were assessed for eligibility. Finally, we retrieved 98 original scientific 
papers investigating the associations between somatic diseases and adult ADHD. We 
extracted the data from the selected studies and grouped them according to the 
disease(s) covered in the specific paper (based on ICD-codes), then distributed to the 
different co-authors based on their area of expertise. Main characteristics of each paper 
were extracted by the first and second author and described in a table, providing an 
overview of the strengths and limitations of each paper. To sum up the findings, we 
grouped the studied diseases into three categories according to the quality of evidence 
describing their association with ADHD. See section 5.4.1 for discussion. 
 Statistics 
Table 3 gives an overview over the statistical methods, covariates and software used to 
analyse data in Paper I, II and III. In Paper I, independent-sample t-tests were used to 
compare the TCI dimensions in the ADHD group with the comparison group. Similar 
analyses were performed in the whole sample 1) to compare the TCI dimensions in the 
participants fulfilling the criteria for ASPD with those not fulfilling these criteria 2) to 
compare the TCI dimensions between those categorized with lifetime anxiety disorder 
and/or lifetime MDD disorder with those not included in this category. We included 
ADHD, ASPD and anxiety/depression in a linear regression model to investigate which 
disorder had the greatest impact on the TCI dimensions scores. The threshold for 
statistical significance adjusted ad modum Bonferroni was 0,002. Thus, we corrected 
for 21 comparisons, i.e. ADHD, ASPD, anxiety/depression multiplied with the seven 




odds ratios (OR) while adjusting for potential confounding variables. In Paper II we 
stratified the analyses by sex, and in Paper III we performed interaction analyses to 
investigate potential effect modifications. In Paper III, we corrected for the number of 
autoimmune diseases, i.e. nine comparisons, giving the Bonferroni-corrected p-value 
0.0056. The ORs were reported with their corresponding 95% confidence intervals 
(CI). See section 5.2.1 (paper I) and section 5.3.1 (papers II and III) for discussion of 
the statistical methods. 
Table 3. Overview of main statistical methods and software (Papers I-III). 
Paper 
No. 
Statistical methods Covariates in the final regression models Software 




Lifetime antisocial personality disorder (yes/no)  
Lifetime anxiety disorder and/or Lifetime major 
depressive disorder (yes/no) 
PASW Statistics 
18a 
II Logistic regression 
 
Primary model: 
Maternal age at delivery (6 categories) 
Parity (3 categories) 
Time period of birth (5-year interval categories 
1967-2008) 
Maternal marital status (4 categories) 
Maternal education (3 categories) 
Expanded models:  
Infant birthweight (5 categories)  
Gestational age (5 categories) 
Each studied maternal disease (yes/no) 
Parental ADHD (based on dispensed ADHD 
medication) 
Subanalysis: 
Maternal smoking (yes/no) 
PASW Statistics 
18a 
Stata version 13b 




Age (continuous)  
Maternal education (3 categories) 
Subanalyses: 
Maternal smoking (yes/no)  




aSPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc. bStataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP.cThe R foundation for statistical computing, Vienna, 
Austria. dRStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA. eIBM Corp. IBM 




 Ethical considerations  
The first three studies were all approved by the Regional Committee for Medical and 
Health research ethics of Western Norway. To acknowledge participation and 
compensate for use of their time, the participants in Paper I received NOK 250, - when 
being enrolled in the project and additional NOK 500, - when interviewed. Further, a 
signed consent was obtained from each participant. Papers II and III were approved by 
the Norwegian Data Inspectorate. These papers were based on data from national 
registries with compulsory notification. Information is already collected and using 
these data should not create extra inconvenience for the study participants. Potential 
disadvantages for study participants could be lack of information about the studies, and 
that they cannot withdraw from the study. Information about the registries are available 
on the websites for each registry. In the linked dataset available for researchers, no data 
are directly identifiable, and it is not possible to identify the participants at an individual 
level. Paper IV was based solely on previously published papers, and additional ethical 
approvals were thus not required.  
Identifying possible risk factors and comorbid disorders associated with ADHD may 
be used to develop preventive measures and improve treatment. Such information is 
highly relevant for the target population of the study, i.e. individuals with ADHD and 
their families. For the health services and health authorities, knowledge of risk factors 
and comorbid disorders is important to facilitate early and adequate treatment, and to 
enable a holistic understanding of the individual´s various challenges and how these 
impact the individual´s function. In addition, the results from our research may be of 
value to patient organisations working with ADHD, and for the health authorities, when 




4. Results  
 Paper I 
In Paper I, we aimed to assess personality traits in ADHD patients and a comparison 
group. We found that persons with ADHD as a group had significantly higher scores 
on both the TCI dimensions Harm Avoidance (p< 0.05) and Novelty Seeking (p< 
0.0005) relative to the comparison group. A person with high Harm Avoidance tends 
to be fearful and pessimistic, whereas an individual with high Novelty Seeking is 
characterised as impulsive and quick-tempered. The ADHD group scored significantly 
lower on the dimensions Reward Dependence (p< 0.0005) and Self-Directedness (p< 
0.0005) compared to the comparison group. People with low scores on Reward 
Dependence are characterised as detached, reserved and independent, whereas those 
with low Self-Directedness scores are described as unreliable and blaming.  
Another aim of this study was to explore how these personality traits were associated 
with comorbid anxiety, depression and ASPD. When including ADHD and these 
comorbid disorders in a linear regression model, the differences in some of the 
personality scores between the ADHD and the comparison group changed 
considerably. ADHD was then no longer associated with high Harm Avoidance (p= 
0.794) or Novelty Seeking (p= 1.112). However, the ADHD group still showed lower 
scores of Reward Dependence (p< 0.001) and Self-Directedness (p= 0.04) compared 
to the comparison group, although only statistically significant for Reward Dependence 
(with a Bonferroni-corrected level of significance, p< 0.002). In this model, high Harm 
Avoidance (p< 0.001) and high Novelty Seeking (p< 0.001) were significantly 
associated with lifetime anxiety and /or depression and ASPD, respectively. These 
findings will be discussed in section 5.2.2, focusing on the dimension Harm Avoidance. 
To our knowledge, this is the first study comparing such personality traits in ADHD, 




 Paper II 
Paper II aimed at investigating whether chronic maternal inflammatory and immune 
system diseases were associated with offspring ADHD. The following maternal 
immune system related disorders were all found to significantly increase the odds of 
ADHD in the offspring; Multiple sclerosis (MS) (adjusted odds ratio (adjOR) = 1.8 
(95% CI(1.2–2.5))), RA (adjOR = 1.7 (1.5–1.9)), T1DM type 1 (adjOR = 1.6 (1.3–
2.0)), asthma (adjOR = 1.5 (1.4–1.6)) and hypothyroidism (adjOR = 1.2 (1.1–1.4)). 
Chronic hypertension, hyperthyroidism and type 2 diabetes mellitus (T2DM) showed 
no significant associations. We adjusted for year of birth, parity, mother’s age at birth, 
her educational level and marital status as possible confounding variables. See section 
5.3.2 for discussion of the findings. 
We also ran several additional statistical models including different adjustment 
variables, including parental ADHD (based on dispensed ADHD medication), infant 
birth weight and gestational age. In all models, adjustment only slightly attenuated the 
associations. Limiting the data to 1999 and onwards, we were also able to adjust for 
maternal smoking habits, which again only very slightly altered the associations, thus 
confirming the primary results. The same was true when adding ADHD patients only 
registered in the NPR to the ADHD case population. None of the associations differed 
significantly when stratifying by sex of the offspring.  
The findings of Paper II supported the hypothesis that brain-immune interactions may 
be causally related to psychopathology in children52. As one of the first large 
epidemiological studies documenting maternal chronic immune related diseases as risk 
factors for offspring ADHD, the study has been an important addition to the scientific 
discussion of this hypothesis. This paper has been much cited since its publication 





 Paper III 
In Paper III, we aimed at comparing the prevalence of autoimmune diseases in 
individuals with and without ADHD, and evaluate whether possible associations varied 
by sex. When adjusting for maternal age and education, strong associations were found 
between ADHD and psoriasis in both females and males, however with stronger 
associations in females (adjOR females 1.57 (95% CI 1.46–1.68), adjOR males 1.31 
(1.23–1.40), p value for interaction 4.4 × 10−6). ADHD was positively associated with 
Crohn`s disease in females (adjOR = 1.44 (1.16–1.79)), while negatively in males 
(adjOR = 0.71 (0.54–0.92)), p-value for interaction = 3.6 × 10−5.. Further, ADHD was 
significantly associated with ulcerative colitis in females (adjOR = 1.28 (1.06–1.54)), 
but not in males (adjOR = 0.86 (0.71–1.03)), p -value for interaction = 0.0023. On the 
other hand, a lower odds of ankylosing spondylitis was found in females with ADHD 
(adjOR = 0.56 (0.32–0.96)), while there was no association in males (adjOR = 1.16 
(0.87–1.55)), p-value for interaction = 0.021. There was no association between ADHD 
and iridocyclitis, MS, RA, systemic lupus erythematosus (SLE) or T1DM in neither 
males nor females. 
Information on smoking habits, body mass index (BMI) and education was available 
for a subgroup of females giving birth from 1999. Associations between ADHD and 
autoimmune diseases were confirmed both when adjusting for smoking and BMI. 
Sensitivity analyses were performed by exploring effects of age and time period, as 
well as using different case definitions. The results were in line with the primary 
analyses for psoriasis, Crohn´s disease and ulcerative colitis for individuals born 1967–
1985. No significant associations were found for those born 1986–2011.  
See sections 5.3.3. and 5.4.2. for discussion of these results, focusing on the main 
analysis and further on the association between ADHD and psoriasis. 
A possibly increased risk for autoimmune diseases in ADHD had hardly been studied 
at the time when Paper III was written. The paper contributed new findings to the 
existing literature regarding relations between psychiatric disorders and autoimmune 




 Paper IV 
Our aim in Paper IV was to summarise the current knowledge of associations between 
ADHD and somatic diseases in adults by doing a systematic literature review. 
According to the quality of evidence, the associations between the somatic comorbid 
diseases and adult ADHD were divided into three categories. The first category 
included diseases where the association with adult ADHD was well established and 
described in meta-analyses or reviews. Asthma, obesity and sleep disorders were 
placed in this category. The second category included cohort or case-control studies 
where adult ADHD was based on a clinical diagnosis, the somatic diseases were not 
only based on self-report questionnaires, and where a strong indication of an existing 
association was found. In this category, migraine and celiac disease were positively 
associated with adult ADHD, whereas cardiovascular disease showed a negative 
association. The majority of diseases were placed in the third category, where current 
evidence was too weak to make conclusions regarding associations with adult ADHD 
due to poor study quality, lack of studies or where the combined results clearly differed. 
The strengths and limitations of this categorization will be discussed in section 5.4.1.  
 
Compared to psychiatric comorbidity, somatic comorbidity has been investigated to a 
much lesser degree. The research on somatic comorbidity in relation to ADHD has 
mainly focused on children with ADHD. At the time when paper IV was written, there 
was a need for a systematic review to describe what was known about somatic 
comorbidity in adults with ADHD, not only to get an overview over the current 
knowledge, but to gather information about fields warranting further attention. This 





5. Discussion  
ADHD is a common, life-spanning neurodevelopmental disorder embracing a 
spectrum from normally distributed personality traits to substantially impairing 
symptoms, and well-known associated features and disorders adding to its burden. The 
main topic of this thesis was to elucidate some of this complexity, emphasizing gaps 
of knowledge in clinical and potentially causal factors associated with ADHD. The 
thesis aimed to give this broad perspective on ADHD by covering personality traits and 
comorbidities, with a special focus on the role of immune related diseases, both as 
prenatal risk factors and as somatic comorbidity in individuals with ADHD. It also 
focused on sex-specific associations. To achieve our aim, we used different research 
designs and methods, including a small clinical study, two large, registry-based 
epidemiological studies and a systematic literature review.  
In the following discussion, I will first introduce terms used in the discussion of Paper 
I-III, then move to the discussion of these same papers. I will then discuss Paper IV, 
while integrating some of the topics from the discussion of Paper III.  
 Terminology 
 Random and systematic errors, validity, reliability  
Study results are prone to be affected by errors, which can be either random or 
systematic. A random error is when the error occurs due to chance alone, and causes 
inaccurate measures of the associations170(p.52). Smaller studies are subject to greater 
sampling variations, leading to less precise estimates171. Random errors can be reduced 
by increasing the sample size170(p.52).  
Bias is an error which causes the results to differ systematically from the true 
value90(p.53). Such a systematic error can lead both to underestimation or overestimation 
of the true effect, and is not affected by sample size171. Biases can further be grouped 




Selection bias occurs when there is a systematic difference between the characteristics 
of those selected to participate in the study and those not selected172. Thus, the selected 
study participants do not represent the underlying source population. This bias arises 
from the procedures of identifying, recruiting and follow-up of study participants173. 
Information bias relates to how the study data are measured, collected and/or 
classified170,174. Bias can occur when data are misclassified, one example being cases 
wrongly classified as controls, or exposure wrongly classified as non-exposure. 
Misclassification can be differential or non-differential. In non-differential 
misclassification, the probability of misclassification is equal in all study groups, as 
opposed to differential misclassifying where this probability varies between groups175. 
Non-differential misclassification usually leads to an underestimation of the true effect 
size, while differential misclassification can lead to both under-and overestimation of 
the true effect. One type of information bias is recall bias, due to inaccurate or 
incomplete memory of past events176. A differential recall of past events between cases 
and controls will lead to differential misclassification90(p.54). Confirmation bias may 
arise if the findings support the preconception of the evaluator, who may then evaluate 
the findings of the case and control group differently177. 
Confounding is the confusion of the effect of an exposure. Bias due to confounding 
appears when parts or all of the association between exposure and outcomes is 
explained by (an)other variable(s)178. Such a variable, a confounder, is associated with 
the exposure, must be an independent risk factor/cause of the outcome, and should not 
be an effect of neither exposure nor outcome179(p.141). It should thus not be an 
intermediate variable on the causal pathway between exposure and outcome. If the 
association is explained by confounding alone, the observed association is true, but not 
causal, and will disappear when confounding is controlled for. 
Validity is a term applied to describe whether measures in a study captures what was 
meant to be measured and can be applied to study variables, exposures, outcomes and 
associations90(p.57). Validity can be divided into internal and external validity. Internal 




source population. The less selection bias, information bias and uncontrolled 
confounding, the higher internal validity90(p.58),180. External validity refers to the 
generalizability of the results, i.e. to what degree the results apply to the target 
population. High internal validity is a prerequisite for external validity. Further, 
conclusion about external validity is made based on knowledge of the research topic 
studied181. 
Reliability refers to what degree measurements/methods replicate the same results 
when repeated 91. One type of reliability is inter-rater reliability, referring to the degree 
to which two different researchers end up with the same conclusion when the same 
method is used (e.g. same diagnosis when the same clinical interview is used)91,182.  
 Hypotheses and statistical significance 
When comparing a specific characteristic between two groups, statistical inference is 
based on a “null hypothesis” of no difference between the groups. The probability of 
getting the result obtained when comparing the two groups if the null hypothesis were 
true, is given by the p-value. A low p-value means a low probability for obtaining this 
result, leading to rejection of the null hypothesis. If the null hypothesis is rejected but 
is in fact true, this is referred to as making a type 1 error183. The acceptable probability 
of making a type 1 error is defined in the study design by setting a level of statistical 
significance. One common level is 0.05, where a p-value <0.05 leads to rejection of the 
null hypothesis. This implies a less than 5% risk of making a type 1 error and rejecting 
a true null hypothesis. Type 2 error is the failure to reject a false null hypothesis183. The 
probability of a Type 2 error decreases as the sample size increases, and the risk of 
random error decreases. 
 Paper I  
The aim of paper I was to assess personality traits in ADHD patients and a comparison 
group, and further explore how these traits were associated with anxiety, depression 
and ASPD. The personality dimensions Novelty Seeking, Harm Avoidance and 




with Novelty Seeking and Harm Avoidance were partly dependent on ASPD and 
anxiety/depression, respectively.  
 Methodological considerations 
ADHD and comparison group  
As described in section 3.1.1, a subsample of the participants from the project “ADHD 
in adults in Norway” participated in a clinical interview. This project aimed to recruit 
a naturalistic sample of adult ADHD patients by including adults with ADHD as 
diagnosed in out-patient clinics all over the country. As we did not make a full clinical 
assessment to validate the ADHD diagnosis at the time of the interview, we did not 
know if the participants currently fulfilled the ADHD criteria. The interviews of the 
ADHD cases took place maximum five years after being included in the “ADHD in 
adults in Norway” project, and as ADHD is seen as a chronic disorder, we considered 
the time frame to be acceptable. One would expect selection bias in this study. Of the 
ADHD cases, 26% were recruited from the Expert Committees of Hyperkinetic 
Disorder/ADHD, i.e. from a time period when the focus on adults with ADHD was 
low. One could thus argue that those recruited from this Committee comprised a severe 
subgroup of patients. Delayed recognition and treatment of ADHD may also increase 
the risk for other psychiatric problems. These aspects may have contributed to 
strengthen the differences found between cases and controls, and to reduce the 
generalizability of the results to patients in other clinical settings. On the other hand, 
the case group was comprised by individuals actually completing questionnaires and 
meeting for an interview, which may be difficult for those with the most severe form 
for ADHD. Another aspect is that those actually participating in the study may have a 
motivation for participating which makes them different from the study population as 
a whole. The overall influence of the patient selection on our results may thus go both 
ways.  
All the participants were categorized as having ADHD or not. Since we did not fully 
assess the ADHD diagnosis, and ADHD is a prevalent disorder we did expect there 
could be some individuals with ADHD also in the comparison group. We excluded two 




ADHD based on total information gathered from the interview. Further, one individual 
had been clinically diagnosed with ADHD and was re-categorized to the ADHD group. 
Consequently, 4% of the participants in the comparison group were suspected or had 
ADHD, a frequency comparable to the general population. In the comparison group, 
the majority (77%) was randomly recruited from MBRN within similar age groups and 
geographic regions as the ADHD patients (see section 3.1.2). However, only 24% of 
the invited individuals responded, and we may assume that those responding differ 
from non-responders by factors like higher education or high functioning. In addition, 
19% in the comparison sample were medical students, who may on average be healthier 
and have different personality profiles than randomly selected controls. This selection 
bias could lead to strengthening of the associations, as the gap between the case group 
and the comparison group may have increased. The main results did, however, not 
change when only including those recruited from the MBRN in the comparison group 
(results not shown). On the other hand, those agreeing to participate from the randomly 
recruited comparison group may also include people more interested in the topic 
because family or friends have ADHD, or even if they suspect that they may have 
ADHD themselves. This could then affect the results in the opposite way, by 
weakening the associations. Finally, 4% of the participants from the original 
comparison group were excluded due to probable ADHD. This could create a selection 
bias in the comparison sample, towards less psychiatric disorders compared to the 
general population. However, we found the prevalence for lifetime anxiety and/or 
depression in adults with ADHD and controls to be 82.5% and 25.0%, respectively. 
Thus, our results are in line with high rates of psychiatric disorders both in individuals 
with ADHD, as described in section 1.4.1, but also significant in the control group..  
Measure of personality traits 
As described in section 3.2.1, we used the self-report inventory TCI to assess 
personality traits in participants with ADHD, ASPD and lifetime anxiety and/or 
depressive disorder, respectively, and compared the results with participants without 
these disorders. Self-report personality inventories have several advantages. They are 




or rating of the answers and it is easy to standardize the results184. However, self-report 
inventories have some limitations, e.g. participants’ lack of insight, tendency to 
respond on the extreme ends of the scale, or to answer in accordance with the most 
social desirable personality characteristics184-186.  
To investigate to what extent the TCI measures the seven personality dimensions in the 
specific test situation (validity), there are items in the questionnaire intending to detect 
inconsistent and careless reporting81(p.75). Further, when 12 or more items are missing, 
the results are not considered valid88. One important aspect of evaluating the quality of 
self-report inventories is the reliability of the findings, in this context to what extent 
the scores measured are reproducible81(p.80-81). One widely used measure of reliability 
is internal consistency, which can be measured by Cronbach´s coefficient alpha187. The 
range of Cronbachs´s alpha is between 0 and ± 1, with values > ±0.70 viewed as 
acceptable188. Including both clinical and non-clinical samples, studies from the United 
States of America (U.S.), Sweden and Finland have shown relatively consistent internal 
consistency on the TCI ranging from 0.55-0.85 for all dimensions71,162,189. Although 
showing similar results, the investigations are limited, only covering three countries. 
Another type of reliability is test-retest reliability, that is to investigate the correlation 
between the results of an individual´s scores measured on two different occasions 
81(p.81). Studies examining the test-retest reliability for the TCI version 9 are scarce. In 
a 1-year longitudinal study including 631 individuals from a U.S. community sample, 
correlations of the TCI traits ranged between r =0.78-0.85, which is considered a strong 
correlation190. The psychometric properties of the Norwegian version have not been 
tested, but the Swedish version has shown good psychometric properties for internal 
consistency and test-retest reliability in adults88,162. Finally, the reliability may be 
affected by the small sample size, one person with ADHD deviating from the “norm” 
would affect the results more than if the sample was larger.  
In general, shorter questionnaires have a greater chance of being completed than long 
ones, however the relevance of the content is also important191. If the questions are 




the total burden of questionnaires and assessment191. The TCI version 9 is 240 items 
long and takes about 30 minutes to complete. The items are in true/false format, which 
enhances the likelihood being answered compared to more complex results answering 
formats191. The TCI was the only questionnaire the participants had to fill out at the 
time of the interview, which could make it more tolerable. However, the length of the 
questionnaire is not favourable for persons with ADHD, who may have difficulties 
concentrating. The validity of the TCI is dependent on people answering it properly, if 
people rush through the questionnaire, the answers may be less valid. On the other 
hand, if persons with ADHD find the topics interesting, they might be very good at 
concentrating. It is difficult to decide whether the participants found the questionnaire 
interesting, as this was not evaluated afterwards.  
Another aspect is the number of participants excluded from the study due to missing 
items in the TCI questionnaire. If individuals with ADHD are more likely to leave out 
12 or more items compared to those in the comparison group, it could lead to 
information bias with differential misclassification. However, only three in the ADHD 
case group and one in the ADHD control group left out 12 or more items and were 
excluded from further analyses. The ASRS scores or demographic variables for those 
three did not differ from the remaining sample. Therefore, it is considered as unlikely 
that exclusion of participants due to too many missing items will influence the main 
results. 
The TCI is not validated in Norway (see section 3.2.1). We decided not to compare the 
TCI scores to validated scores from other countries, such as Sweden88,162, as they do 
not specifically study ADHD or other psychiatric disorders in their validation. By 
comparing the scores from the TCI only within the study, the internal validity is 
satisfactory. However, the external validity is weakened, since we not are able to 
compare our results with other validated data. Personality traits can be assessed in a 
number of ways, such as by observer-based assessment, standard test situations, life 
history analysis and self-report personality inventories, among others186. In Paper I we 
used only one method to assess personality traits, although, ideally, one should 




Anxiety, depression and antisocial personality disorder (ASPD) 
Anxiety, depression and ASPD were measured with the M.I.N.I. Plus interview. As 
described in section 3.2.2, this interview is extensively used for assessing these 
psychiatric disorders in Norwegian research and clinical practice. Although M.I.N.I. 
Plus is not validated in Norway, this aspect enhances the external validity of the 
findings. One criticism against the M.I.N.I interview, which is relevant also for the 
M.I.N.I Plus interview, is the risk of overdiagnosing due to a high rate of false positives 
166. Ideally, these disorders could in addition be evaluated by other methods, such as 
clinical evaluation, information from family, and self-report questionnaires. 
Comparing or summarising results based on different methods would increase both the 
internal and external validity of the study. 
There were no calculations of inter-rater reliability among the interviewers, which may 
decrease the reliability of the findings. To improve the reliability, the interviews were 
recorded and the results discussed between the interviewers, to ensure that the 
interviews were conducted as similar as possible. Further, the interviewers were not 
informed prior to the interview whether the participant was registered in the project as 
diagnosed with ADHD or not, thus reducing the risk of confirmation bias. 
As presented in section 1.3.2, depression and anxiety disorders share many personality 
traits. The sample sizes were small for each of the types of anxiety and depressive 
disorders, making it challenging to compare them with each other. Thus, the different 
anxiety disorders (i.e. panic disorder, with or without agoraphobia, generalized anxiety 
disorder and/or MDD, both current and lifetime), were merged into a single category 
termed lifetime anxiety and/or depressive disorder. Due to the fact that these categories 
were partly based on retrospective data, recall bias could be a concern. The extent of 
inaccurate recall might have differed between persons with and without ADHD, thus 
leading to differential misclassification. For example, persons with ADHD might be 
more prone to remember past psychiatric symptoms compared to persons without 
ADHD. Differential misclassification may lead to either strengthening or weakening 





As described in section 3.3, the threshold for statistical significance adjusted ad modum 
Bonferroni was 0,002. The Bonferroni correction gives a conservative estimate of the 
significance level, decreasing the risk of type 1 error192. On the other hand, the risk of 
type II errors increases, and as previously described, the risk of type II errors is also 
increased due to the small sample size. Thus, one has to be highly aware of the 
possibility of type II error, and not only focus on the p-value. The results were also 
given as estimates with 95% CI, which gives information on the estimate precision in 
addition to information on significance. Further, we presented some of the main results 
as scatter plots, to visualize the actual, individual data and ease the interpretation of the 
findings for the reader. 
The mean age at time of interview was 34 ± 9 years in the ADHD group, compared to 
28 ± 6 years in the comparison group. Adjusting for age did not significantly change 
the results of the primary analysis, and age was thus not included in the final model. 
The sex distribution was quite similar between the ADHD group (women: 54.0%) and 
the comparison group (women: 57%). Due to the small sample size we decided not to 
stratify the analysis by sex. 
 Discussion of findings  
In line with previous findings, we found that persons with ADHD as a group had 
significantly higher scores on the TCI dimension Harm Avoidance (p< 0.05) relative 
to the comparison group. Persons with high Harm Avoidance tend to be fearful and 
pessimistic, features which also are strongly associated with anxiety and depression 
(see section 1.3.2). Further, the trait Neuroticism from the Five-Factor model is 
correlated with Harm Avoidance, and Neuroticism is found to be associated with both 
ADHD, anxiety and depression101,104,193-196(p.14). Thus, findings in the literature using 
another method of measuring personality traits, corroborate the results from our study. 
As the overall findings of comorbidity prevalences and personality trait profiles are in 
line with previous studies, we think that the findings are relevant and representative for 




When including ADHD and comorbid anxiety/depression disorders and ASPD in a 
linear regression model, ADHD was no longer associated with high Harm Avoidance 
(p= 0.794). In this model, Harm Avoidance was significantly associated only with 
anxiety/depression (p< 0.001). This result indicates that Harm Avoidance, is primarily 
associated with anxiety and depression, and not ADHD per se. This is more in line with 
the intuitive understanding of Harm Avoidance (or Neuroticism) to be more related 
symptoms of anxiety and depression than core symptoms of ADHD. However, the 
picture is more complex. In an Italian study by Di Nicola et al. (2014)193, ADHD was 
assessed in euthymic bipolar patients and patients with MDD in remission (N ~ 100 in 
each group). Personality traits were measured based on the Five-Factor Model. 
Evaluating all the clinical subjects together in one group, those with higher levels of 
Neuroticism had higher frequency of ADHD. This suggests that neuroticism is not only 
associated with affective disorders per se, but also with ADHD itself.   
As findings from Paper III show, psoriasis is associated with ADHD. According to a 
Turkish study by Kilic et al. (2008) individuals with psoriasis have been found to have 
significant higher levels of Harm Avoidance and lower levels of Self-Directedness 
compared to healthy controls197. In another Turkish study by Ak et al (2011), males 
with psoriasis showed significantly higher levels of Harm Avoidance and Novelty 
Seeking compared to a control group, even after controlling for symptoms of anxiety 
and depression198. Interestingly, this specific pattern of personality traits thus seems to 
be similar for psoriasis and ADHD. 
The dimension Novelty Seeking has, like Harm Avoidance, consistently been 
associated with ADHD (see section 1.3.2). Surprisingly, when including anxiety, 
depression and ASPD in the same regression model, Novelty Seeking was no longer 
associated with ADHD, but rather with ASPD (p< 0.001). Further, Reward 
Dependence was the only TCI dimension that remained significantly associated with 
ADHD. These results may be somewhat contra-intuitive, as the features of Novelty 
Seeking (impulsive and quick-tempered) are more typical of ADHD core symptoms, 
whereas characteristics of Reward Dependence (detached, reserved, cold and 




influenced by a relatively high overlap of ASPD and ADHD in our sample, with 
insufficient statistical power to detect characteristics of ADHD and ASPD, and vice 
versa. Further, as described in section 1.3.2, studies on TCI and ASPD are scarce and 
the clinical implication of this finding should be cautiously interpreted, before a 
replication of our findings is available.  
Sex and age 
According to a study by Miettunen et al. (2007) personality traits differ by sex. In their 
meta-analysis, including 32 studies on non-clinical samples, women scored 
significantly higher in the dimensions Harm Avoidance and Reward Dependence 
compared to men (p< 0.001)199. Whether the personality profiles as measured by the 
TCI differ between sex in ADHD is poorly studied. A study by Jacob et al. (2007), 
including 173 females and 199 males with ADHD, found higher scores of Harm 
Avoidance (p< 0.0001) and Novelty Seeking (p= 0.045) in females compared to males, 
but no sex differences in Reward Dependence (p= 0.25)132. In our small sample size, it 
was not feasible to stratify the data by sex due to lack of statistical power. However, 
the difference in sex distribution between the ADHD and comparison group was not 
statistical significant (54.0% women in the ADHD group and 57.4% women in the 
comparison group). Sex was not included as a variable in the regression analyses.   
We know that age influences the personality traits, e.g. Harm Avoidance has been 
shown to be associated with ADHD only in adults84. As the prevalence of anxiety and 
depression also changes by age, age may influence the association between comorbid 
anxiety/depression and ADHD with personality dimensions200. In our study, the mean 
age at time of the interview was significantly different between the ADHD group and 
the comparison group (34.4 ± 9.3 years in the ADHD group and 28.3 ± 6.3 years in the 
comparison group). However, adjusting for age did not significantly change the 
estimates in the primary analyses, and was therefore not included as a variable in the 




Clinical implications and future research 
To our knowledge Paper I is the only published study with this design, thus direct 
comparison with other studies is not possible. One limitation of our study is the 
relatively small sample, with low statistical power increasing the risk of type 2 error. 
On the other hand, in small samples, differences that are actually detected and highly 
significant (p< 0.001), are more likely to reflect findings relevant for clinical practice. 
However, statistically significant results are not necessarily clinically significant. 
Clinically significant results are results that are relevant for clinical practice, regardless 
of the magnitude of statistical significance201. We find our results to be relevant for 
clinical practice, both for assessing and treating ADHD and its comorbid disorders. 
This single study, with its limitations, will not alone directly impact clinical practice. 
However, it may contribute to increase the awareness of personality traits in ADHD, 
and hopefully lead to new studies with improved design in the future.  
Future studies could improve knowledge by addressing these questions in a 
community-based sample, where a cohort of randomly selected individuals is assessed 
for ADHD, by doing standardized diagnostic interviews and clinical assessment also 
for other psychiatric disorders. Ideally, a newer edition of TCI with fewer items should 
be used, or even rather the Five-Factor model, as this model is currently more 
extensively used and thus easier to compare with and inform clinical practice. In 
addition, the impact of sex and age should be a topic for research. It would be preferable 
also to do power calculations to determine what sample sizes are needed, as adequate 
sample size increases the precision of the results and reduces the risk of type 2 error.  
Differential diagnosis and comorbidity related to ADHD is an important topic in 
everyday clinical practice. As some specific personality traits are associated with 
different psychiatric disorders, assessment of personality traits may further be used to 
elucidate patterns of comorbidity between the disorders113. Further, personality profile 
can be helpful when tailoring the treatment of each individual patient, shedding light 
on strengths and weaknesses in the person’s behaviour. This knowledge can be used 




 The relationship between personality traits and psychiatric 
disorders 
I will now present different models for explaining the relationship between psychiatric 
disorders and personality traits113. I will use the temperament dimensions Novelty 
Seeking and Harm Avoidance in relation to ADHD to exemplify the models.  
1) Common cause: Personality traits and psychiatric disorders arise from the same or 
overlapping set of aetiological determinants, with no causal influence on each other 
107,113. Shared genetic risk factors is an example of a common cause. Novelty Seeking 
has been found to be genetically associated with both ADHD symptom dimensions 
(inattention and hyperactivity-impulsivity), Harm Avoidance with inattention only203. 
2) Spectrum: Personality traits and psychopathology are part of the same spectrum, 
hence, an individual with a psychiatric disorder has an extreme score of a relevant 
personality trait67,113,204. ADHD is a heterogeneous disorder with multiple aetiological 
pathways, and a personality trait may be a factor in one of these pathways. Nonetheless, 
if a personality trait is associated with several disorders, it is less consistent with the 
spectrum view113. As other psychiatric disorders are associated with some of the same 
traits as ADHD, this make the spectrum model less plausible. However, a specific 
personality trait, for instance Harm Avoidance, might not be directly related to ADHD 
per se but to anxiety, a common comorbidity in ADHD. If that is the case, Harm 
Avoidance and anxiety can be seen as being on the same spectrum. 
3) Vulnerability: The individual is at a greater risk of developing psychopathology 
due to certain personality traits204. Following this hypothesis, it has been claimed that 
personality plays a causal role in the onset of a psychiatric disorder113. ADHD is 
characterised as a neurodevelopmental disorder, implying that symptoms of ADHD 
appear early in life. Thus, it is unlikely that the personality traits per se will cause 
ADHD. However, the vulnerability model is useful in other psychiatric disorders with 
onset later in life, like anxiety disorder. Innate or early developed personality traits such 
as fearfulness and shyness, characteristic parts of the Harm Avoidance dimension, can 
make a person more vulnerable for developing an anxiety disorder. Thus, these 
personality traits act a causal influence on the manifestation of this disorder. As anxiety 




anxiety development is relevant for individuals with ADHD. 
4) Pathoplastic: The personality traits influence the course of the psychiatric disorders; 
such as its severity, presentation and prognosis204. A person with high Harm Avoidance 
is prone to be easily fatigued. The impairment by having ADHD may be more severe 
if the person is much fatigued, making it harder to accomplish daily tasks. 
5) Scar: Psychopathology has an impact on the personality67. Thus, the person’s 
personality can be changed after the development of a psychiatric disorder204. For 
example, a person with ADHD may easily be exposed to dangerous situations due to 
inattentive, hyperactive or impulsive behaviour. After this kind of exposure, the person 
may become more fearful and shy compared to earlier in life. In other words, the person 
will show a higher degree of Harm Avoidance. 
It is plausible that one or several of these models are involved when explaining the 
relationship between personality dimensions and ADHD84. Currently, the knowledge 
in this field is not sufficient to draw any conclusions. A recent meta-analysis by Gomez 
et al. on the relationship between Cloninger's personality dimensions and ADHD 
showed possible support for the spectrum model84. As for Paper I, all the included 
studies lacked longitudinal data. Thus, it was not possible to assess temporal relations, 
which is important to evaluate the plausibility of the other models, with the exception 
of the spectrum model. In a previous meta-analysis by the same authors, information 
on ADHD and personality traits were measured by different methods including the TCI 
and the Five-Factor Model67. The results showed some support for the spectrum and 
the vulnerability model, but lacked information to evaluate the pathoplastic and scar 
models. The authors concluded that the spectrum model alone did not provide sufficient 
explanation for the association between personality and ADHD.  
To gain further insight in which of the models are most plausible, there is a need for 
longitudinal studies to be able to investigate temporal associations (relevant for the 
vulnerability, pathoplastic and scar models)84. Ideally these studies should be drawn 
from population-based cohort studies from an early age (to avoid e.g. selection and 




 Papers II and III  
The aim of Paper II was to investigate if chronic maternal inflammatory and immune 
system diseases are associated with ADHD in the offspring, whereas in Paper III we 
aimed at studying the association between ADHD and autoimmune diseases in males 
and females. We found that maternal MS, RA, T1DM, asthma and hypothyroidism 
significantly increased the risk of ADHD in the offspring. Further, compared to the 
general population, persons with ADHD had a higher prevalence of certain 
autoimmune diseases with evident sex differences, i.e. ADHD increased the odds of 
ulcerative colitis only in females.   
 Methodological considerations 
Papers II and III are large epidemiological studies based on data from population- based 
registries with compulsory notification. The study populations originate from the 
MBRN where routine linkage with the National Registry ensures complete notification. 
The risk of selection bias is therefore minimal. Another major advantage is the large 
number of participants, which strengthens the precision of estimates, leads to less 
random error, and allows the study of rare events205. Since data are collected 
prospectively, recall bias is not a concern. However, these studies are observational 
and non-experimental by design, and may be vulnerable to information bias from 
various sources. The data available are routinely collected, based on standard criteria 
/standard registration forms, and therefore the investigator has no influence on which 
and how the specific data are collected205. Although this excludes the problem of 
investigator bias, the researcher is limited to study the variables already included in the 
registries205. 
ADHD 
ADHD as a variable was based on dispensed ADHD medication as registered in the 
NorPD. Individuals were thus defined as having ADHD if they had been prescribed 
and dispensed medication used to treat ADHD from 2004, when the NorPD was 
established. As described in section 1.1.2, since the prescription of ADHD medication 




dispensed ADHD medication is a good proxy for having received an ADHD diagnosis. 
The exception is when central stimulants are prescribed for narcolepsy. Individuals 
being prescribed central stimulants for this indication were excluded from the case 
population (1.4%) from 2008. However, for the period 2004-2007, the NorPD data did 
not include indications for prescribed medication, and there will therefore be a very 
small group of individuals who have received central stimulants for narcolepsy during 
these years, and who will be misclassified as having ADHD. But as this group is very 
small, it will not influence the main results. 
However, our definition will miss individuals who have been treated for ADHD for a 
period and stopped pharmacological treatment before the NorPD was established. It 
will also miss individuals who have received the diagnosis, but do not use ADHD 
medications either due to contraindications, side effects or other reasons13. We will also 
miss individuals who in reality have ADHD, but who have not yet received the 
diagnosis. This can for instance be due to lack of referral of patients to the specialist 
health care because of mild symptoms, personality difficulties overshadowing the 
symptoms, or low capacity in the specialist health care. We also know that there are 
regional differences in referral rates28(p.19-20). These individuals will all be included in 
the control groups of our studies.  
As emphasized, our case group consists of individuals with ADHD who have received 
pharmacological treatment. Thus, our results may be generalized to this group of 
ADHD patients, whereas they may not be valid for those not having received 
medication. There are no certain numbers of how many persons diagnosed with ADHD 
use medical treatment, but during 2008-2013, around 80% of Norwegian children 
diagnosed with ADHD received pharmacological treatment28(p.29). The sensitivity 
analysis in Paper II, with data from the NPR, showed that 83% of individuals with 
ADHD registered in NPR received ADHD medication. Adding those not treated 
pharmacologically to our case group did not change the overall effect estimates. This 





To sum up, it is quite certain that those defined as ADHD cases based on dispensed 
medication have been diagnosed with ADHD. The risk that persons without diagnosed 
ADHD are misclassified as having ADHD is small, except for the very small group of 
narcolepsy patients receiving medication in 2004-2007. On the other hand, there will 
be individuals with ADHD misclassified as controls. As the control group is very large, 
this will not impact on the results. However, our results are not necessarily valid for 
individuals with ADHD who have not received ADHD medication, although our 
sensitivity analysis using data from NPR suggest that they may be.  
Maternal diseases and comorbid autoimmune diseases  
In Paper II, information on the different maternal diseases (exposures) was collected 
from the MBRN. Not all these diseases are validated, and we may expect that 
ascertainment is not 100%. Some exposed mothers will therefore be misclassified as 
non-exposed. Ideally, we should have included information on maternal diseases from 
other sources for validation purposes, such as from the NorPD or the NPR, but we did 
not have access to such data. However, we studied diseases previously validated206,207 
or described in the literature208-210, or for which the MBRN notification form had 
specific check boxes, to ensure the best possible quality of the diagnoses. Further, this 
misclassification will probably be non-differential, as the registration of the exposure 
diseases is independent of the outcome of interest - ADHD in the offspring. Thus, this 
misclassification will weaken the results. 
 The autoimmune diseases (outcome variables) in Paper III, were defined based on 
information from the NorPD only. We did not have the possibility to compare with 
data from other registries such as the NPR for validation purposes. However, the 
autoimmune diseases were defined on the basis of prescriptions with reimbursement 
codes (indications for prescribing), which implies a careful assessment from the 
clinician and requires the disease to have lasted three months or more. However, 
misclassification may be present also here. It is possible that differences in health- 
seeking behaviour in individuals with and without ADHD may lead to differences in 
being diagnosed with the studied autoimmune diseases. This might lead to differential 




since the studied autoimmune diseases are severe, usually affect patients’ functioning, 
and require treatment, we believe that most patients with these diseases would seek 
health care for their symptoms, independent of having ADHD or not. Thus, we do not 
believe that the possible misclassification is a big threat to the results.  
Confounding variables 
In addition to possible misclassification of exposure and outcome variables, 
misclassification can also occur in the potential confounders. One example is maternal 
smoking in the MBRN, available in the registry from 1999. In contrast to all other 
variables, mothers can refrain from registration of smoking habits resulting in a 
considerable amount of missing values (varying from nearly 20% to less than 10% over 
the years). Underreporting is also a concern with regards to smoking habits. It is 
possible that individuals with ADHD report their smoking habits differently than 
individuals without ADHD, which could lead to residual confounding. However, 
investigations at the MBRN have shown that the amount of missing in maternal 
smoking information is more linked to midwives at certain institutions not registering 
the information than to the mothers refraining the registration (K. Klungsøyr, personal 
communication). Also, the differential misclassification needs to be very large to bias 
the result to a large extent, which we believe is not likely. Other variables included as 
potential confounders in the statistical models of Papers II and III were year of birth, 
parity, mother’s age at birth, mother’s educational level and marital status, where 
misclassification is not a problem. We also included offspring birth weight and 
gestational age, where both variables have good quality. In Paper II we also adjusted 
for parental use of ADHD medication as a proxy for parental ADHD, and in Paper III 
for BMI, where the potential misclassifications are as described above. 
Paper II was designed as a nested case-control study, where we required all individuals 
to be alive at record linkage in 2012. Potentially, different mortality rates in the ADHD 
group versus control group during years before 2012 could bias our results. However, 





We used logistic regression models to evaluate the associations between maternal 
inflammatory and immune system disease and offspring ADHD (Paper II) and between 
ADHD and comorbid autoimmune diseases (Paper III). We adjusted for potential and 
known confounding factors, using maternal educational level as a proxy for maternal 
socioeconomic status. In Paper II, we included several models including different 
covariates. We also investigated possible sex differences by stratifying analyses by sex 
(Paper II) and performing interaction analyses (Paper III). For the purpose of this thesis, 
we performed interaction analyses to investigate effect modification by sex in Paper II. 
The results were in line with the findings from the stratified analyses (results not 
shown). In Paper II, covariates were categorized, since the continuous variables did not 
show linear relations with the outcomes, and we had sufficient power to assess the data 
using categories. In Paper III, we adjusted for age as a continuous variable in the main 
analyses, even if the relationships were not strictly linear (the exception was T1DM, 
where age was categorized). Thus, it could have been relevant to use spline modelling, 
which takes non-linearity into account, but applying this method only slightly altered 
the results211(p.69). In Paper II we calculated cluster-robust standard errors with the 
mothers as a cluster variable, to take account of dependencies between infants born to 
the same mother, with little impact on the results. 
Relative versus absolute effect measures 
Papers II and III were planned under a causal framework. This guided our choice of 
using relative effect measures, as these are commonly used when investigating causal 
relations. While it has been suggested that effect measures and interactions on the 
multiplicative scale are better suited to assess causal relations, risk differences and 
interactions on the additive scale are the most important to assess public health 
relevance, indicating what group may benefit the most from treatment or preventive 
measures.179(p.6l). This was not the aims in Paper II and III and will thus not be focused 
on in this thesis. However, to provide an example using absolute effect measures, the 
absolute risk of ADHD in children to mothers with RA was 4.12%, while it was 2.06% 




(1.56%-2.57%). That is, the absolute risk of ADHD in children to mothers with RA 
was only 2% higher than the risk in children to mothers without RA. On the relative 
scale, the risk was doubled (relative risk 2.0; 95% CI 1.8-2.3). The number needed to 
treat is 49, that is RA must be prevented in 49 mothers in order to avoid one case of 
offspring ADHD. In a clinical context, these numbers show that preventing RA in 
mothers is not an efficient way to prevent ADHD in children, and screening of RA is 
not warranted. Regarding Paper III, due to low prevalences of autoimmune diseases in 
the general population, the absolute risks and risk differences will remain small. 
  Maternal inflammatory and immune system diseases as risk 
factors for ADHD 
In Paper II we found that maternal MS, RA, T1DM, asthma and hypothyroidism 
increased the risk of ADHD in offspring. There were no associations between ADHD 
in offspring and maternal T2DM, hyperthyroidism or chronic hypertension. None of 
the associations differed significantly by offspring sex, however, for asthma, the point 
estimates were higher for females and CI only slightly overlapped (adjOR 1.7 (95% CI 
1.5–1.8)) compared to males (adjOR 1.5 (1.4–1.6)). We aimed to assess the possible 
relationship between maternal inflammatory/immune system disease and offspring 
under a causal framework, and not to emphasise clinical implications.  
However, it is important to bear in mind that since Paper III is based on an 
observational study design, it is not possible to make firm conclusions about causality. 
But several factors point in the direction of a causal relationship between maternal 
inflammatory/immune system disease and offspring ADHD:  
A main strength with a nested case-control design is the possibility to investigate 
temporal relationship: The exposure (maternal disease) is present before the outcome 
(ADHD in offspring). A temporal relationship is a prerequisite for a causal relationship. 
Some of the effect measures were relatively strong, such as MS (adjOR = 1.8 (1.2–
2.5)), RA (adjOR = 1.7 (1.5–1.9)), T1DM (adjOR = 1.6 (1.3–2.0)) and asthma (adjOR 
= 1.5 (1.4–1.6)). Stronger effects may support a causal relationship.  
A limited number of studies have investigated the relationship between maternal 




partly consistent with these findings. Increased risk of ADHD in the offspring of 
mothers with psoriasis152 and T1DM have been found in large population-based 
register studies from Denmark and Sweden152,212. Contrary to our findings, maternal 
T2DM has also been shown to be associated with offspring ADHD in a large birth 
cohort study from the U.S.213. Maternal thyroid diseases in pregnancy have received 
attention, as maternal thyroid hormones pass the placenta barrier into foetal circulation, 
and may thus directly impact the neurodevelopment of the foetus for instance by 
decreased myelination or altered development of synapses between neurons214,215. The 
role of maternal thyroid disease and ADHD in offspring has also shown conflicting 
results. In line with our results, a large registry-based Danish study found that maternal 
hypothyroidism was associated with ADHD in the offspring214. A study including 287 
mother-child pairs from a U.S birth cohort did not find an association between maternal 
thyroid levels as measured by blood samples in the second trimester and ADHD in the 
child, ADHD was here measured by a checklist. This study focused on 
hyperthyroidism215, and was thus in line with our findings. Finally, a large English birth 
cohort comprising 2912 mother-child base-pair did not find any associations with 
maternal thyroid levels as measured by a blood sample in the first trimester and ADHD 
in the child (self-report from parents and children)216. There is a need for more studies 
on this topic, with a thorough diagnostic evaluation of ADHD in the offspring. 
Another factor that may favour the likelihood of a causal relationship is whether the 
association is plausible and in line with current knowledge. As discussed in 1.2.2 it is 
biologically plausible that maternal immune factors may directly impact foetal brain 
development by maternal immune activation. Another example is disrupted thyroid 
levels in the mother as described above.  
The results may, however, also be affected by unknown/unmeasured confounders. One 
example of a possible confounder, unmeasured in our study, is maternal use of 
acetaminophen. Studies have shown increased risk of offspring ADHD related to 
maternal use of acetaminophen, and the use of acetaminophen in mothers with 
inflammatory/immune system diseases may be higher compared to mothers without 




when controlling for the indication of acetaminophen use, and acetaminophen is thus 
likely not a strong confounder217,218.  
Another example of unmeasured confounding is familial confounding (see section 
1.2.1). Familial confounding can be illustrated using smoking as an example: Across 
studies, a clear association between maternal smoking during pregnancy and increased 
risk of offspring ADHD has been shown219. Due to these results, maternal smoking was 
widely accepted as having a causal effect on the development of offspring ADHD220. 
However, conventional cohort studies have not taken shared family factors into 
account, including the possible genetic overlap between smoking and ADHD221. When 
controlling for this unmeasured familial confounding by using other study designs, 
such as sibling design, the association between maternal smoking in pregnancy and 
offspring ADHD is no longer significant221-223. In our study we did not evaluate the 
possibility of familial confounding, i.e. common genetic factors leading both to 
inflammatory/immune system diseases in the mother and ADHD in the offspring. 
Maternal versus paternal associations 
In Paper II, data on paternal diseases was not available in the main study file. However, 
in an additional analysis based on a different datafile, we used data from the NorPD 
where medication used to treat specific diseases was used as a proxy for a few 
inflammatory/immune system diseases in the fathers. Although we found statistically 
significant associations between paternal T1DM and asthma with offspring ADHD, all 
the risk estimates were lower than those found for maternal diseases. This is in 
agreement with the results from two population based Danish studies: Nielsen et al. 
reported maternal, but not paternal, psoriasis to be associated with offspring ADHD152, 
and Andersen et al., reported the same for maternal, but not paternal 
hyperthyreoidism214. Further, Jo et al. found that, although not statistically significant, 
the risk of ADHD was larger if the mother had T1DM than if the father had T1DM212.  
This differences in the maternal versus paternal associations could, as discussed above, 
be explained by an alteration in the foetal brain development due to a maternal immune 




in which the expression of a gene varies depending on whether it is inherited from the 
mother or the father224. Further, most autoimmune diseases are more common in 
females than males (ankylosing spondylitis is one of the exceptions)225. Thus, lack of 
sufficient statistical power to detect a paternal effect may be an additional explanation.  
To conclude, multiple factors, also sex-specific, may contribute to the associations 
between maternal inflammatory/immune system diseases and offspring ADHD. 
Although findings from the literature support the theory of common genetic causes, 
some of the heterogeneity in ADHD may be explained by predominantly immune-
mediated aetiologies, perhaps making it possible to subgroup the disorders according 
to such different aetiologies in the future52.  
 ADHD and comorbid autoimmune disease  
In Paper III we found that there was a close association between ADHD and several 
autoimmune diseases, but with evident sex differences. Relatively strong associations 
were found between ADHD and psoriasis regardless of sex, but significantly stronger 
in females than males. Further, ADHD was positively associated with Crohn`s disease 
in females but negatively associated in males and significantly associated with 
ulcerative colitis in females, but not in males. On the other hand, a lower odds of 
ankylosing spondylitis was found in females with ADHD, while no association in 
males. 
This study aimed to investigate possible associations between ADHD and comorbid 
autoimmune diseases under a causal framework. That is, we aimed to investigate 
possible causal associations, not emphasising clinical implications. However, since 
Paper III is a cross-sectional study, we cannot draw firm conclusions concerning 
causality. Per design, we do not have certain information on the temporal relationship 
between ADHD and comorbid autoimmune diseases. But, as ADHD by definition is a 
neurodevelopmental disorder with onset in (early) childhood, we may assume that the 
autoimmune disorders usually occur after ADHD. When it comes to the 
disorders/diseases included in Paper III, they typically develop later in life than ADHD, 




for the development of autoimmune disease is that stress related to having ADHD may 
be one of the causal factors226.  
Another explanation is that ADHD and the autoimmune disease share common 
underlying causes. In support of common genetic factors, genetic correlations have 
been found between ADHD and some autoimmune diseases (see section 1.4.2)156,157. 
A Swedish study by Li et al. (2019) included information on autoimmune diseases both 
in parents and siblings to individuals with ADHD227. ADHD was associated with 
increased risk of a number of autoimmune diseases in first-degree relatives; psoriasis, 
RA, MS, ulcerative colitis and Crohn’s disease, among others. The authors concluded 
that the associations might be due to common genetic factors. A study by Hegvik et al. 
(2019) using family data from Swedish registries, showed that relatives of persons with 
ADHD (parents, full siblings, aunts, uncles and cousins) had increased odds of several 
autoimmune disorders such as psoriasis and RA (with the exception of RA in uncles)228. 
Thus, it is plausible, that shared genetic factors underlie these associations. Likely, 
however, the aetiology connecting ADHD and its autoimmune comorbid disorders is 
multifactorial, with several mechanisms in action. A further presentation and 
discussion of models on the relationship between comorbid disorders will follow in 
section 5.4.3, focusing on autoimmune diseases as examples.  
We found no associations between ADHD and iridocyclitis, MS, RA, SLE or T1DM, 
regardless of sex. Why some autoimmune disorders are found to be associated with 
ADHD, and others not, is poorly understood. One explanation is methodological 
limitations (see section 5.3.2). Another possibility is that the mechanisms behind the 
comorbid disorders differ. Further, results from studies also differ, some studies have 
for example found ADHD to be associated with T1DM, in contrast to our results131,152. 
A discussion of reasons for such heterogeneity will follow in section 5.4.2. 
Although ADHD and diseases related to the immune system are associated at a group 
level, one cannot make predictions at an individual level. Since the effect sizes are 
small, the findings from paper III corroborate the assumption that ADHD and related 




specific inflammatory processes may contribute to the pathophysiology of ADHD and 
its comorbidities, but the impact is likely to be too small to help individual patients229.  
Sex differences 
The number of studies on sex differences in ADHD and comorbid autoimmune 
diseases is still scarce. In a a large register-based study from Sweden, our findings 
regarding the sex-specific associations in ulcerative colitis, Crohn´s disease and 
ankylosing spondylitis were not replicated228. This study used data from the Swedish 
prescribed drug register and the Swedish National Patient Register, and differences in 
how data are registered in Swedish compared to Norwegian registries may contribute 
to the diverse findings. However, the findings were in line with our results with regards 
to the stronger association between psoriasis and ADHD in females than males, with 
an adjOR 1.65 (1.52-1.79) in females and adjOR =1.38 (1.28-1.49) in males.  
Different factors are discussed as possible contributors to sex differences, both genetic 
and environmental. Interestingly, most autoimmune disease are more common in 
females than males, and X chromosome effects may play a role in this sex pattern 225,230. 
X and Y chromosomes have specific genetic effects, most immune-related genes are 
for example found on the X chromosome161. X and Y chromosomes also exert gonadal 
effects. One example is the higher level of oestrogen in women compared to men. 
Oestrogen may affect the level of thyroid hormone, and also cognitive functioning. 
This may lead to both thyroid disease and difficulties with attention as seen in ADHD 
231. Females do have increased immune reactivity compared to males, which may make 
women more prone to develop autoimmune disease225. Psychosocial stress and stress-
related disorders probably play a role in the exacerbation of autoimmune disease232,233. 
Stressful events related to ADHD may thus lead to increased risk of autoimmune 
diseases, perhaps even more so in females, as men and women tend to react differently 
to stress234. Finally, different behaviours in males and females due to social or cultural 




 Paper IV 
In Paper IV, the aim was to summarise the current knowledge on the associations 
between ADHD and somatic diseases in adults by doing a systematic literature review. 
The associations between adult ADHD and asthma, obesity and sleep disorders were 
based on sound evidence from the literature. 
 Methodological considerations 
A systematic review has several strengths compared to a narrative review. When 
writing a narrative review, the author subjectively selects studies that he/she finds 
relevant. The study inclusion could for instance be based on the size of the study, study 
quality, novel findings and so on. Thus, authors writing a review on the same theme 
may emphasize completely different results235(xii). Although a systematic review is 
designed to be more objective than a narrative review, it will still always have some 
subjective elements, such as deciding on the search strategy and the selection of studies. 
As opposed to a narrative review, the mechanisms behind the decisions of which 
studies to select are, however, transparent235(xxiii).  
In Paper IV, a university librarian with expertise in systematic search assisted in 
developing the search strategy, to ensure the quality of the search. Information on the 
specific search strategy, databases used in the search, language and years of publication 
were all included in Paper IV or it´s Supplementary material. In a systematic review, it 
is practically impossible to locate all the relevant studies on the defined research 
topic235(p.278). We used general search terms such as “disease”, as it would not have 
been practically possible to search specifically for every known existing somatic 
disease. In addition to papers retrieved from the systematic search we also checked 
references, in order to retrieve as many relevant papers as possible. Another concern is 
that overall, papers in English are more likely to be included than other 
languages235(p.279). This is also a limitation in Paper IV, as we restricted the search to 
English language and three major databases due to the broad theme of the paper. This 




as possible, and at the same time restricting the amount of results for practical purposes, 
i.e. to fit into one readable single paper.  
Another specific concern in systematic reviews is publication bias, the fact that studies 
showing significant results are more easily published than those without such results236. 
We were therefore careful to focus studies both on reporting significant associations 
and those who did not (negative/null findings). In our review, cardiovascular disease 
was, for example, not associated with ADHD in adults. We further evaluated the 
quality of the evidence behind the reported associations. In the example of 
cardiovascular disease, we emphasized the lack of studies on this topic, and that more 
research is warranted. We did not a design-based quality checklist or rating tools to 
assess the quality of the different studies, which is a limitation of our review. However, 
we described main characteristics of all selected papers in a detailed table providing an 
overview of the strengths and limitations of study designs in each paper. 
To sum up the findings, we grouped the included studies/diseases into 3 categories. 
The first category included somatic comorbid diseases investigated in several papers, 
including systematic reviews or meta-analyses, thus diseases where an association with 
adult ADHD was based on sound evidence from the literature. We placed obesity, sleep 
disorders and asthma in this group. Among these, asthma was the least studied, with 7 
studies, versus 22 studies on obesity and 25 studies on sleep disorders.  
The second category included studies which were either case-control or cohort studies, 
or where the diagnoses were not only based on self-report questionnaires. Migraine 
was placed in this category 2. Only two studies described its association with adult 
ADHD, and these were both Norwegian237,238. Although both studies had good study 
designs and showed significant associations with ORs around ~2, the tentative 
association between adult ADHD and migraine was based solely on these two studies, 
so information was very limited.  
The third category included studies where ADHD and/or the somatic comorbidities 
were poorly defined, i.e. based on self-questionnaires only, or where the evidence was 




conflicting between the studies, or were important information such as age distribution 
or diagnostic protocols lacked, where also placed in this category. One example is RA, 
where one study was included, a case control study with a small sample of adults with 
ADHD (n=23) and controls (n=208) which found no association between RA and 
ADHD239. The result from this single study is not sufficient to conclude that ADHD 
and RA are not associated. 
 Discussion of findings 
The literature on ADHD and comorbid conditions is vast and has expanded extensively 
since Paper IV was written. It is outside the scope of this thesis to give an updated 
literature review on all the conditions described in Paper IV. However, in the next 
section, I will present an updated systematic literature review on the possible 
association between ADHD and psoriasis, and then discuss the findings. I have chosen 
psoriasis, as this is one of the diseases investigated in Paper III. Further, the 
heterogeneity of findings in the literature on ADHD and comorbid somatic disease will 
be discussed, and models on the relations between ADHD and comorbid disorders 
presented.     
Psoriasis as an example of comorbid autoimmune disease in ADHD 
Psoriasis is a skin disease characterised by itchy, red and scaly skin lesions, also often 
affecting nails and joints. Although the aetiology behind the disease is unclear, it is 
currently understood as an autoimmune disease240. The prevalence in Europe is about 
2-4%, affecting both sexes at an equal rate, with increased frequency by age241.  
A systematic literature search was performed in December 2019 on the topic ADHD 
and comorbid psoriasis (Appendix IV). The search retrieved six eligible papers, in 
addition to data from an unpublished papers, published as a manuscript in a thesis228 
(Appendix V). Main study characteristics and results are listed in Table 4.  
The included studies showed mixed results. Two studies found a clear association 
between ADHD and psoriasis; Paper III (adjOR=1.41(1.34-1.47)) and the Swedish 
study using register data (adjOR=1.48 (1.40−1.57))228. Moreover, these two studies 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































data showed a significantly higher OR in females than in males, with adjOR=1.57 
(1.46-1.68) and adjOR=1.31 (1.23-1.40), respectively. The Swedish study showed the 
same pattern, with adjOR=1.65 (1.52-1.79) for females and adjOR =1.38 (1.28-1.49) 
for males. Four of the studies found no significant association between ADHD and 
psoriasis139,152,242,243. In a Turkish case-control by Kiri et al, children with psoriasis (n= 
54) and healthy controls (n=54) were recruited from a dermatological department at a 
Turkish hospital243. The details on the recruitment of the control group were sparse, 
making it difficult to evaluate the risk of selection bias, and the results only showed 
crude associations. Also, in the study by Radtke et al, using German insurance data, 
there were no adjustments for covariates. Thus, the impact of important covariates such 
as sex and age is not known. In addition, ADHD was defined by using the results from 
a questionnaire, without any clinical assessment242. The Swedish twin study by Alabaf 
et al. only included two individuals with both ADHD and psoriasis. Further, the 
prevalence of psoriasis was only 0.3%, most likely due to the young age of the 
participants. Hence, many of the participants were too young to have developed 
psoriasis and the association between ADHD and psoriasis might have been 
underestimated139. The same mechanism may also apply for the Danish population-
based register study by Nielsen et al. This study showed, although not statistically 
significant, an adjusted incidence rate ratio of 1.39 (95% CI 0.85-2.11), implying a 
possible association between ADHD and psoriasis152. Interestingly, this study also 
showed an increased risk of ADHD in children of mothers with psoriasis. The final 
study retrieved in the search was a study by Ahn et al. using Korean insurance data244. 
The exposures were different skin disorders with ADHD as outcome; no control group 
was included. The study showed no significantly increased risk of ADHD prevalence 
among patients with psoriasis compared to those with atopic dermatitis (AD). To 
conclude, based on the current evidence emphasising the results from the studies with 





Heterogeneity of findings on ADHD and somatic disease 
As seen in the example of psoriasis, the results between the studies were diverging. 
Some studies found an association between ADHD and psoriasis, others not. Such 
contrasting results have also been found for other diseases such as T1DM, autoimmune 
thyroiditis, RA and MS152,155,228,245. Other diseases, such as SLE and iridocyclitis, have 
not shown any association with ADHD152,155,245.  
ADHD has been reported to be associated with migraine, but not with tension headache 
142,143. One study also found migraine to be significantly more common in mothers to 
children with ADHD compared to mothers whose children did not have ADHD142. The 
fact that the pathophysiology of these two kinds of headaches is believed to differ246, 
corroborates the hypothesis of a common aetiology between ADHD and migraine, but 
not between ADHD and tension headache. Individuals with ADHD are more in contact 
with health services and thus probably more prone to be diagnosed with headache 
relative to people without other chronic conditions. However, the differences in in 
health seeking behaviour would not explain the differences in associations found for 
tension headache and migraine.  
The reasons for the conflicting results are not known, but could partly be explained by 
methodological differences between studies. Some studies do not control, or 
inadequately control, for possible confounding factors, as discussed above. Further, 
ADHD or the comorbid somatic disease may be poorly defined, for example screening 
questionnaires are considered to be less valid than an extensive clinical evaluation. 
Moreover, the samples could be non-representative. One example is the study by 
Nielsen et al., where the oldest participants were only 30 years old152. As autoimmune 
diseases usually develop later in life, this could lead to underrepresentation of cases 
with lifetime psoriasis. Finally, although following the same diagnostic criteria, various 
countries have different traditions regarding how ADHD is diagnosed. In Norway, 
ADHD is diagnosed in secondary health care by medical doctors specializing in 
clinically relevant fields, psychiatrists, psychologists or paediatricians. This as opposed 




or general health physicians247. Thus, symptoms may be emphasized differently, 
leading to diverse diagnostic practice and heterogeneity of the findings. 
 Models on the relations between ADHD and comorbid 
disorders 
Several models of the mechanisms behind the association between ADHD and its 
comorbid disorders have been proposed: 
1) The disorders co-occur by chance; no aetiological relationship between them115. 
 
2) The association between the disorders can be explained by a common cause or 
common risk factor120. During the last years, the influence of genes as common factors 
explaining comorbidity has been emphasised. The same set of genes have been found 
to influence a variety of neuropsychiatric disorders, including ADHD248. Moreover, it 
is likely that a subgroup of genes coding for obesity also increases the risk of ADHD141. 
In a large, population-based study from the U.S. by Wang et al., significant genetic 
correlations were found between ADHD and psoriasis, migraine and inflammatory 
bowel disease. No common, persisting environmental associations were found between 
these conditions249. This is in line with two genome-wide association studies, finding 
significant genetic correlations between ADHD and MDD, psoriasis, RA, insomnia 
and obesity, among others156,157. 
 
3) One disorder or the treatment of this disorder directly causes another disorder. This 
model is called the direct causal model250. One example is stimulant treatment for 
ADHD causing hypertension251. 
 
4) Disorders are not really distinct disorders, but only reflect different aspects of the 
same syndrome252. This can be true for specific syndromes caused by chromosomal 
aberrations such as trisomy 21 and fragile X syndrome253. One can here argue that the 
ADHD diagnosis is a part of the syndrome itself, and not a distinct disorder.  
 




relation between AD and ADHD. Itching, a symptom of AD, often leads to disturbance 
of sleep226. Such disturbance may result in disruptive and hyperactive behaviour, poor 
memory and lack of concentration226,254,255. AD usually occurs prior to 3 years of age, 
before the full clinical picture of ADHD has developed226,256. Thus, it has been 
hypothesised that AD may cause ADHD symptoms, so-called “AD-induced 
ADHD”226. It can also be the other way around, emotional and psychosocial stress 
related to having ADHD may be an exacerbating or underlying cause of AD (“ADHD-
induced AD”)226. 
 
6) There is no real comorbidity, meaning that the validity of one of the diagnoses could 
be questioned. For example, that ADHD symptoms are better explained by symptoms 
of another condition, such as sleep disorders257. To use the example of AD, sleep 
disturbances which are related to AD leads to symptoms of ADHD, but not ADHD per 
se. Another example is hypothyroidism, which can cause symptoms mimicking ADHD 
symptoms such as reduced attention and memory258.  
The clinician must consider whether the symptoms of the comorbid disorder could 
explain the ADHD symptoms. Both NICE and Norwegian ADHD guidelines 
emphasize that symptoms of disorders which may mimic ADHD must be considered 
when diagnosing ADHD13,259(p.25). However, if the individual also fulfil the criteria for 
the ADHD diagnosis, it is important to acknowledge this diagnosis to be able to offer 






- Specific personality dimensions such as Novelty Seeking, Harm Avoidance and 
Reward Dependence were highly associated with ADHD. The associations with 
Novelty Seeking and Harm Avoidance were partly dependent on ASPD and 
anxiety/depression, respectively. 
 
- Some maternal immune related diseases such as asthma, MS and RA are shown 
to be associated with ADHD in the offspring. 
 
- Compared to the general population, persons with ADHD have a higher 
prevalence of certain autoimmune diseases, such as psoriasis, asthma, ulcerative 
colitis and Crohn’s disease.       
 
- Sex is shown to significantly modify the association between ADHD and some 
autoimmune diseases. The risk of ulcerative colitis and Crohn’s disease is higher 
in females than males with ADHD. 
 
- Adults with ADHD are at higher risk than adults in the general population of 
suffering from a range of somatic diseases. The best documented comorbid 
diseases are obesity, asthma and sleep disorders such as insomnia. 
 
- Information on personality traits, underlying risk factors and comorbid 
psychiatric and somatic diseases may be useful to improve the understanding of 
the individual ADHD patient, to provide the best treatment, and to inform 











7. Future Perspectives 
The results from this thesis underscore the importance of a comprehensive approach 
when assessing and treating individuals with ADHD. There is a need to go beyond the 
classic symptom domains of ADHD and also pay attention to its associated personality 
traits and comorbid disorders and diseases. Thus, ADHD can be considered as extreme 
dimensions of normal conduct261, occurring along a spectrum of clinical 
presentations262. Altogether, the results of Paper I show that awareness about the role 
of personality traits in ADHD and common psychiatric comorbid disorders should be 
subject to further studies, as such knowledge is useful not only when treating the 
individual ADHD patients, but also to improve our understanding of underlying 
pathophysiology behind this condition and make assumptions on causality.    
The results of Paper II and III underscore the relation between inflammatory and 
immune system diseases and ADHD, both as prenatal risk factors and comorbid 
diseases. However, caution is needed when interpreting associations found in 
epidemiological observational studies and clinical studies, as association does not 
necessarily mean causation. Using different approaches to assess the same underlying 
causal question is helpful to gain deeper insight into possible causal effects. These 
approaches should ideally have different potential biases. Integration of such research 
findings is known as triangulation. If different study designs and type of results lead to 
the same conclusion, the confidence in a finding is strengthened263. In addition to 
independent replication of results from previous studies, triangulation can be a 
powerful tool to advance from associative to causative relationships. In the ADHD 
research field, a recent example of triangulation is found in the large population-based 
study by Solberg et al264. Based on Norwegian registry data, the adjusted prevalence 
ratio of substance use disorder in adults with ADHD compared to the remaining adult 
population was 6.2 (6.1-6.4). In addition, genetic correlations were calculated showing 
significant genetic correlations between ADHD and proxies of substance use disorder. 
Thus, genetic correlations corroborated the results from the investigation based on 
registry data. Ideally, the investigations from the Papers in this thesis should be 




Special attention should be given to investigate the possibility of grouping ADHD 
patients based on specific comorbidity patterns. Such patterns could be comprised of 
certain personality traits, particular psychiatric or somatic disorders/diseases, and also 
include lifespan symptom profile and sex125. These subgroups may potentially have 
their specific aetiology, modifying risk factors as well as different outcomes114. On the 
other hand, all persons with ADHD have their own individual symptom expression and 
specific biological profile. To increase the understanding of the aetiology behind 
ADHD, one approach is to study characteristics of ADHD and its comorbidities not 
only at group level, but also at individual level265. Longitudinal studies are strongly 
warranted, as such studies may identify specific lifetime trajectories both individually 
and across generations3. Information from other family members is of great value, 
making it possible to apply different family-designs, like twin, - sibling,-, half,-sibling 
and cousins comparisons. Such approaches are useful to detect genetic and 
environmental risk factors, both within families and across generations.  
In my work, findings from Paper III and IV show to which extent individuals with 
ADHD are more prone to develop some somatic comorbidities compared to the general 
population. In my opinion, the importance of comorbidities in ADHD, especially 
somatic comorbidities, has not yet been fully appreciated, neither in research nor in 
clinical practice. The work in this thesis is a contribution to focus on these essential 
issues. 
When assessing comorbidity, it is most common to focus on a single index disorder 
and how other disorders/diseases are related to this disorder. A different approach is to 
investigate the causes or consequences of multiple conditions at even terms, without 
giving any condition priority over the others122. Knowledge on the total morbidity 
burden is important to broaden the perspective from a narrow focus on single diseases 
to the overall health of each patient266. In this context, it is also natural to consider the 
impact of both psychiatric and somatic conditions as a whole. As Are Brean, a 
Norwegian neurologist (2015) stated: “We are not a mind and a body, but both, 
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Appendix I. Diagnostic criteria according to DSM-5.  
 
Attention-Deficit/Hyperactivity Disorder (ADHD) 314.0X   
 
A.  A persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with 
functioning or development, as characterized by (1) and/or (2): 
 
 1.  Inattention: Six (or more) of the following symptoms have persisted for at least 6 months to a 
degree that is inconsistent with developmental level and that negatively impacts directly on social 
and academic/occupational activities: 
a. Often fails to give close attention to details or makes careless mistakes in schoolwork, at work, 
or during other activities. 
b. Often has difficulty sustaining attention in tasks or play.  
c. Often does not seem to listen when spoken to.  
d. Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in 
the workplace.  
e. Often has difficulty organizing tasks and activities. 
f. Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort.  
g. Often loses things necessary for tasks or activities. 
h. Is often easily distracted by extraneous stimuli.  
i. Is often forgetful in daily activities. 
 2.  Hyperactivity and impulsivity: Six (or more) of the following symptoms have persisted for at 
least 6 months to a degree that is inconsistent with developmental level and that negatively impacts 
directly on social and academic/occupational activities: 
a. Often fidgets with or taps hands or feet or squirms in seat.  
b. Often leaves seat in situations when remaining seated is expected. 
c. Often runs about or climbs in situations where it is inappropriate. (Note: In adolescents or 
adults, may be limited to feeling restless). 
d. Often unable to play or engage in leisure activities quietly.  
e. Is often “on the go,” acting as if “driven by a motor”. 
f. Often talks excessively.  
g. Often blurts out an answer before a question has been completed.  
h. Often has difficulty waiting his or her turn. 




Note: The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or 
a failure to understand tasks or instructions. For older adolescents and adults (≥ 17), at least five 
symptoms are required. 
B.  Several inattentive or hyperactive-impulsive symptoms were present prior to age 12 years. 
C.  Several inattentive or hyperactive-impulsive symptoms are present in two or more settings 
(e.g., at home, school, or work; with friends or relatives; in other activities). 
D.  There is clear evidence that the symptoms interfere with, or reduce the quality of, social, 
academic, or occupational functioning. 
E.  The symptoms do not occur exclusively during the course of schizophrenia or another 
psychotic disorder and are not better explained by another mental disorder (e.g., mood disorder, 
anxiety disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal). 
Specify whether:  
314.01 Combined presentation: If both Criterion A1 (inattention) and Criterion A2 (hyperactivity-
impulsivity) are met for the past 6 months.  
314.00 Predominantly inattentive presentation: If Criterion A1 (inattention) is met but Criterion 
A2 (hyperactivity-impulsivity) is not met for the past 6 months. 
314.01 Predominantly hyperactive/impulsive presentation: If Criterion A2 (hyperactivity and 
impulsivity) is met but Criterion A1 (inattention) is not met over the past 6 months. 
 
 
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth 































































Appendix II. Examples of TCI items : 
Novelty Seeking:  
“It is difficult for me to keep the same interests for a long time because my attention 
often shifts to something else.”  
“I lose my temper more quickly than most people.”  
“I often follow my instincts, hunches, or intuition without thinking through all the 
details.” 
“I like it when people can do whatever they want without strict rules and 
regulations”. 
Harm Avoidance:  
“I need much extra rest‚ support‚ or reassurance to recover from minor illnesses or 
stress”. 
“I often feel tense and worried in unfamiliar situations‚ even when I others feel there 
is little to worry about”.  
“I usually stay away from social situations where I would have to meet strangers even 
if I am assured that they will be friendly”.  
Reward Dependence:  
“I would like to have warm and close friends with me most of the time”. 
“ I usually do things my own way - rather than giving in to the wishes of other 
people”.  




































































































































































Appendix IV. SEARCH STRATEGY ADHD OG PSORIASIS 
 
Pubmed (December 11, 2019). – 17 studies.  
((attention deficit disorder [TW]) OR (adhd [TW]) OR (addh [TW]) OR (hyperkinetic 
disorder [TW]) OR (attention deficit hyperactivity disorder [TW])) AND ((Psoriatic* [TW])  
OR (psorias* [TW])) 
Embase (December 11, 2019) – 95 studies 
1 (ADHD or attention deficit* or hyperactivity disorder* or hyperactive child 
syndrome or childhood hyperkinetic syndrome or addh or overactive child syndrome 
or (attent* adj3 (disorder* or hyperactiv* or hyper?activ* or adhd or addh or ad??hd)) 
or ((hyperkin* or hyper?kin*) adj3 (disorder* or syndrome* or hkd))).mp. 
2 psoriasis.mp. 
3 psoriatic*.mp. 
4 2 OR 3 
5 1 AND 4 
6 Limit 5 to human 
7 Limit 6 to conference abstract 
8 6 NOT 7 
9 Limit 8 to (books or chapter or "conference review") 
10 8 NOT 9 
11 Limit 10 to clinical trial 
12 10 NOT 11  
Psychinfo (December 11, 2019) – 8 studies 
1 (ADHD or attention deficit* or hyperactivity disorder* or hyperactive child 
syndrome or childhood hyperkinetic syndrome or addh or overactive child syndrome 
or (attent* adj3 (disorder* or hyperactiv* or hyper?activ* or adhd or addh or ad??hd)) 
or ((hyperkin* or hyper?kin*) adj3 (disorder* or syndrome* or hkd))).mp. 
2 psoria*.mp. 
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ADHD is a neurodevelopmental disorder characterized by 
symptoms of hyperactivity, impulsivity, and inattention. 
According to the Diagnostic and Statistical Manual of 
Mental Disorders (4th ed., text rev.; DSM-IV-TR; American 
Psychiatric Association [APA], 2000), ADHD is divided 
into three subgroups: the predominantly inattentive, the 
predominantly hyperactive/impulsive, and the combined 
type (APA, 2000). Adults with ADHD are a heterogeneous 
group showing high comorbidity with other psychiatric dis-
orders like anxiety disorders, mood disorders, substance use 
disorders, and personality disorders (Downey, Stelson, 
Pomerleau, & Giordani, 1997; Kessler et al., 2006).
ADHD has also been associated with specific personal-
ity traits. The Temperament and Character Inventory (TCI) 
by C. R. Cloninger (Cloninger, Svrakic, & Przybeck, 1993) 
describes a person’s temperament and character using seven 
different dimensions. The four temperament dimensions 
Harm avoidance, Novelty seeking, Reward dependence, 
and Persistence are according to Cloninger’s model moder-
ately heritable and stable throughout life (Klein et al., 
2012). The three character dimensions Self-directedness, 
Cooperativeness, and Self-transcendence are more influ-
enced by social learning and develop throughout life.
Studies have shown an association between adult 
ADHD and these dimensions, and adults with ADHD have 
consistently been found to have high scores on Novelty 
seeking (Anckarsater et al., 2006; Downey, Pomerleau, & 
Pomerleau, 1996; Downey et al., 1997; Faraone, Kunwar, 
Adamson, & Biederman, 2009; Gomez, Woodworth, Waugh, 
& Corr, 2012; Jacob et al., 2007; Lynn et al., 2005; Sizoo, 
van den Brink, Gorissen van Eenige, & van der Gaag, 
2009; Smalley et al., 2009). This is to be expected, as peo-
ple with high Novelty seeking tend to be impulsive, quick-
tempered, easily bored, and behaving disorderly (Cloninger, 
Przybeck, Svaric, & Wetzel, 1994), all of which are symp-
toms common in ADHD. An association between high 
Harm avoidance and adult ADHD has also been found 
(Anckarsater et al., 2006; Downey et al., 1996; Downey 
et al., 1997; Faraone et al., 2009; Gomez et al., 2012; Jacob 
et al., 2007; Sizoo et al., 2009). Individuals with high Harm 
avoidance are portrayed to be cautious, careful, nervous, 
and negativistic (Cloninger et al., 1994). However, Smalley 
et al. (2009) reported no association of Harm avoidance 
with ADHD (Smalley et al., 2009). Thus, the findings 
regarding Harm avoidance and ADHD are less consistent 
than for Novelty seeking, and also less intuitive, as the 
characteristics of Harm avoidance are very different from 
the core symptoms of ADHD.
Furthermore, a few studies have shown an association 
between adult ADHD and low scores on the dimensions 
Persistence (Faraone et al., 2009), Reward dependence 
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(Anckarsater et al., 2006; Faraone et al., 2009; Gomez et al., 
2012; Jacob et al., 2007), Self-directedness (Anckarsater 
et al., 2006; Gomez et al., 2012; Sizoo et al., 2009; Smalley 
et al., 2009), and Cooperativeness (Anckarsater et al., 2006; 
Faraone et al., 2009; Gomez et al., 2012; Sizoo et al., 2009). 
A high score on Self-transcendence has been shown in 
adults with ADHD (Faraone et al., 2009; Lynn et al., 2005; 
Sizoo et al., 2009; Smalley et al., 2009).
However, most previous studies have not controlled 
for psychiatric comorbidity. Depression and anxiety dis-
orders are associated with high Harm avoidance (Celikel 
et al., 2009; Cloninger et al., 1994; Cloninger, Zohar, 
Hirschmann, & Dahan, 2012), and it has been discussed 
whether the high scores on Harm avoidance in adults with 
ADHD may be due to the comorbidy with anxiety or 
depressive disorders (Cho et al., 2008; Downey et al., 
1996). According to Downey et al. (1997), ADHD 
patients with concurrent axis 1 psychopathology had 
higher scores on Harm avoidance than ADHD patients 
without such psychopathology. However, Faraone et al. 
(2009) adjusted for comorbidity and concluded that the 
group differences they observed were not accounted for 
by anxiety disorders and depression.
The relationship between the TCI dimensions and the 
different subtypes of ADHD has also been examined. On a 
dimensional and symptomatic level, high Harm avoidance 
has been associated with inattention and high Novelty seek-
ing with hyperactivity/impulsivity (Gomez et al., 2012; 
Muller et al., 2010; Salgado et al., 2009). Interestingly, in a 
recent twin study, Novelty seeking was genetically associ-
ated with inattention and hyperactivity/impulsivity, and 
Harm avoidance with inattention symptoms alone 
(Merwood, Asherson, & Larsson, 2012).
ADHD has been associated with different personality 
disorders, in particular borderline and antisocial personal-
ity disorder (ASPD; Kooij et al., 2012; Sobanski, 2006). 
However, other Clusters B and C personality disorders like 
narcissistic and avoidant personality disorders are also 
reported to be more common in adults with ADHD 
(Cumyn, French, & Hechtman, 2009; Matthies et al., 2011; 
Miller et al., 2008). In general, the TCI dimensions low 
Self-directedness and in particular low Cooperativeness 
indicate a personality disorder (Richter & Brandstrom, 
2009). ASPD has, similarly to ADHD, in some studies 
been related to high scores of Novelty seeking (Basoglu 
et al., 2011), high scores of Harm avoidance (Basoglu 
et al., 2011; Svrakic, Whitehead, Przybeck, & Cloninger, 
1993), and low scores of Self-directedness (Basoglu et al., 
2011). To our knowledge, the impact of comorbid ASPD 
on the TCI dimensions in adult ADHD patients has not 
been studied.
The aims of this study were to examine personality traits 
using the TCI in adult ADHD patients compared with a 
control group and to investigate the impact of common 
comorbid psychiatric disorders on these personality mea-
sures. We hypothesized that comorbid anxiety or mood dis-
order could account for high scores of Harm avoidance and 




This study is a part of a long-term project at the University 
of Bergen that includes almost 800 adult ADHD patients 
(>18 years) who have been diagnosed at outpatient clinics 
or hospitals in Norway, and a population-derived control 
group. The recruitment procedure has been described in 
detail in former publications (Halleland, Lundervold, 
Halmoy, Haavik, & Johansson, 2009; Halmoy, Fasmer, 
Gillberg, & Haavik, 2009; Halmoy et al., 2010; Johansson 
et al., 2008). Our aim was to study a representative sample 
of ADHD patients as they are naturally encountered in clin-
ical practice. Thus, the patients were not rediagnosed after 
inclusion and there were no exclusion criteria. All partici-
pants completed questionnaires concerning past and current 
ADHD symptoms, comorbid psychiatric disorders, and 
substance abuse. There was no specific information regard-
ing ADHD subtype, as the different subtypes are not spe-
cifically coded in the diagnostic manual formally used in 
Norway; the International statistical classification of dis-
eases and related health problems 10th revision (ICD-10; 
World Health Organization, 2008).
In this study, a subsample of 66 patients and 69 controls 
living in and nearby Bergen were subjected to further clini-
cal assessments. Most of the controls were randomly 
selected from the database of the Medical Birth Registry of 
Norway (n = 53), and the remaining were students from the 
University of Bergen (n = 13), friends of the patients (n = 
2), or recruited through advertisement at the local hospital 
(n = 1). The controls were not screened for ADHD before 
inclusion. However, after the clinical assessment two con-
trols were excluded because they had symptoms consistent 
with persistent ADHD.
Comorbidity was assessed with the Mini International 
Neuropsychiatric Interview Plus (M.I.N.I. Plus) and per-
sonality traits by the TCI. The interviews were carried out 
between 2005 and 2011 by two clinical psychiatrists and 
two MDs specializing in psychiatry. The interviewers were 
blinded regarding ADHD diagnosis.
In addition to the psychiatric interview, the participants 
were also subjected to neuropsychological testing (Halleland, 
Haavik, & Lundervold, 2012). Neuropsychological data 
showed that two patients had an IQ below 80. None of the 
participants had mental retardation, that is, IQ below 70 
(Widiger & Costa, 2012).
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Measures
All participants completed a Norwegian version of the 
Adult ADHD Self-Report Scale (ASRS) as described by 
Kessler in 2005 (Kessler et al., 2005). The ASRS consists of 
18 items where the first nine items address symptoms of 
inattention and the last nine items symptoms of hyperactiv-
ity and impulsivity. Using the Diagnostic and Statistical 
Manual of Mental Disorders (APA, 2000) criteria adapted 
to adults, it is designed to measure ADHD symptoms dur-
ing the last 6 months on a 5-point Likert-type item scale 
(0 = never/seldom and 4 = very often), giving a maximal 
score of 72 points. We used the ASRS to define subtypes of 
ADHD categorically. The inattentive subtype was defined 
as having a score of 21 or more on the first nine items 
(Part 1), the hyperactive/impulsive subtype as having a 
score of 21 or more on the last nine items (Part 2), and the 
combined subtype having a score of 21 on both parts.
The TCI is a self-administered paper-and-pencil ques-
tionnaire. The participants completed a Norwegian transla-
tion of the TCI version 9 that includes 240 items with a 
true–false response format (Cloninger et al., 1994).
The M.I.N.I. Plus (Mini International Neuropsychiatric 
Interview Plus version 5.0.0; Sheehan et al., 1998) is a 
structured interview for the major axis 1 psychiatric disor-
ders in DSM-IV and ICD-10. It also includes modules for 
ADHD and ASPD.
The M.I.N.I Plus, the ASRS, and the TCI have not yet 
been formally validated in Norwegian adults, but are cur-
rently being used in clinical practice and research 
(Bjørnebekk, Westlye, Fjell, Grydeland, & Walhovd, 2012; 
Halmoy et al., 2009; Westlye, Bjørnebekk, Grydeland, 
Fjell, & Walhovd, 2011).
Statistical Analyses
All analyses were carried out with PASW Statistics 18. 
Participants with 12 or more missing items on the total TCI 
were excluded from the study. A TCI dimension was omit-
ted from the analysis if one or more items were missing in 
that dimension. Thus, the number of participants for each 
dimension varies slightly.
The data were first analyzed using descriptive methods. 
Independent-sample t tests were used for the comparisons 
of the TCI dimensions between the ADHD and control 
groups, and Regression Analyses were performed to adjust 
for comorbid disorders. We reported the difference to be 
significant at the Bonferroni-corrected level of .002 (i.e., 
corrected for 21 comparisons).
Ethics
Written consent was obtained from the participants when 
joining the study and at the time of the interview. The 
ADHD study has been approved by the Regional Committee 
for medical and health research ethics of Western Norway 
(IRB #3, FWA00009490, IRB00001872).
Results
Clinical Characteristics
Three patients and one control were omitted from the analy-
ses due to 12 or more missing items on the 240-item TCI 
questionnaire. The demographic variables or ASRS scores 
of the excluded patients did not differ from the rest of the 
sample (data not shown). In Table 1, demographic and clin-
ical characteristics including comorbid disorders of the 
included participants are presented. The mean age at the 
time of the interview was 34.4 ± 9.3 years in the patient 
group (n = 63), compared with 28.3 ± 6.3 years for the con-
trols (n = 68). Although the difference in age distribution 
between the groups was significant, adjusting for age gave 
no significant change in the primary analyses, and age was 
therefore not included as a variable for further analyses. 
There was no significant difference in the sex distribution 
between the patient and control group (54.0% women in the 
ADHD group vs. 57.4% in the control group). Thus, gender 
was also omitted from further analysis. The most common 
comorbidities among the participants with ADHD were 
major depressive disorder in the past (74.6%) and lifetime 
ASPD (40.3%; Table 1).
Of the participants diagnosed with adult ADHD 12.7% 
had been officially diagnosed with ADHD during child-
hood and 60% used ADHD medication, of whom 84% used 
methylphenidate only.
TCI Measures
As shown in Table 2, the patient group had significant 
higher scores on Harm avoidance (Figure 1), Novelty seek-
ing (Figure 2), and Self-transcendence, and significant 
lower scores on Reward dependence, Self-directedness, and 
Cooperativeness compared with the control group. There 
was no significant difference in the Persistence dimension 
between the groups.
The participants with ASPD (25 patients and 1 control) 
showed as a group significantly higher Novelty seeking and 
Self-transcendence and lower Cooperativeness compared 
with participants without ASPD. Participants with anxiety 
disorders and/or mood disorders (52 patients and 17 con-
trols) had significantly higher Novelty seeking, Harm 
avoidance and Self-transcendence, and lower 
Self-directedness.
Significantly higher scores on Novelty seeking and Self-
transcendence also correlated with current or past alcohol 
abuse or dependence, current or past substance dependence 
and current substance abuse. Persons with current alcohol 
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abuse and dependence reported significantly lower scores 
on Cooperativeness.
The sample sizes for each of the types of anxiety and 
depressive disorders were small, making it difficult to 
compare them with one another. Thus, current and life-
time panic disorder, with or without agoraphobia, gener-
alized anxiety disorder and major depressive disorder 
were merged into a single category, termed lifetime 
anxiety and/or depressive disorder. The mean Harm 
avoidance scores for adults with ADHD and controls 
were 16.9 ± 8.0 and 13.7 ± 5.2, respectively. When con-
trolling for lifetime anxiety and/or depression, the asso-
ciation between high Harm avoidance and ADHD was no 
longer significant (Table 3). Thus, the high Harm avoid-
ance score in the ADHD group was explained by the high 
rate of comorbid anxiety and depressive disorders. The 
association with low Reward dependence for ADHD 
remained significant, whereas ADHD was no longer 
Table 1. Demographic and Clinical Characteristics of ADHD Patients and Controls.
Control group ADHD group
 % n/total n % n/total n
Number (total) 68 63
Sex (women) 57.4 39/68 54.0 34/63
Age (in years) 28.3a ±6.3b 34.4a ±9.3b
Major depressive episode, current 2.9 2/68 16.1 10/62
Major depressive episode, past 23.5 16/68 74.6 47/63
Anxiety disorder, currentc 2.9 2/68 27.0 17/63
Anxiety disorder, pastd 10.3 7/68 31.7 19/60
Anxiety disorder and/or depression, lifetimee 25.0 17/68 82.5 52/63
Antisocial personality disorder, lifetime 1.5 1/66 40.3 25/62
Alcohol abuse or dependence, current 4.4 3/68 6.5 4/62
Alcohol abuse or dependence, lifetime 9.1 6/66 32.8 20/61
Nonalcohol substance abuse or dependence, current 1.5 1/68 4.8 3/62
Nonalcohol substance dependence, lifetime 3.1 4/68 32.3 20/62
aMean.
bStandard deviation.
cCurrent panic disorder with or without agoraphobia and current generalized anxiety disorder are merged into one category called “anxiety disorder, 
current.”
dGeneralized anxiety disorder and panic disorder, with or without agoraphobia, in the past, are merged into one category called “anxiety disorder, 
past.”
eCurrent and/or past anxiety disorder and/or major depressive episode.
Table 2. Temperament and Character Inventory Scores (Mean and t Tests) for Participants With ADHD, Antisocial Personality 
Disorder (ASPD), and Anxiety/Depression.b
ADHD ASPDa Anxiety/depressiona,b


















Harm avoidance 13.7 (5.2) 66 16.9 (8.0)* 57 15.0 (6.6) 97 16.3 (7.9) 24 12.2 (5.1) 58 17.9 (7.1)** 65
Novelty seeking 19.3 (6.1) 65 25.3 (6.4)** 56 20.7 (6.1) 97 28.8 (5.9)** 22 19.0 (6.1) 58 24.8 (6.5)** 63
Reward dependence 16.9 (3.6) 61 14.1 (3.8)** 56 15.8 (4.0) 93 14.6 (3.5) 23 15.8 (3.7) 55 15.3 (4.1) 62
Persistence 4.3 (1.9) 67 4.8 (1.9) 62 4.5 (1.8) 102 4.6 (2.1) 25 4.5 (1.9) 61 4.6 (1.9) 68
Self-directedness 34.8 (6.3) 59 26.7 (8.7)** 53 32.1 (7.9) 90 25.5 (9.6)* 20 35.0 (5.5) 54 27.3 (9.2)** 58
Cooperativeness 34.0 (4.9) 61 31.6 (5.9)* 51 33.8 (4.6) 88 29.5 (7.4)* 22 33.4 (5.2) 56 32.4 (5.8) 56
Self-transcendence 7.7 (5.1) 65 11.9 (6.1)** 53 8.6 (5.6) 95 14.2 (5.5)* 21 7.8 (5.1) 57 11.2 (6.2)* 61
Note. t tests: ADHD vs. control group, ASPD+ vs. ASPD÷, and anxiety/depression+ vs. anxiety/depression÷. “÷” = not fulfilling diagnostic criteria; “+” 
= fulfilling diagnostic criteria.
aIncludes ADHD patients and controls.
bLifetime anxiety disorder (generalized anxiety disorder and panic disorder, with or without agoraphobia) and/or lifetime major depressive disorder.
*p < .05. **p < .0005.
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associated with high Novelty seeking, high Self-
transcendence, low Self-directedness, and low Coop-
erativeness after controlling for comorbidity. Participants 
with ASPD showed significantly higher Novelty seeking 
compared with those without, also when taking comorbid-
ity into account (p < .001).
When adjusting for the effect of alcohol and substance 
use disorders, the results were essentially the same as when 
controlling for ASPD (results not shown).
We did not have any baseline information regarding 
ADHD subtype. As referred to in the “Method” section, 
using the ASRS score we divided the adult ADHD group 
into three subtypes; inattentive (n = 13), hyperactive/impul-
sive (n = 2), and combined (n = 41). Due to the small sam-
ple size, the hyperactive/impulsive group was omitted from 
further analysis. Analyses by subtypes did not change the 
results.
Discussion
In accordance with previous findings, we found that the 
ADHD group had significantly higher Novelty seeking 
and Harm avoidance compared with the control group 
(Anckarsater et al., 2006; Downey et al., 1996; Downey 
et al., 1997; Faraone et al., 2009; Gomez et al., 2012; 
Jacob et al., 2007; Lynn et al., 2005; Sizoo et al., 2009; 
Smalley et al., 2009; Svrakic et al., 1993). However, 
when adjusting for lifetime anxiety and/or depressive dis-
order, the difference in Harm avoidance was no longer 
significant. The difference in Novelty seeking was corre-
lated with ASPD and lifetime anxiety/depression, with 
ASPD having the greatest impact. The adult ADHD group 
was still associated to low scores in Self-directedness 
adjusting for these comorbid conditions.
People with high scores on Harm avoidance tend to be 
fearful, nervous, tense, and negativistic, traits that are 
closely related to anxiety and depression. In our study, 
16.1% of the adults with ADHD filled the criteria for cur-
rent major depressive disorder and 27% for current anxiety 
disorder, as opposed to 2.9% for both disorders, respec-
tively, in the control group. Ongoing depression has shown 
to correlate to some extent with high scores on Harm avoid-
ance (Joffe, Bagby, Levitt, Regan, & Parker, 1993; Nery 
et al., 2009; Svrakic, Przybeck, & Cloninger, 1992), and 
Cloninger has suggested that current level of the partici-
pants’ mood and anxiety should be taken into account when 
interpreting TCI results (Cloninger et al., 1994). When 
restricting our analyses to current major depression 
only, the mean Harm avoidance score increased from 
17.9 ± 7.1 to 22.1 ± 6.6, but did not change the main results.
Figure 1. Harm avoidance scores for the whole sample of ADHD patients and controls, including grouping by comorbid disorders.
Note. The line indicates the mean Harm avoidance scores in the different groups of ADHD and controls, ASPD+, ASPD÷, anx/depr+, and anx/depr÷. 
ASPD = antisocial personality disorder; “+” = fulfilling diagnostic criteria; “÷” = not fulfilling diagnostic criteria; anx/depr = lifetime anxiety disorder 
(generalized anxiety disorder and panic disorder, with or without agoraphobia) and/or lifetime major depressive disorder.
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Most of our patients used medication for ADHD, and 
one could question if, and how, medical treatment could 
potentially influence TCI scores. The cross-sectional 
nature and relatively small sample sizes of subgroups in 
our study did however not permit any informative analyses 
on this subject. To our knowledge, no studies have so far 
investigated how TCI scores may be influenced by ADHD 
medication.
Due to the high comorbidity it is important to adjust for 
common comorbid psychiatric disorders when assessing 
personality traits. We found that lifetime anxiety and/or 
depression actually accounted for the differences in Harm 
Figure 2. Novelty seeking scores for the whole sample of ADHD patients and controls, including grouping by comorbid disorders.
Note. The line indicates the mean Novelty seeking scores in the different groups of ADHD and controls, ASPD+, ASPD÷, anx/depr+, and anx/depr÷. 
ASPD = antisocial personality disorder; “+” = fulfilling diagnostic criteria; “÷” = Not fulfilling diagnostic criteria; anx/depr = lifetime anxiety disorder 
(generalized anxiety disorder and panic disorder, with or without agoraphobia) and/or lifetime major depressive disorder.
Table 3. Correlation Between TCI Scores and ADHD, ASPD, and Anxiety/Depression (Results From Linear Regression Analysesa).
ADHD ASPDb,c Anxiety/depressionc,d
 B 95% CI p B 95% CI p B 95% CI p
Harm avoidance 0.40 [−2.6, 3.4] .794 −1.47 [−4.7,1.8] .374 5.96 [3.2, 8.7] <.001***
Novelty seeking 2.18 [−0.5, 4.9] .112 5.58 [2.5, 8.6] <.001*** 2.93 [0.4, 5.4] .022
Reward dependence −3.78 [−5.5, −2.0] <.001*** 0.37 [−1.5, 2.3] .698 1.67 [0.1, 3.3] .041
Persistence 0.67 [−0.2, 1.5] .128 −0.23 [−1.2, 0.7] .634 −0.29 [−1.1, 0.5] .479
Self-directedness −5.20 [−8.7, −1.7] .004 −1.71 [−5.7, 2.3] .403 −4.67 [−8.0, −1.4] .006
Cooperativeness −1.41 [−4.1, 1.3] .308 −3.74 [−6.6, −0.8] .012 0.75 [−1.7, 3.2] .548
Self-transcendence 2.10 [−0.6, 4.8] .126 3.83 [0.9, 6.8] .012 1.26 [−1.2, 3.8] .317
aThe model includes ADHD, antisocial personality disorder, and anxiety/depression as independent variables with a Bonferroni-corrected level of 
significance p < .002.
bASPD = lifetime antisocial personality disorder.
cIncludes ADHD patients and controls.
dLifetime anxiety disorder (generalized anxiety disorder and panic disorder, with or without agoraphobia) and/or lifetime major depressive disorder.
***p < .002.
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avoidance between the adults with ADHD and the control 
group. A few other studies have investigated the possible 
impact of comorbidity on these personality traits in adult 
ADHD. Our results are in line with Downey et al. (1997), 
who found that ADHD patients with concurrent axis 1 psy-
chopathology had higher scores on Harm avoidance than 
ADHD patients without. However, Faraone et al. (2009) did 
not find that comorbid anxiety and depressive disorders 
accounted for the high Harm avoidance in adult ADHD. 
This may be due to differences in the sample size, selection 
of the participants, or different comorbidity profile.
Novelty seeking includes items like “It is difficult for me 
to keep the same interests for a long time because my atten-
tion often shifts to something else,” “I lose my temper more 
quickly than most people,” and “I often follow my instincts, 
hunches, or intuition without thinking through all the 
details.” Such items describe clinical features of ADHD, 
like impulsivity and quick-temperedness, and also seem 
related to ASPD. Our results showed a close connection 
between ASPD and Novelty seeking. Somewhat unex-
pected, Novelty seeking was more closely connected to 
anxiety/depression than to ADHD alone, in an adjusted 
regression model. There may be several explanations to this 
finding. First, a great majority of the ADHD patients have a 
history of comorbid anxiety and depression, and ADHD 
without such comorbidity might not be representative for a 
clinical adult ADHD population. Second, although comor-
bid anxiety and depression often co-occur, the two kinds of 
disorders may be differentially related to Novelty seeking. 
In particular, ADHD with comorbid depression may be part 
of bipolar spectrum disorders or borderline personality dis-
order, which have been associated with high Novelty seek-
ing (Fassino et al., 2009; Young et al., 1995). Harm 
avoidance may, however, be more connected with anxiety 
disorders and related depressive symptoms (Nery et al., 
2008). Due to small subsamples, we were not able to disen-
tangle between the different disorders, but these differential 
relations could be addressed in larger studies.
According to Cloninger’s model, ASPD is characterized 
by low Harm avoidance, high Novelty seeking, and low 
Reward dependence (Cloninger et al., 1994; Svrakic et al., 
1993). When adjusting for comorbidity, we found that the 
ASPD group showed a low score of Cooperativeness. Low 
score on Cooperativeness is considered to be an important 
indicator of a personality disorder (Richter & Brandstrom, 
2009), and individuals low on Cooperativeness are charac-
terized as revengeful, intolerant, self-absorbed and primar-
ily looking out for themselves (Cloninger et al., 1994). Such 
features are consistent with one of the core traits in ASPD: 
“lack of remorse, as indicated being indifferent to or ratio-
nalizing having hurt, mistreated, or stolen from another” 
(APA, 2000, p. 292). Although ASPD and ADHD have 
some symptoms in common, these conditions seem to be 
correlated with different TCI profiles theoretically and 
empirically.
A person who has low scores on Reward dependence 
can be described as practical, independent, and unrespon-
sive to social pressure, and an individual who has low 
scores on Self-directedness is often characterized as irre-
sponsible, unreliable, blaming, and weak-willed (Cloninger 
et al., 1994). Reward dependence and Self-directedness 
were lower in the ADHD group compared with the control 
group, although only the difference in Reward dependence 
was statistically significant (corrected p < .002). This is 
consistent with earlier findings, and suggests that low 
Reward dependence and low Self-directedness tap person-
ality traits common in adult ADHD. However, the score on 
Reward dependence and Self-directedness in the ASPD 
group did not differ significantly from the control group. 
According to Cloninger’s model and from the existing pre-
vious studies, Reward dependence and Self-directedness 
were expected to show significantly lower scores in the 
ASPD group as well (Basoglu et al., 2011; Cloninger et al., 
1994; Svrakic et al., 1993).
The correlation between ASPD, alcohol and substance 
use, is well known (De Fruyt et al., 2006; Kessler et al., 
2006). In our study, the effects of alcohol and substance use 
disorders on the TCI dimensions were closely related to 
ASPD.
In our sample, 40.3% in the adult ADHD group had 
comorbid lifetime ASPD. This is higher than in other stud-
ies, which show prevalences of 12% to 16% (Downey et al., 
1997; Klein et al., 2012). We used the M.I.N.I Plus to assess 
for comorbidity. The M.I.N.I Plus covers only one person-
ality disorder, and the interview mainly focuses on antiso-
cial behavior rather than personality traits, which are a part 
of the ASPD diagnosis. This might explain the high rate of 
ASPD found in our adult ADHD group, and why the per-
sonality traits for ASPD in this study differ from other find-
ings. In clinical practice more information about the patient 
would normally be collected before a diagnosis of personal-
ity disorder is to be given. Ideally, it would have been of 
interest to have the possibility to adjust for other personality 
disorders than ASPD, for instance to adjust for cluster C 
personality disorders in Harm avoidance.
ASRS scores were used to classify the adult ADHD 
group into subgroups, and it can be discussed how suitable 
the ASRS is for this purpose. In contrast to previous studies, 
our results showed no significant differences in TCI scores 
between the ADHD subtypes.
The patients included had previously been diagnosed 
with adult ADHD in clinical practice and were not diag-
nosed again at the time of interview. We wanted to assess a 
representative sample of adults with ADHD. Due to this 
naturalistic study design, our sample might be more hetero-
geneous compared with samples in other studies. Although 
a diagnosis of ADHD in adults requires the presence of 
symptoms and behavior of ADHD from childhood, only 
12.7% of our adult patients had been formally diagnosed 
with ADHD as children. This may reflect the low 
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awareness and diagnostic rate of ADHD in Norway at the 
time when these adults grew up. There were no significant 
differences in the TCI dimensions between those previously 
diagnosed in childhood and the other patients, except for 
Self-transcendence, which was higher in the group only 
diagnosed as adults (data not shown).
Personality traits can be described in different ways, and 
one widely used model is the Five-Factor Model of person-
ality (De Fruyt, Mervielde, Hoekstra, & Rolland, 2000). The 
NEO Personality Inventory–Revised (NEO PI-R) is fre-
quently used to assess personality according to this model 
(Glover, Crego, & Widiger, 2012). NEO PI-R includes five 
different domains: Neuroticism, Extraversion, Openness, 
Agreeableness, and Conscientiousness. Individuals with 
high Neuroticism are described as fearful, anxious, 
depressed, helpless, and unable to resist impulses (De 
Fruyt et al., 2000). ADHD has been associated with high 
Neuroticism (Di Nicola et al., 2014), and it has been dis-
cussed whether there is a link between symptoms of inatten-
tion and anxiety/depression (Widiger, Lynam, Miller, & 
Oltmanns, 2012). This would be in line with our results, as 
Harm avoidance has been positively correlated with 
Neuroticism (Nigg et al., 2002).
Some of the heterogeneity in ADHD can be explained by 
associated personality traits and comorbidity profile. The 
high level of anxiety and depressive disorders among adults 
with ADHD may indicate that ADHD with comorbid anxi-
ety/depression makes up an important subgroup of ADHD. 
Our findings show the importance of taking comorbidity 
into account when examining personality traits in ADHD. 
Studies exploring the biological underpinnings of these per-
sonality dimensions could expand our understanding of the 
complex relation between temperament, character, and dis-
order (Tuominen et al., 2013). Longitudinal studies are 
needed to explore the direction of these associations, that is, 
do certain personality traits precede the development of 
depression or antisocial behavior, or is the personality pro-
file we measure in adults a result of lifelong comorbidity? 
In clinical practice, comorbidity profile and personality 
traits are important factors to improve the understanding of 
each ADHD patient, and to optimize the treatment for the 
individual patient.
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Offspring of Mothers With Inflammatory and
Immune System Diseases
Johanne T. Instanes, Anne Halmøy, Anders Engeland, Jan Haavik, Kari Furu, and
Kari Klungsøyr
ABSTRACT
BACKGROUND: Prenatal inflammatory mechanisms may play a role in the pathogenesis of psychiatric disorders
and could be relevant for attention-deficit/hyperactivity disorder (ADHD). We investigated maternal chronic somatic
diseases with immune components as possible risk factors for ADHD in offspring.
METHODS: We performed a population-based nested case-control study by linking data from longitudinal
Norwegian registers. We included all individuals born during the period 1967–2008 and alive at record linkage
(2012). Individuals receiving ADHD medication during the years 2004–2012 were defined as patients with ADHD (N 5
47,944), and all remaining individuals (N 5 2,274,713) were defined as control subjects. The associations between
maternal diseases and ADHD in offspring were analyzed using logistic regression models.
RESULTS: The following chronic diseases with immune components were related to ADHD in offspring: multiple
sclerosis (adjusted odds ratio [OR] 5 1.8; 95% confidence interval [CI] 5 1.2–2.5), rheumatoid arthritis (adjusted OR
5 1.7; 95% CI 5 1.5–1.9), type 1 diabetes (adjusted OR 5 1.6; 95% CI 5 1.3–2.0), asthma (adjusted OR 5 1.5; 95%
CI 5 1.4–1.6), and hypothyroidism (adjusted OR 5 1.2; 95% CI 5 1.1–1.4). In contrast, chronic hypertension and
type 2 diabetes showed no significant associations. Estimates were almost unchanged with additional adjustment for
parental ADHD, infant birth weight, and gestational age. Although point estimates for male and female offspring were
different for some diseases (e.g., maternal asthma [adjusted OR 5 1.7; 95% CI 5 1.5–1.8 for female offspring and
adjusted OR 5 1.5; 95% CI 5 1.4–1.6 for male offspring]), none of the associations differed significantly by
offspring sex.
CONCLUSIONS: Several maternal somatic diseases with immune components were found to increase the risk of
ADHD in offspring. The associations could involve several causal pathways, including common genetic predis-
position and environmental factors, and increased insight into the mechanisms behind these relationships could
enhance our understanding of the etiology of ADHD.
Keywords: ADHD, Attention-deficit/hyperactivity disorder, Immune disease, Inflammatory disease, Maternal effects,
Risk factors
http://dx.doi.org/10.1016/j.biopsych.2015.11.024
Attention-deficit/hyperactivity disorder (ADHD) is a neurode-
velopmental disorder that affects children and adults world-
wide, with prevalence estimates 5% in children (1) and 3%
in adults (2). The prevalence varies among studies; in a
Norwegian study of children 8–10 years old, it was estimated
to be 1.7% (3). The disorder is two to three times more
frequent in boys than girls (4), although the sex distribution
becomes more equal with age (5). The etiology of ADHD is
complex, involving interactions between genetic and environ-
mental factors, and many risk pathways may lead to its clinical
features (6).
Previous studies described several prenatal and perinatal
risk factors for ADHD. Low birth weight (7–12), preterm birth
(8,9,13–16), and small size for gestational age (8,16) have
consistently been related to an increased risk of ADHD or
ADHD symptoms. Exposure to maternal smoking (17) and
other substances in utero (6) also have been reported to be
associated with increased risk of ADHD. Furthermore, associ-
ations with ADHD in offspring have been found for some
maternal medical conditions, including obesity (18) and epi-
lepsy (8). It has been hypothesized that ADHD may be caused
by an exaggerated central nervous system inflammatory
response in the fetus caused by maternal inflammation, such
as in allergy or autoimmune disease (19). It is difficult to draw
conclusions about causal pathways, as associations between
maternal diseases and ADHD in offspring can involve several
different, partly overlapping, causal pathways. Common
genetic predisposition, environmental factors such as mater-
nal medication exposures, and fetal inflammatory response
are examples of such causes. Because few studies have
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evaluated maternal immune system diseases, we investigated
whether such diseases were associated with ADHD in off-
spring using data from nationwide registers in Norway. Addi-
tionally, we assessed whether these risk factors differed by
patient’s sex.
METHODS AND MATERIALS
This study was approved by the Norwegian Data Protection
Authority, the Norwegian Directorate of Health, and the
Regional Committee for Medical and Health Research Ethics
(2011/2272). The data were treated anonymously, and so no
further consent was required.
We performed a population-based nested case-control
study by linking information from the Medical Birth Registry
of Norway (MBRN), the Norwegian Prescription Database
(NorPD), and the National Educational Database. In a sensi-
tivity analysis, we also included data from the Norwegian
Patient Registry.
The nationwide MBRN was established in 1967 and con-
tains information on nearly 2.6 million births up to 2012. The
registration is based on compulsory notification and includes
information on all live births and fetal losses/stillbirths from 16
weeks of gestation. A standardized form is used to document
information on maternal health before and during pregnancy,
complications during pregnancy and delivery, and birth out-
comes. For the years 1967–1998, information was mainly
documented as free text specifications to items such as
“Maternal health before pregnancy,” “Maternal health during
pregnancy,” “Complications in relation to birth,” and “Infant
outcomes.” A more detailed documentation form, introduced
in 1999, included information on maternal smoking habits and
check boxes for specific conditions in addition to free text (20).
The NorPD covers all prescribed drugs dispensed to individ-
uals in Norway since 2004. From 2008, NorPD includes
diagnostic codes (ICD-10/International Classification of Pri-
mary Care, Second edition) for reimbursed drugs (21). The
level of education of all Norwegian inhabitants from 16 years
of age is registered annually in the National Education Data-
base. The Norwegian Patient Registry provides information on
diagnoses of all patients having contact with specialist health
services from 2008.
Study Population and Variable Information
Record linkage was established by using the personal identity
number unique to every Norwegian resident. This study
included all individuals born from 22 weeks of gestation or
with birth weight at least 500 g in Norway during the period
1967–2008 who were still alive at record linkage in 2012 (N 5
2,322,657).
Cases in this study consisted of all registered individuals in
MBRN born during the period 1967–2008 who had been
prescribed and dispensed ADHD medications during the years
2004–2012 and were .3 years old at last prescription.
The dispensed and reimbursed ADHD medications meth-
ylphenidate (Anatomical Therapeutic Chemical Classification
System [ATC] code N06BA04), atomoxetine (ATC code
N06BA09), and racemic amphetamine (ATC code N06BA01)
were extracted from the NorPD. The use of ADHD medication
is restricted in Norway; medical treatment of ADHD is
initiated only after thorough assessment of the patient by a
specialist in psychiatry or child psychiatry. Dexamphetamine
(ATC code N06BA02) was off label in Norway during
the study period and is not used as a first-option treatment
and therefore was not included in our case definition.
Drugs used to treat ADHD may also be used for narcolepsy.
Using the reimbursement codes from 2008, we found that
117 individuals (1.4%) were dispensed stimulant medication
with the indication narcolepsy, and these were excluded from
the case group. Thus, for patients who were dispensed
medicine in the period 2004–2008 only, there may be a
small number of individuals with narcolepsy left in the
case group.
The control group included all registered individuals in
MBRN born during the period 1967–2008 and alive at record
linkage who had not been dispensed ADHD medication during
the period 2004–2012. The 117 individuals who were dis-
pensed stimulant drugs for narcolepsy in the period 2008–
2012 were included in the control population (N 5 2,274,713).
Thus, by design, the control group included people with a
diagnosis of ADHD who did not receive ADHD medication or
who had used (and stopped using) ADHD medication before
2004 when the NorPD was established.
Maternal educational level was used as a measure for
socioeconomic level and grouped in three categories: low
(,10 years), medium (10–12 years), and high (.12 years).
Description of Variables
As potential prenatal risk factors for ADHD, we studied the
following maternal chronic somatic diseases, all with inflam-
matory or immune components of pathologic relevance: multi-
ple sclerosis, asthma, rheumatoid arthritis, hypothyroidism,
hyperthyroidism, and pregestational type 1 diabetes. Preges-
tational type 2 diabetes and chronic hypertension were also
included. Because we assumed that immunologic/inflamma-
tory mechanisms are less strongly involved in these condi-
tions, they were included to serve as contrasting chronic
diseases in the analyses. We chose the diseases included in
the analyses using several criteria. Our focus was immune
system diseases, and we selected diseases for which the
MBRN registration was previously validated (pregestational
type 1 and 2 diabetes, rheumatic arthritis, asthma) (20,22),
diseases that were previously described in the literature with
data from MBRN (multiple sclerosis) (23–25), diseases for
which the MBRN notification form from 1999 had specific
check boxes (asthma, diabetes type 1 and 2, rheumatic
arthritis and chronic hypertension), and diseases for which
the MBRN reported significantly increasing time trends in
prevalence and for which associations with ADHD in offspring
was previously discussed (thyroid disorders) (26–29). The
maternal diseases were diagnosed before or during pregnancy
for the target individual. Pregestational diabetes, without
subtyping, has been registered in the MBRN from 1967 and
specified as type 1 and type 2 since 1988 (n = 32,984 cases,
n = 1,113,011 controls).
Statistical Analyses
Analyses were performed with PASW Statistics 18 (SPSS
Hong Kong, Quarry Bay, Hong Kong) and Stata version 13
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(StataCorp LP, College Station, Texas). Data were analyzed
using descriptive statistics with χ2 tests, and we calculated
relative risks and crude odds ratios (ORs) for categorical
variables. We used logistic regression analyses to calculate
ORs adjusting for the following factors: maternal age at
delivery, parity, time period of birth (5-year categories),
maternal marital status, and maternal educational level. All
factors were modeled as categorical variables as specified in
the footnotes in Tables 1 and 2 and Table S1 in Supplement 1.
We further included one model adding maternal and paternal
use of ADHD medication from NorPD (2004–2012) as adjust-
ment variables. This information was used as a proxy for
maternal and paternal ADHD. In a final model, we included all
the studied maternal diseases in addition to infant birth weight
and gestational age. We also included maternal smoking in a
subanalysis for individuals born after 1998, when smoking
information was available. We stratified analyses by sex and
compared associations between male and female offspring.
Crude and adjusted ORs were reported with 95% confidence
intervals (CIs). We also analyzed mothers with more than one
birth by calculating OR with robust standard errors using the
mother as the cluster variable.
RESULTS
Sociodemographic Characteristics
Overall, there was a larger male proportion in the ADHD group
(65.7%) (Table 1) compared with the control group (50.9%).
Mothers of offspring with ADHD were younger, were more
often single, and had lower educational level compared with
mothers of control subjects. Similarly, fathers of offspring with
ADHD were younger and had lower education compared with
fathers of control subjects (data not shown).
Association Between Maternal Somatic Diseases
and ADHD in Offspring
We found higher frequencies of several immune system
diseases among mothers of offspring with ADHD compared
with mothers of control subjects (Table 2), with significantly
higher overall odds for maternal multiple sclerosis, rheumatoid
arthritis, type 1 diabetes, asthma, and hypothyroidism. Mater-
nal chronic hypertension, type 2 diabetes, and hyperthyroid-
ism were not associated with ADHD in offspring.
The associations between maternal immune-related dis-
ease and ADHD in offspring did not depend on offspring sex.
Figure 1 shows that although the point estimates for the
maternal disease–offspring ADHD associations to some extent
differ between male and female offspring, CIs overlap. How-
ever, for maternal asthma, where the point estimate for ADHD
in female offspring was 1.7 and for male offspring was 1.5, the
CIs around the estimates overlapped only slightly (95% CI 5
1.5–1.8 for female offspring and 95% CI 5 1.4–1.6 for male
offspring). Furthermore, for maternal multiple sclerosis and
ADHD in offspring, where the point estimates were 2.2 for
female offspring and 1.6 for male offspring, the CIs were
broad, and we may have lacked power to detect a possible
true sex difference.
We repeated all analyses with data from 1999 to adjust for
maternal smoking habits. The results were not altered notice-
ably. For example, adjusted OR between maternal asthma and
ADHD in offspring was 1.5 (95% CI 5 1.4–1.6), and when also
adjusting for smoking, OR was 1.7 (95% CI 5 1.5–2.0) for
female offspring and 1.4 (95% CI 5 1.3–1.6) for male offspring.
Although we set the level of significance at p , .05, all
the above-listed significant results had p values , .01.
The associations with maternal asthma, rheumatoid arthritis,
and type 1 diabetes had p values , .0001 (Table S1 in
Supplement 1).
Sensitivity Analyses
Because we defined our ADHD cases only on the basis of
dispensed ADHD medication, it may be that our cases
represent a special subgroup of patients. For the period
2008–2012, we also had available data from the Norwegian
Patient Registry. Of the 12,223 individuals registered with an
ADHD diagnosis in the Norwegian Patient Registry, only 2040
(17%) individuals did not receive ADHD drugs. Adding these
Table 1. Sociodemographic Characteristics of Patients







Male Sex 31,514 (65.7) 1,158,422 (50.9)
Year of Birth
1967–1978 6517 (13.6) 675,929 (29.7)
1979–1988 8443 (17.6) 485,773 (21.4)
1989–1998 23,501 (49.0) 556,250 (24.5)
1999–2008 9483 (19.8) 556,761 (24.5)
Marital Status of Mother (n 5 47,314) (n 5 2,246,177)
Single 7588 (16.0) 187,218 (8.3)
Married/cohabiting/partnership 38,535 (81.5) 2,028,282 (90.3)
Divorced/separated/widowed 850 (1.8) 19,479 (.9)
Other/unknown 341 (.7) 11,198 (.5)
Parity (n 5 47,314) (n 5 2,246,177)
Para 0 21,015 (44.4) 925,190 (41.2)
Para 1 15,886 (33.6) 784,852 (34.9)
Para 21 10,413 (22.0) 536,135 (23.9)
Maternal Age (Years) (n 5 47,314) (n 5 2,246,176)
,20 4367 (9.2) 127,279 (5.7)
20–34 39,150 (82.8) 1,882,572 (83.8)
$35 3797 (8.0) 236,325 (10.5)
Paternal Age (Years) (n 5 46,689) (n 5 2,230,886)
,20 1149 (2.5) 28,334 (1.3)
20–39 42,398 (90.8) 2,025,111 (90.8)
$40 3142 (6.7) 177,441 (8.0)
Educational Level (Mother)a (n 5 46,995) (n 5 2,228,246)
Low 15,528 (33.0) 529,358 (23.8)
Medium 20,028 (42.6) 970,395 (43.6)
High 11,439 (24.3) 728,493 (32.7)
ADHD, attention-deficit/hyperactivity disorder.
aMaternal educational level: high (.12 years of education), medium
(10–12 years of education) and low (#9 years of education).
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2040 individuals to our case population did not change any
results (data not shown).
We also ran several additional models. In one model, we
included maternal and paternal use of ADHD medication as
possible confounding variables. Overall, the associations were
unchanged or only slightly weakened (Table 2). We also looked
at overall offspring ADHD including all risk diseases as
covariates, with additional adjustment for gestational age
and infant birth weight. None of the estimates changed much
(Table 2). Results also did not change much when calculating
ORs with robust standard errors and the mother as cluster
variable (data not shown).
As shown in Table 2, the OR for type 1 diabetes increased
from 1.1 (95% CI 5 .9–1.3) in the unadjusted model to 1.6
(95% CI 5 1.3–2.0) in the adjusted model. To explore this
association further, we performed an additional analysis using
data after 1998, when a precoded checkbox for type 1
diabetes was introduced in the MBRN registration form. In
this analysis, the unadjusted OR (1.5; 95% CI 5 1.2–2.0) was
similar to the adjusted OR (1.6; 95% CI 5 1.2–2.0). Thus, we
consider that the low OR for type 1 diabetes association in the
early time period may be an artifact caused by insufficient data
collection.
DISCUSSION
This large nationwide register-based study with prospective
data showed that several chronic maternal diseases with
immune components, including multiple sclerosis, rheumatoid
arthritis, asthma, hypothyroidism, and type 1 diabetes were
associated with ADHD in offspring. Maternal multiple sclerosis
and rheumatoid arthritis were associated with 80% and 70%
higher odds of ADHD in offspring, respectively, and maternal
asthma was associated with 50% higher odds, independent of
maternal smoking. There were no statistically significant sex
differences, although we may have lacked power to detect
possible true sex differences for some maternal diseases.
This study has several strengths. It is large and includes
the entire Norwegian population over a period of 45 years.
The genetic homogeneity of the Norwegian population is an
advantage when studying other biological risk factors as
well as external risk factors. The unique Norwegian per-
sonal identity number ensured a valid linkage between the
registers involved. The data were prospectively collected with


















Asthma 1857 (3.9) 47519 (2.1) 1.9 (1.8–2.0) 1.5 (1.4–1.6) 1.5 (1.4–1.5) 1.5 (1.5–1.6)
Rheumatoid
Arthritis
250 (.5) 5813 (.3) 2.0 (1.8–2.3) 1.7 (1.5–1.9) 1.7 (1.5–1.9) 1.6 (1.4–1.9)
Hypothyroidism 235 (.5) 11,625 (.5) 1.0 (.8–1.1) 1.2 (1.1–1.4) 1.2 (1.0–1.3) 1.2 (1.0–1.4)
Hyperthyroidism 68 (.1) 3070 (.1) 1.1 (.8–1.3) 1.2 (.9–1.5) 1.1 (.9–1.4) 1.2 (.9–1.5)
Type 1
Diabetesd
88 (.3) 2825 (.3) 1.1 (.9–1.3) 1.6 (1.3–2.0) 1.7 (1.3–2.1) 1.5 (1.2–1.9)e
Type 2
Diabetesd
19 (.1) 1135 (.1) .6 (.4–.9) 1.1 (.7–1.8) 1.2 (.7–1.9) 1.1 (.7–1.8)e
Multiple
Sclerosis
31 (.1) 880 (0) 1.7 (1.2–2.4) 1.8 (1.2.–2.5) 1.8 (1.3–2.6) 1.8 (1.2–2.6)
Hypertension,
Chronic
155 (.3) 6496 (.3) 1.1 (1.0–1.3) 1.1 (.9–1.3) 1.1 (.9–1.3) 1.1 (.9–1.2)
ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval; OR, odds ratio.
aAdjusted by year of birth (5-year interval 1967–2008), parity (para 0, para 1, para 21), mother’s age at birth (,20, 20–24, 25–29, 30–34, 35–39,
.39 years), mother’s educational level (low/medium/high), mother’s marital status (married/cohabiting/partnership, single, divorced/separated/
widowed, other/unknown).
bAdjusted by the same covariates listed in a adding maternal and paternal use of ADHD medication.
cModel including all risk diseases as covariates listed in a in addition to birth weight (5 categories [,1500, 1500–1999, 2000–2499, 2500–4499,
$4500 kg]) and gestational age (5 categories [22–31 weeks, 32–36 weeks, 37–41 weeks, $42 weeks]).
dData from 1989 and later.
eAll variables, including risk diseases, selected from 1989 and later when analyzing diabetes.
Figure 1. Associations (adjusted odds ratios with 95% confidence
intervals) between maternal diseases and attention-deficit/hyperactivity
disorder (ADHD) in offspring by sex in Norway, 1967–2012. Female patients
with ADHD (white circles); male patients with ADHD (black circles).
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compulsory notification, minimizing selection and follow-up
bias. On one hand, by using the nationwide prescription
database to define the case population, thus including only
patients who were medicated with reimbursement as cases,
we ensured that cases had a valid diagnosis of ADHD. On the
other hand, the ADHD cases in this study probably represent
the most severely affected patients, as medical treatment is
indicated only when substantial loss of function is present. The
diagnostic classification system used in Norway is ICD-10. We
use data from NorPD during 2004-2012 to define our cases.
According to national guidelines published during these years,
ADHD should be diagnosed according to ICD-10 criteria,
although allowing the inattentive subtype in DSM-IV as
sufficient for the diagnosis. Other psychiatric disorders may
also be present, as long as the ADHD criteria are fulfilled
before the comorbid disorder appears. As some clinicians may
have used the more restricted ICD-10 criteria, persons with the
inattentive subtype may be underrepresented in our case
group. Thus, our results may be most valid for more severe
cases of ADHD and the combined subgroup. Moreover, in the
Norwegian population, the indications for starting ADHD
medication for treating ADHD symptoms could vary slightly
from other populations, which may limit to a certain degree the
generalizability of our results. Still, our sensitivity analysis
showed that only 17% of registered patients during the period
2008–2012 did not receive ADHD medication. Some people
included in the control group could have used medication for
ADHD before 2004 when NorPD was established; however,
this would tend to weaken the associations. Because our
control group is very large, the few false-negative ADHD cases
should not represent an important source of bias.
We report a robust association between ADHD in offspring
and maternal disorders with underlying immune factors,
including multiple sclerosis, rheumatoid arthritis, asthma,
hypothyroidism, and type 1 diabetes. It has been suggested
that maternal diseases with immune components, such as
infections, allergy, and autoimmune disease, may cause an
exaggerated central nervous system inflammatory response in
the fetus (19). Subsequently, this exaggerated inflammatory
response could harm the developing brain. Inflammatory
mechanisms are believed to play a role in the pathogenesis
of psychiatric disorders such as schizophrenia (30) and autism
(31), and similar mechanisms may be relevant for the develop-
ment of ADHD. Altered fetal neurodevelopment has been
associated with diverse maternal infections during pregnancy,
suggesting the maternal immune response in itself can alter
fetal brain development, as shown in a primate model (32).
Ghassabian et al. (27) reported that children of mothers with
elevated levels of maternal thyroid peroxidase antibodies had
more ADHD symptoms. These antibodies could play a part
both in the development of autoimmune thyroid disease
leading to maternal hypothyroidism and in the fetal neuronal
development leading to ADHD.
Patients with ADHD have an increased risk of asthma, the
association being highest in female patients (33). However, the
present study is the first to show an association between
maternal asthma and ADHD in offspring. It was unchanged
when adjusting for parental ADHD medication as well as with
additional adjustment for maternal smoking and could support
shared etiological pathways to ADHD and asthma.
We did not find associations between maternal chronic
hypertension or type 2 diabetes and ADHD in offspring.
Although it has been proposed that inflammation also may
contribute to these disorders (34,35), these chronic conditions
are less clearly related to immune system components
compared with rheumatoid arthritis and multiple sclerosis, in
which the immunopathology is well defined; this indicates that
maternal immunological factors could play a role in the
pathogenesis of ADHD in offspring.
We controlled for many potential and known confounders.
Information on maternal smoking was available only from
1999. However, results using data from 1999 with additional
adjustment for smoking were in agreement with the main
results. Including maternal and paternal use of ADHD medi-
cation in the regression model weakened some of the
associations slightly, but they were still in line with the main
results.
This study has several limitations. The diagnostic validity of
reported diagnosis in the MBRN has not been formally studied
for all the studied diseases. The sensitivity of reported
rheumatoid arthritis (22) and type 1 diabetes (20) in MBRN is
high, estimated to be 88% for rheumatoid arthritis and 90% for
type 1 diabetes. For severe asthma, the sensitivity is lower
(73%) (20). However, potentially missed maternal cases would
most likely attenuate the associations.
The observational design of the study does not allow for
definite causal inference. The observed associations could
be explained by unmeasured environmental confounding,
such as maternal medication use during pregnancy,
unmeasured genetic confounding, or an inflammatory
response in the fetus; furthermore, these pathways could
overlap.
It is known that ADHD is a partially genetic disorder; the
heritability has been estimated to .7–.9 (36,37). Environmental
factors and the interplay between genetic and environmental
factors are also important (38). Analyses of genome-wide
genetic markers demonstrated genetic correlations between
many traits as well as between somatic and psychiatric
disorders (39). Shared genetic susceptibilities could explain
some of our findings. For example, the SLC9A9 gene has been
implicated in ADHD and multiple sclerosis (40–42). We did not
have data on chronic immune diseases in the fathers in the
present data file. However, in a different data set, we had
information on prescribed medications of fathers. We used this
data set to look at fathers who had been prescribed insulin
(2% of the fathers), thyroid replacement drugs (2%), and
antiasthmatic drugs (13%) as indications of paternal type 1
diabetes, hypothyroidism, and asthma. Adjusting for the same
variables as in the maternal models, we found an adjusted OR
for ADHD in offspring related to paternal type 1 diabetes of 1.2
(95% CI = 1.1–1.3), paternal hypothyroidism of 1.1 (95% CI =
1.0–1.2), and paternal asthma of 1.3 (95% CI = 1.3–1.3). In
other words, even though there were statistically significant
relationships for paternal asthma and type 1 diabetes with
ADHD in offspring, the risk estimates were lower than the risk
estimates found for maternal chronic immune disease. This
finding is an indication that at least some of the relationship
between maternal chronic immune disease and ADHD in
offspring may be explained by inflammatory mechanisms
during pregnancy.
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We adjusted for maternal and paternal ADHD, but we had
information about parental ADHD only through data registered
in the NorPD for parents who had been dispensed ADHD
medication during the period 2004–2012. However, before the
late 1990s, ADHD was mainly thought of as a childhood
disorder, and adults were not given the diagnosis. Therefore,
information about parental ADHD is lacking in all data sources
until the late 1990s. We cannot exclude residual confounding
by shared genetic factors in the present study.
The mechanisms behind our reported findings can also be
related to effects of maternal medication use during preg-
nancy. Acetaminophen used in pregnancy has been associ-
ated with an increased risk of hyperkinetic disorder in offspring
(43), although the mechanism behind this association is not
understood. Acetaminophen may act as a hormone disruptor,
interfering with thyroid and reproductive function important for
brain development (44). However, it is not completely under-
stood if the association is due to a toxic effect of acetamino-
phen itself or the underlying causes for women taking these
medications during pregnancy. Use of antipsychotics and
selective serotonin reuptake inhibitors in pregnancy may affect
fetal and infant neurobehavioral development (45,46). It is
possible that women with chronic immunological disorders
use medications such as acetaminophen and selective sero-
tonin reuptake inhibitors during pregnancy more frequently
than women without such disorders. Certain antiasthmatic
drugs are associated with an increased risk of birth defects in
offspring (47) and could theoretically affect neurodevelopment.
However, severe maternal asthma exacerbations are also
associated with an increased risk of birth defects in offspring
(48). With our data, we could not separate the possible effects
of medication taken in pregnancy for the studied diseases
from the possible direct effects of the underlying diseases.
Inflammatory response in the fetus can also explain our
findings. Abnormal exposure of the fetus to immunomodula-
tory molecules may play a crucial role in linking adverse
pregnancy experiences with altered fetal development. Cyto-
kines are involved in the modulation of the immune system,
and elevated cytokine levels resulting from chronic inflamma-
tion may affect fetal development in different ways: either
directly interfering with neuronal development or by epigenetic
mechanisms resulting in altered gene expression (49). This
example shows that the activation of the immune system may
be a causative agent in the development of neurodevelop-
mental disorders.
People with chronic illnesses are more frequently in contact
with health care services compared with healthy people.
Symptoms of ADHD exhibited by their children could be more
easily detected and diagnosed than such symptoms in
children of mothers without chronic disorders. However, in
this case, we would have expected a more uniform increased
risk associated with all chronic disorders, including chronic
hypertension and type 2 diabetes. In Norway, women of
childbearing age with chronic hypertension and type 2 dia-
betes are closely followed by the family doctor; this would be
the natural place to focus on family issues, such as ADHD
symptoms in the children.
Besides immunological processes, other disease-related
factors may be involved in the association between chronic
maternal disease and ADHD in offspring, as ADHD is considered
a multifactorial disorder. Although epilepsy is not viewed as an
disease with immune components, a clear association was
previously reported between maternal epilepsy and ADHD in
offspring (8). This association may have several explanations,
such as teratogenic effects of antiepileptic medication (49) or
fetal hypoxic states caused by maternal seizures. Genetic
factors may also be important (50). Thus, different maternal
disorders with different pathophysiology may lead to ADHD in
the offspring through different underlying pathways.
In conclusion, maternal chronic diseases with immune
components as part of the pathogenetic mechanism (multiple
sclerosis, type 1 diabetes, hypothyroidism, rheumatoid arthri-
tis, and asthma) were associated with increased risk of ADHD
in offspring. The associations did not differ by sex. The
etiology of ADHD is probably multifactorial, and the mentioned
associations can reflect different causal pathways to ADHD.
Maternal disease may impact fetal development through
common genetic factors, through environmental factors, or
directly through an altered fetal immune response, leading to
ADHD in offspring. Further studies are needed to elucidate the
mechanisms underlying these relationships, clarifying how
genetic vulnerabilities may interact with environmental factors
to shape disease risk and clinical presentation. Increased
understanding of these pathways could pave the way for
new preventive and treatment strategies targeting neurodeve-
lopmental disorders.
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and Immune System Diseases 
Supplemental Information 
 
Table S1. Maternal chronic diseases and offspring ADHD; results from adjusted logistic 
regression model with P-values included. 
 Adjusted OR (95% CI)a P-Values 
Asthma 1.5 (1.4-1.6) p<< 0.0001 
Rheumatoid Arthritis 1.7 (1.5-1.9) p<< 0.0001 
Hypothyroidism 1.2 (1.1-1.4) 0.006 
Hyperthyroidism 1.2 (0.9-1.5) 0.237 
Diabetes Type 1b 1.6 (1.3-2.0) p< 0.0001 
Diabetes Type 2b 1.1 (0.7-1.8) 0.581 
Multiple Sclerosis 1.8 (1.2.-2.5) 0.002  
Hypertension, Chronic 1.1 (0.9-1.3) 0.279 
aAdjusted by year of birth (5 years interval 1967-2008), parity (para 0, para1, para2+), mother’s 
age at birth (<20, 20-24, 25-29, 30-34, 35-39, >39 years), mother´s educational level (low/ 
medium/high), mother’s marital status (married/cohabiting/partnership, single, divorced/ 
separated/widowed, other/unknown). 
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Abstract
Several studies have demonstrated associations between neuropsychiatric disorders, such as attention-deficit/hyperactivity 
disorder (ADHD), and the immune system, including autoimmune diseases. Since ADHD and many autoimmune diseases 
show sex-specific properties, such associations may also differ by sex. Using Norwegian national registries, we performed 
a cross-sectional study based on a cohort of 2,500,118 individuals to investigate whether ADHD is associated with com-
mon autoimmune diseases. Associations between ADHD and autoimmune diseases in females and males were investigated 
with logistic regression and effect modification by sex was evaluated. Several subanalyses were performed. The strong-
est association was found between ADHD and psoriasis in females, adjusted odds ratio (adjOR) = 1.57 (95% confidence 
interval: 1.46–1.68) and males, adjOR = 1.31 (1.23–1.40); p value for interaction < 0.0001. Furthermore, among females, 
ADHD was associated with Crohn’s disease, adjOR = 1.44 (1.16–1.79) and ulcerative colitis, adjOR = 1.28 (1.06–1.54). In 
contrast, males with ADHD had lower odds of Crohn’s disease, adjOR = 0.71 (0.54–0.92), in addition to a trend for lower 
odds of ulcerative colitis, adjOR = 0.86 (0.71–1.03); p values for interaction < 0.0001 and 0.0023, respectively. In a group 
of females where information on smoking and body mass index was available, adjustment for these potential mediators did 
not substantially alter the associations. Our findings support previously reported associations between ADHD and diseases 
of the immune system. The associations differ by sex, suggesting that sex-specific immune-mediated neurodevelopmental 
processes may be involved in the etiology of ADHD.
Keywords ADHD · Autoimmunity · Neuropsychiatry · Comorbidity · Psoriasis · Neuroimmunology
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder characterized by the symptoms 
of inattention, hyperactivity and impulsivity. The symptoms 
of this childhood onset condition often persist into adult-
hood [1]. Furthermore, patients often suffer from comorbid 
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psychiatric disorders [2, 3] and face socioeconomic hardship 
[4]. The etiology of ADHD is largely unknown, but in twin 
studies, the heritability of the disorder has been estimated 
to be 70–80%, implicating a strong genetic basis [1, 5, 6]. 
Environmental factors and perinatal factors such as preterm 
birth and growth restriction have also been shown to influ-
ence the development of ADHD [1, 7, 8].
Numerous studies have reported associations between 
neuropsychiatric disorders and immune system abnormali-
ties [9–16]. However, these associations remain uncertain 
[17–19]. Likewise, several immune-related disorders, such 
as atopic dermatitis, asthma, ankylosing spondylitis, ulcera-
tive colitis (UC), juvenile arthritis, autoimmune thyroid dis-
ease and celiac disease have been associated with ADHD 
[20–23]. Additionally, maternal autoimmunity has been 
associated with offspring ADHD, implying that maternal 
immune system dysfunction may affect the in utero environ-
ment and again fetal neurodevelopment [21, 24]. Despite 
the genetic architecture of ADHD being relatively unknown, 
some tentative genetic associations between ADHD and the 
immune system have been noted. For example, a study on 
genetic pathways of ADHD, which was based on genome-
wide association studies (GWAS), found an increased bur-
den of polymorphisms in and around genes involved in toll-
like receptor signaling [25]. These signaling pathways are 
highly involved in the innate immune responses and have 
also been shown to regulate hippocampal plasticity and neu-
rogenesis, and memory formation [26]. Furthermore, the 
single nucleotide polymorphism (SNP) which showed the 
strongest association signal in a recent ADHD GWAS, which 
included more than 20,000 ADHD patients and 35,000 con-
trols, is located in the gene ST3GAL3 [27]. Knockout of the 
ST3GAL3 gene affects both eosinophilic immune responses 
[28] and brain development [29].
ADHD has an approximate male:female ratio of 3:1 dur-
ing childhood and adolescence, which approaches 1:1 in 
adults [1]. Moreover, ADHD displays sex-specific manifes-
tations [30]. For example, females are more often primarily 
affected by inattention, whereas males more often display 
additional symptoms of hyperactivity and impulsivity [31]. 
Likewise, autoimmune diseases have prevalence rates and 
symptom burdens that may differ by sex [32–34]. Interest-
ingly, GWASs have reported SNPs to be associated with an 
autoimmune disease in one sex, but not the other [35] and 
genetic effects being in opposite directions depending on 
sex have been reported [36, 37]. Further, sex hormones are 
believed to have immune-modulating properties, as exempli-
fied by symptom remission of multiple sclerosis and rheuma-
toid arthritis during pregnancy [33, 34]. Neural functioning 
might also be regulated by these hormones, as demonstrated 
by menstrual cycle-associated seizures of certain types of 
epilepsy [38]. Besides, behavior may be affected by sex hor-
mones. For instance, females exposed to elevated prenatal 
androgen levels may develop more aggressive behavior later 
in life as compared to non-exposed females [39], and moreo-
ver, aggressive behavior is associated with ADHD [40].
In sum, if sex-specific genetic pleiotropy, or other sex-
specific mechanisms, underlie any associations between 
ADHD and autoimmunity, these associations may differ 
substantially by sex. In other words, sex could be an effect 
measure modifier.
To further explore possible associations between autoim-
munity and ADHD, and to evaluate whether these associa-
tions vary by sex, we conducted a large cross-sectional study 
based on Norwegian national registries.
Materials and methods
The Medical Birth Registry of Norway (MBRN)
The Medical Birth Registry of Norway (MBRN) was estab-
lished in 1967 to collect medical and familial information 
on parents and births in Norway [41]. Registration in the 
MBRN is mandatory for all pregnancies from 16 completed 
weeks of gestation, and is based on a standardized notifi-
cation form. Maternal smoking habits have been included 
in the registry since December 1998, but is one of few 
variables where mothers can refuse registration. Still, for 
approximately 84% of the births smoking information is reg-
istered. Since 2006, electronic notification of births to the 
MBRN has been introduced gradually, based on standard-
ized extraction from medical records at the delivery units, 
and has included information on maternal height and weight 
before and at the end of pregnancy. However, it was not until 
2014 that electronic notification was in place at all delivery 
units and in 2013, information on height and weight was still 
missing for approximately 36% of the pregnancies.
Data for the current study was obtained for all live births 
in the MBRN from January 1st 1967 to December 31st 2013.
The Norwegian Prescription Database (NorPD)
The Norwegian Prescription Database (NorPD) was estab-
lished in 2004 and provides information on all medical pre-
scriptions dispensed to patients from all Norwegian phar-
macies, and includes the Anatomical Therapeutic Chemical 
Classification System (ATC) codes [42]. Information on 
medication received during hospitalization is not available 
on an individual basis. From 2008, the NorPD has included 
information on diagnostic codes for reimbursed medication 
based on either the International Classification of Primary 
Care (ICPC) or the International Statistical Classification of 
Diseases and Related Health Problems 10th version (ICD-
10), used in specialist health care. From 2004 to 2008, 
the NorPD also included diagnostic codes for prescribed 
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reimbursed medication. However, these diagnostic codes 
were less specific, and therefore not used in this study.
For the present study, information was obtained for all 
dispensed drugs between January 1st 2004 and December 
31st 2015.
The National Education Database
The National Education Database holds information on the 
education of all Norwegian citizens from the age of 16 years. 
The database covers all levels of education from primary 
school to PhD-level. For the present study, data on education 
as registered in 2012 was available.
The National Registry
The National Registry supplied information on emigration 
and dates of death.
Included individuals and record linkage
All individuals registered in the MBRN as born between 
1967 and 2011, who were alive and residing in Norway on 
December 31st 2015, were included in the study. In addi-
tion, the mothers of those registered in the MBRN between 
1998 and 2013, were identified for supplementary analyses 
allowing adjustment for body mass index (BMI) and smok-
ing. Mothers who had died or emigrated by December 31st 
2015 were excluded from these supplementary analyses (see 
below).
All Norwegian citizens have a unique personal identifi-
cation number. This number was used to establish linkage 
between the registries.
ADHD case definition
ADHD cases were defined as all individuals, regardless of 
age, who had been dispensed reimbursed ADHD medication 
(ATC N06BA) (n = 63,721), without reimbursement codes 
for “narcolepsy”, G47 in ICD-10 and “sleep disturbance”, 
P06 in ICPC (n = 407), during 2004–2015.
The remaining population served as the comparison 
group (n = 2,436,397).
Autoimmune diseases
Autoimmune disease cases were defined from reimburse-
ment codes or specific dispensed drugs corresponding to one 
of several predefined and common autoimmune diseases. 
The set of diseases was based on a Danish study describing 
the prevalence of 30 autoimmune diseases [43].
The estimated coverage of the autoimmune disease cases 
was compared with the reported prevalence rates of the auto-
immune diseases in the general population by utilizing Eaton 
et al. 2010 [43] in addition to Norwegian and Swedish prev-
alence studies. Autoimmune diseases where the available 
reimbursement codes were considered too unspecific, that 
had unlikely prevalence estimates, or with less than 1000 
cases in total (< 4 pr 10,000), were excluded. Nine autoim-
mune diseases passed the inclusion criteria (see Table 1) and 
were included in the study.
Table 1  Definitions of ADHD and the autoimmune diseases assessed in the primary analyses
ADHD attention-deficit/hyperactivity disorder, ATC Anatomical Therapeutic Chemical Classification System, ICD-10 International Statistical 
Classification of Diseases and Related Health Problems 10, ICPC International Classification of Primary Care, SLE systemic lupus erythemato-
sus
a  The ICD-10 and ICPC codes for multiple sclerosis are not used in Norway at drug prescribement due to health-regulatory reasons. ATC codes 
for multiple sclerosis-specific drugs therefore defined multiple sclerosis
Disease/disorder Definition of case
ADHD Prescribed and dispensed at least one reimbursed drug once with ATC-code N06BA excluding those with reimburse-
ment code ICD-10 G47 (narcolepsy) or ICPC P06 (sleep disturbance)
Ankylosing spondylitis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 M45
Crohn’s disease Prescribed and dispensed at least one drug once with reimbursement code ICD-10 K50
Iridocyclitis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 H20
Multiple  sclerosisa Prescribed and dispensed at least one drug once with ATC-code L03AB07, L03AB08, L03AB13, L03AX13, 
L04AA23, L04AA27, L04AA31, L04AA34, L04AC01, N07XX07 or N07XX09
Psoriasis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 L40 or ICPC S91
Rheumatoid arthritis Prescribed and dispensed at least one drug once with reimbursement codes ICD-10 M05 or M06
SLE Prescribed and dispensed at least one drug once with reimbursement code ICD-10 M32
Type 1 diabetes Prescribed and dispensed at least one drug once with reimbursement code ICD-10 E10 or ICPC T89, excluding those 
who have been dispensed at least one drug once with ATC-code A10B
Ulcerative colitis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 K51
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Statistical analysis
Possible associations between ADHD and the autoimmune 
diseases were estimated as odds ratios (OR) with 95% con-
fidence intervals (CI) using logistic regression. p values are 
presented uncorrected for multiple testing. The threshold for 
statistical significance was adjusted ad modum Bonferroni 
(p = 0.05 divided by the number of autoimmune diseases 
included in the primary analyses) to p = 0.0056. The thresh-
old for nominal significance was defined as p = 0.05. Data 
management and statistical analyses were performed with R 
[44], RStudio [45] and IBM SPSS [46].
Primary analyses
In the primary analyses, associations between autoimmune 
diseases and ADHD were investigated with adjustment for 
age as a continuous covariate, except for type 1 diabetes 
where age was categorized into four (years of age in 2015: 
4–10; 11–15; 16–20; 21–48). All analyses were stratified by 
sex [1, 30–34]. Effect modification by sex was evaluated on 
a multiplicative scale including an interaction term in the 
logistic regression model, and statistical significance was 
evaluated by Wald test.
Socioeconomic status as defined by maternal education 
was adjusted for as a categorical covariate with three catego-
ries, low (< 10 years of education), medium (10–12 years) 
and high (> 12 years).
Statistically significant associations in the primary analy-
ses were further investigated in supplementary analyses con-
cerning potential confounders, mediators and biases.
Adjustment for smoking and body mass index 
(mother analyses)
Tobacco smoking and BMI may be mediating factors 
between ADHD and autoimmune diseases. Smoking is 
known to be associated with ADHD [47, 48] and has been 
associated with increased risk of several autoimmune dis-
eases in prospective studies [49–51]. The similar applies to 
BMI in ADHD [20, 52] and autoimmunity [53–56]. To con-
duct a sensitivity analysis on whether the associations dis-
covered in the main analyses were mediated mainly through 
smoking and/or BMI, a new study population including data 
on smoking and BMI was defined. The MBRN supplied data 
on smoking for women giving birth from December 1998 to 
2013, and these mothers defined the study population when 
assessing the effect of smoking (from now on referred to 
as the “mother analyses”). Smoking during pregnancy was 
used as a proxy for smoking at linkage. As proxy for BMI at 
linkage, pre-pregnant BMI (kg/m2) of the mothers was used. 
Mothers with registered height below 130 cm or BMI below 
15 or above 60 were set to missing as these values were 
considered biologically implausible. Socioeconomic status 
was defined as the education of the mother in 2012 catego-
rized into three: low (< 10 years), medium (10–12 years) 
and high (> 12 years). For females who had given birth to 
several children, only data from the last registered birth was 
included.
Logistic regression was used to investigate associations 
between ADHD and autoimmune diseases among these 
mothers with and without adjustment for the mother’s smok-
ing habits and with education as covariate. Further, a similar 
logistic regression was conducted with the inclusion of BMI, 
modelled as a continuous covariate, in addition to smok-
ing and education. Substantial attenuation of the estimated 
associations between ADHD and autoimmune diseases when 
adjusting for smoking and BMI, would indicate that much 
of the effect of ADHD on these diseases might be mediated 
through these mediators [57, 58].
Several additional subanalyses were also conducted, 
when possible, to scrutinize statistically significant associa-




We identified a total of 2,500,118 individuals in the MBRN 
fulfilling our inclusion criteria for the primary analyses, 
1,219,669 females and 1,280,449 males.
22,878 (1.9%) of the females had ADHD with the highest 
prevalence among those born in 1993 (3.5%). Of the males, 
40,843 (3.2%) had ADHD, with the highest prevalence 
among those born in 1996 (6.8%) (supplementary Fig. 1). 
ADHD was associated with lower socioeconomic status, as 
defined by maternal educational level (see Table 2).
The total number of patients per autoimmune disease 
ranged from 1197 (5 per 10,000) for systemic lupus ery-
thematosus (SLE) to 62,418 (250 per 10,000) for psoriasis. 
The female-to-male ratios varied across the autoimmune 
diseases, with 42.3% of type 1 diabetes patients being 
female, to 85.5% of SLE patients. All autoimmune diseases 
increased in prevalence with age (supplementary Fig. 1). All 
autoimmune diseases were associated with lower socioeco-
nomic status.
Primary analyses
ADHD was significantly associated with increased odds of 
psoriasis in both females, adjusted (adj) OR = 1.57 (95% CI 
1.46–1.68) and males, adjOR = 1.31 (95% CI 1.23–1.40). 
Associations were significantly stronger for females than 
males, p value for interaction by sex = 4.4 × 10−6.
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Sex differences were even larger for Crohn’s disease (CD) 
and UC: Females with ADHD had a significantly higher 
odds of CD, adjOR 1.44 (95% CI 1.16–1.79), and UC, 
adjOR = 1.28 (95% CI 1.06–1.54), than females without 
ADHD. Males with ADHD, on the other hand, seemed pro-
tected, with a lower odds of CD than males without ADHD, 
adjOR = 0.71 (95% CI 0.54–0.92; nominal statistically sig-
nificant), and a tendency to lower odds of UC, adjOR = 0.86 
(95% CI 0.71–1.03). There were significant interaction 
effects between ADHD and sex on the odds for both CD, 
p = 3.6 × 10−5, and UC, p = 0.0023. Despite not reaching 
the threshold for statistical significance, UC was taken to 
supplementary analyses as UC shares many characteristics 
with CD and displayed statistically significant interaction 
effects by sex.
ADHD was further associated with lower odds of anky-
losing spondylitis among females, but only at nominal sta-
tistical significance, adjOR = 0.56 (95% CI 0.32–0.96). 
No association was found for males, adjOR = 1.16 (95% 
CI 0.87–1.55). A nominally significant interaction effect 
between ADHD and sex was noted, p = 0.021.
The primary analyses were also adjusted for prematurity, 
gestational age ≥ 37 weeks or < 37 weeks, with little effect 
on the results (data and results not presented).
See Table 3 for detailed results and Fig. 1 for graphi-
cal representation of the sex-specific associations between 
ADHD and the autoimmune diseases.
Adjustment for smoking and BMI (mother analyses)
512,957 females gave their last birth between December 
1998 and December 31st 2013 during which time smoking 
habits were registered in the MBRN. Of these, 373,672 
(72.8%) were themselves also registered in the MBRN 
at their own birth. There was information on educational 
level for 497,005 (96.9%) of the mothers, and of these, 
information on smoking for 420,050 (84.5%). Of these 
420,050, 73,891 (17.6%) were defined as smokers, and 
additional information on pre-pregnant BMI for was avail-
able for 110,008 (26.2%). The mean and standard devia-
tion of pre-pregnant BMI was 24.4 and 4.8, respectively, 
and 13,304 (12.1%) of these 110,008 females were defined 
as smokers. Thus, data on educational level, smoking and 
BMI was available for 21.4% of all females delivering their 
last recorded birth since the introduction of smoking infor-
mation in December 1998 and up to December 31st 2013. 
See supplementary Fig. 2 for flowchart.
In the mother analyses, ADHD was associated with 
increased odds of psoriasis, adjOR  =  1.62 (95% CI 
1.44–1.81) also after additional adjustment for smoking, 
adjOR = 1.49 (95% CI 1.33–1.67) and BMI, adjOR = 1.29 
(95% CI 1.04–1.60).
ADHD was associated with CD, adjOR = 1.77 (95% CI 
1.23–2.54) and UC, adjOR = 1.87 (95% CI 1.42–2.46). 
Adjustment for smoking did not materially change 
ADHD’s association with CD, adjOR = 1.63 (95% CI 
1.13–2.34) nor UC, adjOR = 1.90 (95% CI 1.45–2.50). 
Similarly, additional adjustment for BMI did not alter the 
ADHD-CD association, adjOR = 2.20 (95% CI 1.24–3.88) 
nor the ADHD-UC association, adjOR = 2.10 (95% CI 
1.30–3.39).
Similar analyses stratified by smoking and overweight, 
BMI < 25 or ≥ 25, were also conducted. The results were 
in line with the presented findings (data and results not 
presented). See Table 4 for detailed results.
Table 2  Characteristics of the study population in the primary analyses
ADHD attention-deficit/hyperactivity disorder, SLE systemic lupus erythematosus
Disease/disorder n (per 10 000) Mean age in 
2015










Total study sample 2,500,118 25.8 1,219,669 (48.8) 23.1 42.0 33.9 0.1
ADHD 63,721 (255) 23.4 22,878 (35.9) 31.5 42.1 25.7 0.7
Ankylosing spondylitis 3504 (14) 37.4 1480 (42.2) 28.9 47.6 23.0 0.5
Crohn’s disease 6292 (25) 32.1 3284 (52.2) 27.6 46.0 25.9 0.5
Iridocyclitis 7596 (30) 34.0 3470 (45.7) 26.3 46.7 26.6 0.4
Multiple sclerosis 3739 (15) 38.1 2621 (70.1) 29.6 49.6 20.5 0.4
Psoriasis 62,418 (250) 33.8 32,190 (51.6) 29.6 46.2 23.7 0.6
Rheumatoid arthritis 8560 (34) 37.2 5662 (66.1) 30.9 47.8 20.8 0.4
SLE 1197 (5) 35.9 1024 (85.5) 30.2 45.6 23.6 0.7
Type 1 diabetes 14,273 (57) 29.5 6041 (42.3) 23.7 46.4 29.6 0.4
Ulcerative colitis 10,960 (44) 34.3 5392 (49.2) 26.3 47.3 26.0 0.4
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Fig. 1  Sex-specific associations 
(odds ratios with 95% confi-
dence intervals adjusted for 
age and maternal education) 
between ADHD and the autoim-











































































































Table 3  Associations between ADHD and autoimmune diseases among males and females, and the p-value for the interaction between ADHD 
and sex, with adjustment for age and maternal education
Italics: p < 0.05
Bold and italics: p < 0.0056
ADHD attention-deficit/hyperactivity disorder, CI confidence interval, OR odds ratio, SLE systemic lupus erythematosus
a  Age was categorized into four, years of age in 2015: 4–10; 11–15; 16–20; 21–48 and adjusted for as a nominal covariate
Autoimmune disease Females Males All
Adjusted for age  
n = 1,219,669  
ADHD n = 22,878
Adjusted for age and 
maternal education  
n = 1,207,694  
ADHD n = 22,741
Adjusted for age  
n = 1,280,449  
ADHD n = 40,843
Adjusted for age and 
maternal education  
n = 1,267,647  
ADHD n = 40,544
p value of interaction 
between ADHD and 
sex adjusted for age and 
maternal education  
n = 2,475,341  
ADHD n = 63,285
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) p
Ankylosing spondy-
litis
0.56 (0.32–0.96) 0.56 (0.32–0.96) 1.17 (0.88–1.56) 1.16 (0.87–1.55) 0.021
Crohn’s disease 1.47 (1.18–1.82) 1.44 (1.16–1.79) 0.71 (0.54–0.92) 0.71 (0.54–0.92) 3.6 × 10-5
Iridocyclitis 0.84 (0.64–1.12) 0.83 (0.63–1.10) 1.11 (0.92–1.34) 1.11 (0.92–1.34) 0.084
Multiple sclerosis 1.20 (0.90–1.60) 1.19 (0.90–1.59) 0.95 (0.61–1.46) 0.95 (0.61–1.46) 0.35
Psoriasis 1.60 (1.49–1.72) 1.57 (1.46–1.68) 1.34 (1.25–1.43) 1.31 (1.23–1.40) 4.4 × 10-6
Rheumatoid arthritis 1.05 (0.85–1.28) 1.02 (0.83–1.26) 1.01 (0.78–1.30) 0.98 (0.75–1.26) 0.65
SLE 1.26 (0.82–1.94) 1.25 (0.81–1.93) 1.28 (0.52–3.13) 1.29 (0.53–3.16) 0.98
Type 1  diabetesa 1.00 (0.83–1.19) 1.00 (0.84–1.20) 0.98 (0.87–1.11) 0.98 (0.87–1.11) 0.79
Ulcerative colitis 1.27 (1.06–1.53) 1.28 (1.06–1.54) 0.86 (0.71–1.03) 0.86 (0.71–1.03) 0.0023
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Psoriasis, Crohn’s disease and ulcerative colitis
As a robust positive association between psoriasis and 
ADHD was identified, this association was further exam-
ined, both in regards to psoriasis case definition and age- and 
period effects. The supplementary analyses confirmed the 
results of the primary analyses (see supplementary material 
for both specification of analyses and results).
The diagnoses CD and UC partly overlapped as 2334 
individuals in the primary analyses were defined as hav-
ing both conditions (37.1% of the CD patients and 21.3% 
of the UC patients). Supplementary analyses were con-
ducted after redefining all individuals with both CD and 
UC as having neither. The results confirmed the positive 
associations in females, and the interaction by sex, but the 
negative associations in males were now not present (see 
supplementary material for both specification of analyses 
and results). To assess age- and period effects of ADHD on 
CD and UC, analyses stratified on birth years, 1967–1985 
and 1986–2011, were conducted. For CD, the results were 
in line with the main analyses for both individuals born 
1967–1985 and those born 1986–2011, including the sex-
effects. However, for UC, the positive association in females, 
and negative association in males, were only noted in those 
born 1967–1985. For those born 1986–2011, no associations 
were noted (see supplementary material for further specifi-
cation of analyses and results).
Discussion
In our large cross-sectional study based on population-
wide registries, ADHD was clearly and positively associ-
ated with psoriasis. This association was present regard-
less of sex, but with a significantly stronger association in 
females than males. Furthermore, in females, ADHD was 
positively associated with CD and UC. In contrast, among 
males, ADHD showed a negative association with CD, and 
a similar tendency with UC.
Psoriasis is a skin disorder characterized by red scaly 
skin plaques, papules or patches and is generally consid-
ered an autoimmune disease [43]. The etiology behind 
psoriasis is complex, including environmental and life-
style factors [50, 53, 59] and several genetic risk variants 
have been identified, mainly in and around genes involved 
in the immune response and skin barrier regulation [60]. 
In agreement with our findings, a Danish registry-based 
study noted a possible association between psoriasis and 
ADHD [21]. However, the association was not statistically 
significant (p = 0.09), which may be due to the study’s 
prospective study design where the autoimmune diseases 
had to debut prior to ADHD. In contrast, we utilized a 
cross-sectional design. Moreover, we investigated both 
children and adults, 4–48 years of age at linkage, whereas 
the Danish study only examined children and young adults, 
5–22 years old at linkage, which lead to a smaller study 
sample. In addition, many of the individuals in the Danish 
study were simply too young to have developed psoriasis 
[59] or to have been diagnosed with ADHD [1].
Several different mechanisms may account for the asso-
ciation between ADHD and psoriasis. A recent family-based 
epidemiological study reported a significant genetic correla-
tion between ADHD and psoriasis [61], indicating that there 
could be pleiotropic genetic effects in shared risk pathways. 
For example, complement factor C3 is highly expressed 
in both psoriatic lesions [62] and is important for synap-
tic pruning in the brain [63]. Lifestyle and environmental 
factors associated with ADHD, such as smoking and high 
BMI [20, 47, 48, 52], may also provoke psoriasis [50, 53]. 
However, in our mother analyses, adjustment for these risk 
factors did not attenuate the association, implying alternative 
etiological pathways [57, 58]. Furthermore, emotional and 
social stressors associated with ADHD [4, 64] could perhaps 
trigger psoriasis in predisposed individuals [65].
Table 4  Associations between ADHD and Crohn’s disease, ulcerative colitis and psoriasis among females with adjustment for education, smok-
ing and body mass index
ADHD attention-deficit/hyperactivity disorder, BMI body mass index, CI confidence interval, OR odds ratio
a  Restricted to females with information on smoking
b  Restricted to females with information on BMI
Females Adjusted for  educationa  
n = 420,050  
ADHD n = 5636
Adjusted for education and 
smoking n = 420,050  
ADHD n = 5636
Adjusted for education 
and  smokingb  
n = 110,008  
ADHD n = 1814
Adjusted for education, smoking and 
BMI n = 110,008  
ADHD n = 1814
n OR (95% CI) OR (95% CI) n OR (95% CI) OR (95% CI)
Crohn’s disease 1225 1.77 (1.23–2.54) 1.63 (1.13–2.34) 329 2.27 (1.29–4.01) 2.20 (1.24–3.88)
Psoriasis 14,226 1.62 (1.44–1.81) 1.49 (1.33–1.67) 3919 1.39 (1.12–1.72) 1.29 (1.04–1.60)
Ulcerative colitis 2479 1.87 (1.42–2.46) 1.90 (1.45–2.50) 676 2.00 (1.24–3.22) 2.10 (1.30–3.39)
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CD and UC are both diseases primarily affecting the gas-
trointestinal system [51]. They are considered separate dis-
ease entities, but share many similarities, both clinically and 
etiologically, and are referred to collectively as inflammatory 
bowel disease (IBD). More than 150 genetic risk variants 
have been identified for both, many of which are shared, and 
environmental factors are highly implicated in the etiology 
[51, 66, 67]. In a study from Taiwan, ADHD was associated 
with UC, but not CD [22]. However, the authors did not 
report sex-specific effects, raising the possibility that the 
common estimate may be biased, and that the sex-specific 
effects present in our study, were not identified. Moreover, 
the prevalence-ratio of CD to UC was > 10:1 among the 
controls, indicating possible age-effects in addition to ethnic 
differences.
The increased odds of CD and UC in females with 
ADHD, with a reverse relation in males is striking. In addi-
tion, ADHD females had significantly higher odds of pso-
riasis than ADHD males. Sex, including both hormonal and 
non-hormonal influences, is a key determinant of immune 
system functioning [33, 34], brain development, neural func-
tioning and psychiatric disease [30, 31, 38, 39, 68, 69]. A 
possible etiology for the sex-specific effects may involve 
glial cells, which are neuron-and homeostasis-supportive 
cells of the nervous system with immunomodulatory prop-
erties [33, 68, 70]. Glial cells have been shown to modulate 
sex-determined neurodevelopmental processes, including 
synaptic patterning and neurite pruning [68, 69]. Further, 
there are studies suggesting a role for glial cells located 
along the gut in the etiology of CD and UC, in addition to 
several other gastrointestinal disorders [70].
Genetically, pleiotropic associations between psychiat-
ric disorders and autoimmune diseases have been reported 
[16], and so have sex-specific reverse genetic effects [36, 
37]. Thus, we might hypothesize that the inverse associa-
tions observed in our study could be the result of pleiotropic 
variants, exhibiting sex-specific associations in opposite 
directions in either ADHD and/or IBD. Another potential 
mechanism could be that there is a tendency for more genetic 
variants positively associated with both ADHD and IBD to 
be located on the X-chromosome, while on the Y-chromo-
some, there is a greater burden of variants positively asso-
ciated with ADHD, but negatively associated with IBD 
[35]. As the sex chromosomes have been largely ignored in 
GWASs owing to analytical difficulties, this is an area where 
further research is warranted.
Alternatively, smoking and BMI may play a role in the 
sex-discordant associations between ADHD and IBD [20, 
47, 48, 52, 56]. However, adjustment for these potential 
mediators did not affect the associations much in our mother 
analyses, implying that they are weak mediators. Further, 
smoking has been shown to protect against UC, but confer 
risk for CD [51] and can consequently not easily explain our 
results as we then would have expected a negative associa-
tion between ADHD and UC in females. Regarding BMI, 
prospective studies have only associated premorbid BMI 
with CD and not UC [56], which is not in agreement with 
our findings.
It could be that living with ADHD as a female gives rise 
to more stress, for example through social expectations and 
cultural norms, which again might lead to more autoimmun-
ity [51, 65] and potentially, the sex-specific associations. 
However, one study showed that even though ADHD symp-
toms predispose to more stressful life events, female sex has 
been shown not to predispose to more stressful life events 
among those with ADHD symptoms [64].
Our study has several strengths. The use of compulsory 
population-wide registries minimize the risk of selection 
bias, and may provide the statistical power needed to inves-
tigate potential associations between ADHD and different 
autoimmune diseases. Further, the compulsory registration 
of prescription data protects against follow-up bias. How-
ever, we do not have information on medication given to 
hospital inpatients and nursing homes. Considering that the 
individuals in the primary analyses were all under 50 years, 
and that chronic diseases were investigated, we assume these 
factors to be of minor importance.
Another strength is the possibility to adjust for smoking 
and BMI in the mother analyses to assess mediating effects. 
However, we make the assumption that BMI and smoking at 
last registered pregnancy is “representative” of lifetime sta-
tus up to 2015, which is sub-optimal. As the mother analyses 
were based on females, the generalizability to males could 
be questioned. Nonetheless, we consider it biologically 
unlikely that the positive association between psoriasis and 
ADHD is mediated purely by smoking and BMI in males, 
but not in females. In addition, several types of bias may 
occur as the mother analyses were based on only females 
who had given birth, and many autoimmune diseases are 
associated with reduced fertility [71], again possibly affect-
ing the generalizability of the study. We are also aware that 
adjusting for intermediate variables, as we did in the mother 
analyses, may introduce collider stratification bias due to 
unmeasured variables affecting both smoking, BMI and the 
autoimmune diseases [57, 58]. Caution should therefore be 
exercised in the interpretation of these analyses. Also, we 
had problems with missing data for both smoking and BMI.
In Norway, the prescription of medication used in the 
treatment of ADHD is restricted and the drugs are only pre-
scribed after thorough diagnostic evaluation in specialist 
health care. ADHD patients as defined by dispensed drugs 
is therefore presumably specific for ADHD. Nonetheless, 
we have missed patients who used ADHD medication only 
prior to 2004, and those who have never been prescribed 
medications due to contraindications, mild symptoms or 
patients who declined pharmacological treatment. However, 
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a previous study using similar data from the same period, 
demonstrated that only 17% of registered ADHD patients 
had not received ADHD medication [24]. Furthermore, 
our ADHD case definition includes individuals who in 
2004–2008 were prescribed stimulants for treatment of nar-
colepsy, but as this is a very minor number, it should not 
influence the results.
Dispensed medication and reimbursement codes (ICD-10 
codes and ICPC codes as indications for dispensed medica-
tion) were used as proxies for autoimmune diseases. Thus, 
our definitions of autoimmune diseases may not capture all 
patients. For example, patients with primary-progressive 
multiple sclerosis, which constitute 10–15% of multiple scle-
rosis patients, will often not be identified by our approach as 
until recently there have been limited pharmacological treat-
ment options for this group [72]. Further, the reimbursement 
codes may not always be used correctly. Despite the limita-
tions of our disease identification, we believe that a drug 
prescribed with a reimbursement code, indicates thorough 
diagnostics, especially considering that many of the drugs 
may have serious side effects and are not used without due 
consideration.
We found no robust statistically significant associations 
between ADHD and the autoimmune diseases iridocyclitis, 
rheumatoid arthritis, SLE, ankylosing spondylitis, multiple 
sclerosis or type 1 diabetes. This could be due to a genu-
ine lack of association between these autoimmune diseases 
and ADHD. Nonetheless, it could be that the low share of 
individuals born prior to 1990 who have dispensed ADHD-
medication (supplementary Fig. 1) as compared to those 
born later, may reflect ADHD symptom remission before 
2004 when the NorPD was established, or historical underdi-
agnosis and undertreatment of ADHD. Consequently, these 
ADHD individuals are not identified by our case definition. 
On the contrary, many autoimmune diseases are diagnosed 
later in life. Combined, our study may be inadequate for 
discovering associations between ADHD and autoimmune 
diseases with late debut. This may also partly explain the 
absence of any associations between ADHD and UC among 
individuals born 1985–2011 (supplementary material).
As our study is cross-sectional and we exclude all 
deceased or emigrated individuals, this may constitute a 
source of bias as ADHD is associated with increased mor-
tality [73] and so are many of the autoimmune diseases [74, 
75]. However, we do not believe that such bias underlies the 
findings of our study. First, the increased mortality associ-
ated with ADHD, mostly accidents, is unlikely to differ by 
autoimmune diseases nor constitute a large absolute num-
ber. Second, our cohort is relatively young with the old-
est in the main analyses being 48 years of age at linkage. 
Therefore, most of the cohort is too young for cardiovascu-
lar death, which constitute a large portion of the mortality 
associated with autoimmune diseases [74–76]. In addition, 
the findings regarding CD and psoriasis could be identi-
fied among younger individuals in the birth year-stratified 
analyses. On the other hand, not excluding individuals who 
died or emigrated before the end of study could have lead 
to bias. Individuals who received ADHD medication after 
2004, and thus captured by our study as ADHD patients, 
but developed autoimmune diseases and died or emigrated 
before 2008 would be lost.
Another source of bias could be that ADHD patients, 
already in contact with the health services, may get a diag-
nosis of comorbid diseases more easily than individuals 
who do not have an established link with the health ser-
vices. However, one should then expect increased odds of all 
autoimmune diseases, and for both females and males, which 
was not the case. The symptoms of an autoimmune disease 
could also be mistaken for ADHD symptoms. For example 
the itch of psoriasis could lead to lower sleep quality and 
daytime sleepiness [77, 78], which may be mistaken for the 
impaired attention of ADHD. Yet, one would again expect 
increased odds of all autoimmune diseases.
In conclusion, our study supports previous reports on 
associations between ADHD and autoimmune diseases, 
and adds new knowledge about sex-specific associations and 
even reverse direction by sex for some associations. Our 
results also suggest that these associations are not medi-
ated by smoking or BMI. Overall, our study suggests that 
sex-specific immune-mediated neurodevelopment may play 
a role in ADHD etiology, warranting further investigation. 
Future studies investigating the relationship between autoim-
munity and neuropsychiatric disorders should be aware of 
sex-specific effects.
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In the primary analysis, a robust association between attention-deficit/hyperactivity disorder 
(ADHD) and psoriasis was found. To confirm that this association was not due to an unknown 
bias affecting our case definition, we applied several stringent psoriasis case definitions. 
Psoriasis patients were first defined as those who had been dispensed the “topical 
antipsoriatics” calcipotriol (ATC D05AX02), calcitriol (ATC D05AX03) or calcipotriol 
combination (ATC D05AX52) which we believe to be specific, though not sensitive, for 
psoriasis (topical corticosteroids are commonly used in monotherapy) at least once. Secondly, 
as it is not unreasonable to believe psoriasis is more accurately diagnosed in specialist health 
care, psoriasis cases were defined as only those who had been prescribed a drug for psoriasis 
in specialist health care as defined by the ICD-10 code L40, effectively defining all those 
treated exclusively in general practice since 2008 as non-psoriasis individuals. Thirdly, 
psoriasis patients were defined as only those who had been dispensed two or more 
prescriptions for psoriasis based on ICD-10 L40 and/or ICPC S91. Similar analyses as in the 
primary analyses were then conducted. 




Supplementary table 1: Associations between ADHD and psoriasis by different definitions 
among males and females, and the p value for the interaction between ADHD and sex, with 
adjustment for age and maternal education 
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8.5 × 10-7 
a Calcipotriol (ATC D05AX02), calcitriol (ATC D05AX03) and calcipotriol combination (ATC D05AX52) 
b Only based on reimbursement code ICD-code L40 
c Based on reimbursement code ICD-10 L40 or ICPC S91 
ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval; OR, odds ratio 
 
Further, we assessed whether there were any period effects on the association between 
psoriasis and ADHD. We grouped all birth years into 5-year categories and performed 
stratified analyses.  
The results suggested that there were no major period effects. See supplementary table 2. For 
those born years 2002-2006, 9-13 years at time of linkage, there were no associations, for 
neither females nor males. However, for individuals born 2007-2011, 4-8 years at time of 
linkage, the association between ADHD and psoriasis was present for both sexes. The 
associations for 2007-2011 were primarily driven by prescriptions from general practitioners 
(ICPC) (not shown).  
Supplementary table 2: Associations between ADHD and psoriasis per 5-year birth year 
category, 1967-2011bmi 
Females      
Birth 
year  
Total n Psoriasis n Psoriasis specialist na ADHD 
n 
Non-adjusted  
     OR (95% CI) 
1967-
2011 
1 219 669 32 190 12 500 22 878 1.47 (1.37-1.57) 
1967-
1971 
151 219 6937 2746 1643 1.67 (1.38-2.01) 
1972-
1976 
135 848 5819 2227 1784 1.65 (1.37-1.99) 
1977-
1981 
118 015 4478 1774 1804 1.32 (1.07-1.64) 
1982-
1986 
117 810 4235 1578 2261 1.35 (1.11-1.65) 
1987-
1991 
136 399 4081 1532 4129 1.61 (1.39-1.87) 
1992-
1996 
141 336 3176 1203 4770 1.29 (1.08-1.53) 
1997-
2001 
138 641 1963 804 3975 1.37 (1.09-1.73) 
2002-
2006 
135 761 1087 467 2225 1.24 (0.81-1.90) 
2007-
2011 
144 640 414 169 287 3.70 (1.18-11.59) 
Males      
Birth 
year  
Total n Psoriasis n Psoriasis specialist na ADHD 
n 
Non-adjusted 
     OR (95% CI) 
1967-
2011 
1 280 449 30 228 12 341 40 843 1.00 (0.94-1.07) 
1967-
1971 
156 295 7305 2992 1718 1.46 (1.20-1.76) 
1972-
1976 
140 673 6033 2545 2022 1.23 (1.01-1.50) 
1977-
1981 
123 417 4519 1919 2168 1.61 (1.34-1.94) 
1982-
1986 
124 579 3759 1565 2966 1.37 (1.14-1.65) 
1987-
1991 
143 863 3203 1220 6195 1.12 (0.95-1.32) 
1992-
1996 
150 394 2364 883 9364 1.23 (1.05-1.44) 
1997-
2001 
145 859 1562 611 9243 1.20 (0.99-1.45) 
2002-
2006 
142 557 955 398 6130 1.15 (0.86-1.55) 
2007-
2011 
152 812 528 208 1037 2.55 (1.32-4.95) 
a Prescribed drug for psoriasis in specialist health care 
ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval; OR, odds ratio  
 
Crohn’s disease and ulcerative colitis 
Sex-specific associations were noted between ADHD and Crohn’s disease (CD), and ADHD 
and ulcerative colitis (UC) in the primary analyses. However, as 2334 individuals had been 
defined as having both CD and UC (37.1% of the CD patients and 21.3% of the UC patients), 
we investigated whether these associations were linked to only one of the autoimmune 
diseases. To define “pure” CD and UC, all individuals with both diagnoses were redefined as 
having neither CD nor UC. Similar analyses to the primary analyses were then conducted.  
The results confirmed the findings of the primary analysis for females, with ADHD being 
associated with increased risk of both CD, adjusted odds ratio (adjOR) = 1.52 (95%CI: 1.17-
1.99), and UC, adjOR = 1.28 (95%CI: 1.03-1.58).  However, the negative association 
between ADHD and CD among males did not pass the threshold for nominal statistical 
significance, adjOR = 0.79 (95%CI: 0.58-1.08) and no trend for association between ADHD 
and UC among males was noted. The interaction effects were still present, albeit attenuated. 







Supplementary table 3: Associations between ADHD and the autoimmune disorders 
Crohn’s disease and ulcerative colitis after redefining those diagnosed with both autoimmune 
diseases as having neither 
Autoimmune 
disease 
Females Males All 
 n Adjusted 
for age 
n = 








1 207 694 





1 280 449 






n = 1 267 647 
ADHD n = 
40 544 










2 475 341 
ADHD n = 
63 285 




 OR (95% 
CI) 























ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval; OR, odds ratio 
 
Period and age-effects may play a role in the associations between ADHD and the 
inflammatory bowel disorders. We therefore stratified the sample into those born in 1985 or 
earlier, 30 years or older at linkage, and those born after 1985, 29 or younger at linkage. 
Logistic regression analyses similar to the main analyses were then conducted stratified on the 
age groups, including adjusting for age as a linear covariate and maternal education.  
For CD, the results were largely in line with the main analyses, if to accept non-statistically 
significant trends. In females, ADHD increased the odds of CD, while male sex lowered the 
odds. Age and period effects were of minor importance. However, for UC, only among those 
born 1967-1985, were the results similar to the main analyses, with ADHD conferring 
increased odds of UC among females, and decreased odds among males. For individuals born 
1986-2011, no association between ADHD and UC was noted in either sex. See 
supplementary table 4 for detailed results. 
Supplementary table 4: Associations between ADHD and the autoimmune diseases Crohn’s 
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ADHD is a common neuropsychiatric disorder defined by 
a persistent pattern of inattention and/or hyperactivity/
impulsivity that interferes with functioning or develop-
ment (American Psychiatric Association [APA], 2013). 
The first systematic studies of ADHD focused on school-
aged boys (Still, 1902). Later, it was recognized that many 
girls have similar problems, and that symptoms persist 
into adulthood in the majority of cases, with worldwide 
prevalence estimates of ADHD around 2.5% to 3% in the 
adult population (Polanczyk, de Lima, Horta, Biederman, 
& Rohde, 2007; Simon, Czobor, Balint, Meszaros, & 
Bitter, 2009).
In addition to the core clinical symptoms of ADHD, psy-
chiatric and non-psychiatric coexisting problems and clini-
cal conditions have been described in ADHD patients 
(Angold, Costello, & Erkanli, 1999). In particular, psychiat-
ric comorbid conditions are recognized in both children and 
adults, and pose considerable clinical and public health 
challenges (Angold et al., 1999; Halmoy et al., 2010).
Recognition of medical/somatic conditions is also a key 
component in the routine clinical assessment of psychiatric 
patients. Failure to diagnose medical conditions can lead to 
misdiagnosis or incorrect treatment, with potentially seri-
ous consequences. According to the current diagnostic 
criteria for ADHD in the Diagnostic and Statistical Manual 
of Mental Disorders (5th ed.; DSM-5; APA, 2013), the diag-
nosis of ADHD is only considered appropriate if the distur-
bance is not judged to be the direct pathophysiological 
consequence of a specific medical condition (e.g., multiple 
sclerosis, stroke, hypothyroidism). However, in the most 
recent version of the International Classification of Diseases 
and Related Health Problems (ICD-10; World Health 
Organization, 1992), it is also emphasized that psychiatric 
syndromes may be causally related to cerebral and systemic 
diseases, and that proper diagnosis will require two codes: 
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one for the psychopathological syndrome and the other for 
the underlying disorder.
Compared with the extensive descriptions of psychiatric 
comorbidity, somatic comorbidity in ADHD has received 
less attention in the research literature, particularly among 
adults. This discrepancy is obvious in the recent diagnostic 
definition of ADHD (APA, 2013), where many psychiatric 
disorders are listed either as possible differential diagnoses 
or as comorbid conditions. The only non-psychiatric disor-
der specifically mentioned is medication-induced symp-
toms of ADHD. Associated medical conditions have been 
studied more in other psychiatric disorders, where they are 
also considered to contribute to a lower quality of life and 
reduced life expectancy. In schizophrenia, it is known that 
weight gain, diabetes, metabolic syndrome, and cardiovas-
cular disease are common, and it is speculated that a shared 
vulnerability for psychosis and medical conditions can 
explain some of this comorbidity (Ringen, Engh, Birkenaes, 
Dieset, & Andreassen, 2014). Population-based prospective 
studies have documented an increased risk of premature 
death and reduced life expectancy also for ADHD patients 
(Dalsgaard, Ostergaard, Leckman, Mortensen, & Pedersen, 
2015), but it is unclear if this risk is mediated by coexisting 
medical diseases.
The primary objective of this review was to obtain an 
overview of, and evaluate, the literature covering this topic 
during the past 20 years. Secondary objectives were to 
inform clinicians on the most common somatic comorbid 
conditions to enhance optimal patient evaluation and treat-
ment, and to identify particular areas of research that should 
be further investigated.
Method
Literature Search Strategies and Data Sources
We performed a systematic review of the literature address-
ing aADHD and somatic comorbidity. The search strategy 
was developed in collaboration with a university librarian 
experienced in systematic medical literature searches. The 
electronic databases Embase, Psychinfo, and Medline were 
searched in December 2014 and January 2015, limiting the 
search to study participants above 18 years of age. The 
search was finalized on January 26, 2015, retrieving 4,091 
papers. The detailed electronic search strategy is provided 
in Supplementary 1.
After removing duplicates and studies published prior to 
1994 when the Diagnostic and Statistical Manual of Mental 
Disorders (4th ed.; DSM-IV; APA, 1994) was introduced, 
J.T.I. screened title and abstract in the remaining studies, 
excluding papers that clearly did not fulfill the inclusion cri-
teria listed below. Furthermore, reference lists of the 
retrieved papers were hand searched to identify additional 
relevant articles. Other papers of interest found in manual 
search published January 2015 to February 2016 were also 
included. In total, 208 papers were assessed in full text by at 
least one of the authors, depending on their experience and 
fields of expertise, and all papers were discussed by at least 
two. Extraction of data was checked and harmonized by 
two authors (J.T.I. and K.K). Of the 208 papers, 82 were 
excluded using the criteria listed below. Of the 126 remain-
ing papers, 98 contained original data, 26 were classified as 
reviews, one a letter to the editor and one an annotation.
The specific number of included and excluded papers at 
each step is provided in a PRISMA flow chart (Figure 1).
All the 126 studies, both the individual studies and 
reviews, are referred to in the text. Sources of bias in the 98 
individual studies were considered to be mainly related to 
study design, the selection of participants, the size of the 
study, and the methods used to define ADHD and the 
comorbid disorders. All these characteristics were therefore 
assessed and are tabulated in a supplementary table 
(Supplementary 2). Reviews are omitted from this table 
(Supplementary 4 for list). Some additional studies not ful-
filling the inclusion criteria have been mentioned as part of 
the discussion.
Study Selection Criteria
Inclusion criteria. Studies focusing on the comorbidity 
between somatic disease and ADHD in adults (i.e. 18 years 
or older) were included. ADHD was defined according to 
ICD or DSM criteria (ICD-9/ICD-10/DSM-III/DSM-IV/
DSM-5). As indicated in a supplementary table (Supple-
mentary 2), different protocols have been used to classify 
individuals as having aADHD, that is, either (a) aADHD 
clinically diagnosed, included the use of semi-structured 
interviews; (b) ADHD medication used as a proxy for 
ADHD diagnosis; (c) symptoms of ADHD measured by a 
validated ADHD Symptom Rating scale; (d) information on 
ADHD cases from clinical databases. The properties and 
utility of some aADHD instruments have been reviewed 
(Haavik, Halmoy, Lundervold, & Fasmer, 2010) and are 
summarized in Supplementary 3.
For all studies, the reported diagnoses of somatic dis-
ease/comorbidity were fit into broad disease categories as 
defined in the ICD-10. In the cited studies, these diagnoses 
were obtained either after clinical evaluation or from self-
reports. Due to the large number of somatic comorbidities 
studied and the different protocols involved, it was not fea-
sible to systematically describe the inclusion criteria for 
each of the individual somatic comorbidities, but an over-
view of how the somatic diseases are defined, is summa-
rized in Supplementary 2.
Instruments used for ADHD assessment and the most 
commonly used methods to assess for comorbid disorders 
described in the included studies are briefly described and 
listed in Supplementary 3.
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Exclusion criteria. The following exclusion criteria were 
applied: (a) studies not including ADHD as described under 
inclusion criteria, (b) studies including only children and ado-
lescents, (c) publications not subject to peer review, (d) non-
English papers, (e) single case studies, (f) studies describing 
only psychiatric comorbidities as classified in ICD-10 Chapter 
V: Mental and behavioral disorders, and (g) pharmacological 
trials, for example, focusing on specific treatment options and 
not on the comorbid disorder itself. We also excluded studies 
on traumatic incidents, as we consider these to be outside our 
main focus which is somatic diseases comorbid with aADHD.
Classification of Studies
Based on available evidence, the 98 individual studies were 
classified into three categories (Table 1). Category 1 includes 
conditions where the association between ADHD and somatic 
disease is well established and described in meta-analysis or 
systematic reviews. Category 2 includes conditions where 
there is tentative evidence for an association, the associations 
being described in cohort or case-control studies with clini-
cally diagnosed ADHD and the somatic diseases not only 
being based on self-report questionnaires. Comorbidities 
shown in large population-based studies with diagnoses 
retrieved from clinical databases were also included in this 
category. Category 3 includes conditions where the evidence 
was considered too weak to make conclusions, including 
associations described only in studies where ADHD and/or 
somatic comorbidities are not clinically diagnosed (i.e., 
based on self-report questionnaires only) or where the evi-
dence is limited. This category also includes conditions 
where the combined results clearly showed conflicting 
results. Studies on conditions lacking information on diag-
nostic protocols or the age distribution of the ADHD partici-
pants were also categorized in Category 3.
The somatic diseases included in the present review have 
been broadly grouped using ICD-10 codes, although this 
classification in some instances may be arbitrary (e.g. clas-
sifications of sleep problems), due to the application of 
various diagnostic criteria.
Measurements
ADHD scales. The Adult ADHD Self-Report Scale (ASRS) 
was developed in conjunction with the World Health Orga-
nization and is designed to measure current ADHD 
Figure 1.  Flow diagram (from PRISME).
Source. Moher, Liberati, Tetzlaff, and Altman (2009).
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symptoms. A high symptom score on ASRS is not sufficient 
to clinically diagnose ADHD in adults but is frequently used 
in research literature to define study populations with possi-
ble ADHD (Kessler et al., 2005). The Wender Utah Rating 
Table 1. Name of Disease Category, ICD-10 Code, and Number of Individual Studies Investigating the Association Between Adult 




Association and quality of 
evidencea
In general 4  
 Resistance to thyroid hormone E07.8 1 Association (3)
 Hypothyroidism E00-E03 1 Association (3)
 Diabetes E10-E14 3 No/negative association (3)
Nutritional diseases
 Obesity E66 22 Association (1)
Metabolic disorders E70-E90  
 In general 1 Association (3)
 Albinism E70.3 1 Association (3)
 Maple syrup urine disease E71.0 1 Association (3)
Diseases of the nervous system
 Restless legs G25 6 Association (3)
 Dementia with Lewy bodies G31.83 1 Association (3)
 Epilepsy G40 3 Association (3)
 Migraine G43 2 Association (2)
 Sleep disorders G47 25 Association (1)
 Myotonic dystrophy G71.1 2 Association (3)
 Chronic fatigue syndrome G93.3 2 Association (3)
Diseases of the circulatory system Chapter IX 4 No association (2)
Allergic diseases
 In general 2 Association (3)
 Allergic rhinitis J30 1 Association (3)
Respiratory disorders Chapter X  
 In general 2 Association (3)
 Asthma J46 7 Association (1)
Diseases of the digestive system Chapter K  
 In general 1 Association (3)
 Irritable bowel syndrome K58 2 Association?b (3)
 Celiac disease K90.9 3 Association (2)
Skin disorders Chapter XII  
 In general 1 No association (3)
 Atopic dermatitis L20 1 Association (3)
 Alopecia areata L63 1 No association (3)
 Acne (ICD-10: L70) L70 1 Association (3)
Musculoskeletal disorders Chapter XIII  
 In general 3 Association (3)
 Rheumatoid arthritis M05-M06 1 No association (3)
 Systemic lupus erythematosus M32 2 Association (3)
 Fibromyalgia M79.7 2 Association (3)
 Calvé-Legg-Perthes M91.1 1 Association (3)
Congenital syndromes and anomalies Chapter XVII 12  
Symptoms/signs involving the urinary system R30-R39  
 In general 1 No association (3)
 Enuresis R32 3 Association?b (3)
Note. ICD-10 = International Classification of Diseases; Conditions classified in (1) or ( 2) in bold.
aThe reported studies were classified into conditions (1) where the association between ADHD and the somatic disease is well established, (2) where 
there is tentative evidence for an association, and (3) where evidence is still too weak to make conclusions.
bConflicting evidence. One study shows no association, another study/studies show association. See text for more information.
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Scale (WURS) retrospectively assesses symptoms of ADHD 
in childhood (Ward, Wender, & Reimherr, 1993). For addi-
tional measurements, see Supplement 3.
Measure of obesity. Body mass index (BMI) is defined as 
weight in kilograms divided by height in meters squared. In 
adults, <18.5 kg/m2 is defined as underweight, 18.5 to <25 
kg/m2 is defined as normal, 25.0 to <30 kg/m2 is defined as 
overweight, and a BMI of ≥30 kg/m2 is defined as obese 
(WHO, 1995). BMI is as simple and easy way to evaluate 
obesity and is useful to evaluate obesity trends in the gen-
eral population. However, BMI does not provide an accu-
rate measurement of body fat, nor does it take sex, age, and 
ethnicity into account (Bhurosy & Jeewon, 2013). For addi-
tional measurements, see Supplement 3.
Sleep measurements. Polysomnography is used to record 
several physiologic parameters relevant to sleep, such as 
electroencephalography (EEG), electrooculography 
(EOG), electrocardiography (ECG), chin- and anterio tibi-
alis electromyography (EMG), respiratory effort, airflow, 
and oximetry (Chesson et al., 1997). Polysomnography is 
used in assessing a number of different sleep-related dis-
orders, such as restless legs syndrome periodic limb move-
ments during sleep, central hypersomnias, circadian 
rhythm sleep disorder, and sleep-disordered breathing 
(Kushida et al., 2005). For additional measurements, see 
Supplement 3.
Results
Literature Search and Selection of Papers
A range of different medical conditions have been studied 
in connection with ADHD in adults, as shown in Table 1. 
Most studies represent small clinical samples of ADHD 
patients assessed for a limited number of comorbid condi-
tions, or clinical studies of somatic diseases where comor-
bid aADHD or ADHD symptoms also were diagnosed. A 
limited number of population-based cohort studies have 
also been published during this 20-year period.
The diagnostic protocols and quality of the clinical 
assessments of ADHD varied between studies, as was the 
case for the somatic/medical comorbid conditions. However, 
for the purpose of this literature study, we did not consider 
it appropriate to limit this overview to a specific diagnostic 
protocol or classification system. Thus, the cited preva-
lences are not directly comparable.
ADHD comorbidity with sleep disorders or obesity has 
previously been reviewed. However, for the majority of 
conditions mentioned, the differences in research designs, 
the limited number of cases, and the fact that most condi-
tions were only described in few studies made it unfeasible 
to perform meaningful meta-analyses of prevalences.
Somatic Health in General
ADHD is associated with generally impaired somatic 
health (Nigg, 2013) and increased medical costs (Secnik, 
Swensen, & Lage, 2005) when compared with unaffected 
sex- and age-matched controls, even when no differences 
in health habits were identified (Spencer, Faraone, Tarko, 
McDermott, & Biederman, 2014). In a prospective U.S. 
study including 72 ADHD cases and 479 controls, ADHD 
was diagnosed through clinical interviews in adolescence. 
When reassessed at >10 years, having ADHD was signifi-
cantly associated with impaired general physical health 
(Brook, Brook, Zhang, Seltzer, & Finch, 2013). When ret-
rospectively investigating U.S. health care claims for 2006, 
matching adults with ADHD (n = 31,752) to non-ADHD 
(n = 95,256), adults with ADHD had more physical comor-
bidities and were more likely to use non-psychiatric health 
care compared with controls (Hodgkins, Montejano, 
Sasane, & Huse, 2011).
Obesity (ICD-10: E66)
Clinical samples. Obesity is one of the most frequently 
reported comorbid medical conditions in aADHD. The 
prevalences of clinically diagnosed ADHD and suspected 
ADHD based on rating scales have been reported to be 10% 
to 32% in studies exploring adults with obesity or obesity 
treatment, mainly including female participants (Alfonsson, 
Parling, & Ghaderi, 2012; Altfas, 2002; Docet, Larranaga, 
Fernandez Sastre, & García-Mayor, 2010; Fleming, Levy, 
& Levitan, 2005; Levy, Fleming, & Klar, 2009; Pagoto 
et al., 2010; Vogel et al., 2015). Similarly, in a Dutch study 
with 202 clinically assessed aADHD patients and 189 con-
trols, 16.8% of the ADHD patients had BMI 30 to 39, com-
pared with only 3.7% of the controls (p < .001; Bijlenga, 
van der Heijden, et al., 2013). In contrast, a small U.S. study 
(137 ADHD participants, 124 controls) found no significant 
differences between participants in age-corrected BMI 
(Biederman, Spencer, Monuteaux, & Faraone, 2010).
It is unclear whether the association between ADHD and 
obesity is dependent on ADHD subtypes (Davis et al., 
2009), but there are indications of higher proportions of 
inattentive symptoms/subtypes (Altfas, 2002; Fleming 
et al., 2005).
Non-clinical samples. The above studies were conducted in 
clinical settings. When examining population-based, non-
clinical samples, results have been less consistent. In a pop-
ulation-based U.S. study, Pagoto et al. assessed 6,735 
participants between 18 and 44 years (52% females; Pagoto 
et al., 2009). A diagnosis of aADHD was associated with 
increased risk of overweight and obesity, also when adjust-
ing for demographic characteristics and major depressive 
disorder, but not when controlling for binge eating disorder 
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in the past year. In a French study using ASRS to assess 
aADHD symptoms, the prevalence of being overweight and 
obese was approximately doubled for persons reporting 
ADHD symptoms (Caci, Morin, & Tran, 2014). In a Ger-
man cross-sectional study including 1,622 residents 
between 18 and 64 years, the prevalence of ADHD based on 
self-reported symptoms in obese participants was 9.7% (de 
Zwaan et al., 2011). Similar to findings of Altfas and Pagoto 
et al. (Pagoto et al., 2009), the prevalence increased with the 
degree of obesity. The associations between estimated 
ADHD and obesity were significant when adjusting for 
sociodemographic characteristics, symptoms of anxiety and 
depression and also purging behaviors, indicating that the 
relationship between obesity and ADHD in adulthood is not 
fully explained by binge eating. A small non-clinical Cana-
dian study also found associations between ADHD symp-
toms and overweight/obesity, independent of binge eating 
(Davis, Levitan, Smith, Tweed, & Curtis, 2006).
A population-based U.S. study included 34,653 partici-
pants who were asked about ADHD symptoms (Cortese, 
Faraone, Bernardi, Wang, & Blanco, 2013). In this study, 
remittent ADHD was not significantly associated with obe-
sity, whereas there was an association in adults with persis-
tent ADHD. However, after adjusting for mood and anxiety 
disorders, the association was no longer significant. In con-
trast, a 33-year follow-up study including 111 males, remit-
tent, but not persistent ADHD was associated with obesity, 
also after adjusting for sociodemographic characteristics 
and lifetime mental disorders (Cortese, Ramos-Olazagasti, 
et al., 2013).
The prevalence and comorbidity of ADHD in older 
adults have generally been little explored. In a Dutch study 
including 231 random older participants from the popula-
tion registries (Meanage = 71.6 years), 23 of the participants 
were clinically diagnosed with ADHD (Semeijn et al., 
2013). In this age group, there was no association between 
ADHD and BMI or waist circumference.
Meta-analyses. In a meta-analysis by Cortese et al., on the 
association between aADHD and obesity, 11 data sets with 
a total of 2,046 aADHD participants and 63,747 controls 
were analyzed, including previously unpublished studies 
(Cortese et al., 2015). Studies of individuals in bariatric 
clinics were excluded. The pooled prevalence of obesity 
was 28.2% (95% confidence interval [CI] = [22.8%, 
34.4%]) in adults with ADHD relative to 16.4% [13.4%, 
19.9%] in those without ADHD. When analyzing all age 
groups, age did not influence the association between 
ADHD and obesity, indicating that the relationship may be 
present from childhood (Cortese et al., 2016). This was sup-
ported by two prospective cohort studies from the United 
States (Anderson, Cohen, Naumova, & Must, 2006; Cor-
tese, Ramos-Olazagasti, et al., 2013). The association 
between ADHD and obesity found in the meta-analysis by 
Cortese et al. remained significant when limiting to studies 
where ADHD was diagnosed by direct interview, using 
directly measured height and weight and after adjusting for 
confounding factors.
In a meta-analysis conducted by Nigg et al., a total of 43 
population-based samples or case-control studies including 
703,937 participants in all age groups were included (Nigg 
et al., 2016). The pooled effect size expressed as odds ratio 
(OR) was 1.22 [1.11, 1.34], increasing to 1.37 [1.19, 1.58] 
when limiting data to adults of 18 years or more, and was 
not significant for children.
Combined ADHD and obesity comorbid with other 
conditions. The combination of obesity and ADHD also 
shows comorbidity with other psychiatric disorders, for 
instance mood and anxiety disorders (Cortese, Faraone, 
et al., 2013), and disturbed eating behavior/binge eating 
(Alfonsson et al., 2012; Davis et al., 2006; Nazar et al., 2014; 
Strimas et al., 2008). Compared with obese adults without 
ADHD, obese people with ADHD symptoms are three times 
more likely to suffer from abnormal eating behaviors (Docet, 
Larranaga, Perez Mendez, & Garcia-Mayor, 2012). Obesity 
is also associated with excessive sleepiness, which may pro-
duce ADHD symptoms (Cortese, Konofal, & Lecendreux, 
2008). A mediation analysis conducted as part of a clinical 
study, including 114 patients with obesity, 202 aADHD 
patients, and 154 controls, showed that both sleep duration 
and unstable eating patterns mediated the association 
between BMI and ADHD symptoms. A link between ADHD, 
obesity, and iron deficiency has also been discussed (Cortese 
& Angriman, 2014).
Implications for treatment. Several of the cited studies have 
emphasized the importance of recognizing comorbid condi-
tions for planning optimal treatment of either ADHD or 
obesity. Treatment for obesity in people with ADHD may 
be less successful compared with obese people without 
ADHD (Altfas, 2002; Pagoto et al., 2010), and treatment of 
comorbid ADHD in obese individuals may improve the 
treatment for obesity (Cortese & Castellanos, 2014). Clini-
cians should also consider abnormal eating behaviors as 
contributing to obesity in ADHD patients (Cortese & Mor-
cillo-Peñalver, 2010; Nazar et al., 2014).
Treating ADHD successfully might help people with 
obesity and ADHD to better manage overeating ( Davis, 
2009), reduce self-blame, and facilitate the process of 
regaining control for persons with abnormal eating behav-
iors (Cortese, Bernardina, & Mouren, 2007). Behavioral 
treatment may contribute to weight reduction, but this has 
not yet been investigated in well-controlled studies (Cortese 
& Morcillo-Peñalver, 2010). ADHD medication may act on 
brain pathways involving both ADHD and mediating abnor-
mal eating behaviors (Cortese, Angriman, et al., 2008). It 
has been hypothesized that stimulant treatment may 
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decrease impulsiveness and thus improve abnormal eating 
behaviors (Cortese & Morcillo-Peñalver, 2010). Treatment 
of comorbid ADHD in obese individuals may improve the 
otherwise poor effects of standard treatment strategies for 
obesity (Cortese & Angriman, 2014). This is supported by a 
small Canadian study where ADHD patients treated with 
stimulant medication had a significant weight reduction, 
whereas the weight increased in the non-medicated group 
(Levy et al., 2009). Furthermore, a meta-analysis by Cortese 
et al. limited to studies on unmedicated patients only 
showed a pooled estimate for obesity of OR = 1.43 [1.23, 
1.67], compared with OR = 1.00 [0.87, 1.15] when limiting 
to medicated patients only (Cortese et al., 2016).
Finally, clinicians should be aware that comorbid anxi-
ety and mood disorders may be more directly linked to obe-
sity than to ADHD itself, and also take these disorders into 
account when planning treatment (Cortese, Faraone, et al., 
2013).
Restless Legs Syndrome (RLS; ICD-10: G25)
RLS is a neurological disorder which makes it difficult to 
fall asleep. RLS has a reported population prevalence of 
3% to 34%, generally increasing by age and highest in 
women (Allen et al., 2005; Milligan & Chesson, 2002; 
Rijsman, Neven, Graffelman, Kemp, & de Weerd, 2004). It 
is characterized by an unpleasant feeling in the feet or other 
limbs, combined with an urge to move the limb to relieve 
the discomfort. The symptoms primarily occur when a per-
son is relaxed or trying to sleep, and is often combined with 
paresthesias or dysesthesias. Poor quality of sleep associ-
ated with RLS can lead to hyperactivity and lack of con-
centration, and dopaminergic agents are used to treat the 
condition.
Two small studies showed that the prevalence of RLS is 
higher in persons with ADHD compared with controls 
(Schredl, Alm, & Sobanski, 2007; Zak, Fisher, Couvadelli, 
Moss, & Walters, 2009), and another small study showed 
that ADHD is also more common among patients with RLS 
compared with controls (Wagner, Walters, & Fisher, 2004). 
People with combined ADHD and RLS had more severe 
ADHD symptoms compared with those with ADHD with-
out restless legs symptoms (Zak et al., 2009). In a German 
population- based sample (Roy et al., 2015), crude analysis 
showed that aADHD was associated with RLS. However, 
this association was no longer significant when adjusting 
for sleep disturbances. Pearson et al. reported a non-signifi-
cant increase in the use ADHD medication (amphetamines) 
in 110 restless legs patients (Mage 61 years; p = .09) com-
pared with 54 age- and race-matched controls (Pearson 
et al., 2008). Steinlechner (Steinlechner et al., 2011) found 
that parents of children with ADHD had an increased risk of 
RLS compared with the population prevalence. There is 
also evidence of increased psychiatric comorbidity and 
RLS in families with ADHD (Steinlechner et al., 2011), and 
that symptoms of restless legs are related to depressive 
symptoms among ADHD patients (Schredl et al., 2007). 
Appropriate management of RLS can in some cases cause 
improvement of the comorbid disorder (Becker & Novak, 
2014).
Epilepsy (ICD-10: G 40)
Epilepsy is a common neurological brain disorder defined 
as “an enduring predisposition to generate epileptic sei-
zures” and “the neurobiologic, cognitive, psychological, 
and social consequences of this condition” (Fisher et al., 
p. 471, 2005).
The cognitive dysfunction and behavioral disturbances 
associated with epilepsy have similarities with both the core 
symptoms and adjunctive features of ADHD. The cognitive 
deficits may be a consequence of recurrent seizure activity 
in the brain, adverse effects of anti-epileptic drugs, or it 
could represent an inherent part of the syndrome.
The prevalence of epilepsy in the general population is 
estimated to be around 0.4% to 1% (Forsgren, Beghi, Oun, 
& Sillanpaa, 2005; Russ, Larson, & Halfon, 2012), with 
decreasing prevalence and incidence with age. Thus, like 
for ADHD, the majority of cases with childhood-onset epi-
lepsy will remit over time, although accompanying symp-
toms, comorbidity, and impairment may remain (Sillanpaa 
et al., 2015).
A reciprocal comorbidity between ADHD and epilepsy 
is well known in pediatric populations (Davis et al., 2010; 
Socanski, Aurlien, Herigstad, Thomsen, & Larsen, 2013); 
however, less is known about the comorbidity between the 
two disorders in adults. We found only two studies investi-
gating the prevalence and co-occurrence of ADHD in adult 
patients with epilepsy (from both the same group and sur-
vey [Ettinger et al., 2015; Ottman et al., 2011]) and no pub-
lished study investigating the prevalence of epilepsy in 
adult patients with ADHD. In their population-based, longi-
tudinal health survey including more than 172,000 adults 
aged 18 years or more, Ottman et al. (2011) found a preva-
lence ratio of ADHD of 2.4 (2.0-2.8) among adults with epi-
lepsy relative to a control group without epilepsy. Both the 
diagnoses of epilepsy and ADHD were based on self-
reported lifetime occurrence of the disorders. In a follow-up 
of these data, Ettinger et al. (2015) investigated the pres-
ence and impact of ADHD symptoms in adults with self-
reported epilepsy (Ettinger et al., 2015). Using ASRS, they 
found that 18.4% of adults with epilepsy screened positive 
for ADHD. A positive screen for ADHD was associated 
with greater severity of epilepsy (frequency of seizures, 
more use of anti-epileptic drugs), more comorbidity with 
anxiety and depression, lower quality of life, and worse 
functioning/more disabilities in work and social life. A 
Dutch study found that 2.4% of patients with epilepsy 
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admitted to a special clinic for epilepsy were diagnosed 
with ADHD (van der Feltz-Cornelis & Aldenkamp, 2006), 
compared with a 1% prevalence of ADHD in the Dutch 
population (Kooij et al., 2005).
The comorbidity between ADHD and epilepsy may have 
diagnostic, prognostic, and treatment implications for both 
disorders. Central stimulants may theoretically increase sei-
zure susceptibility, although the documentation for this in 
patients with epilepsy is limited and shows conflicting 
results (Brown, Becker, Pollard, & Anderson, 2013; 
Gonzalez-Heydrich et al., 2010). We found only two small 
studies of methylphenidate (MPH) treatment in adults with 
epilepsy (Moore, McAuley, Long, & Bornstein, 2002; van 
der Feltz-Cornelis & Aldenkamp, 2006); none of these 
demonstrated adverse effects of this treatment.
Migraine (ICD-10: G43)
Migraine is an episodic headache disorder, with attacks of 
pain and time-limited neurological dysfunction. Migraine is 
common in the general population and usually starts in ado-
lescence or early adulthood. The prevalence is approxi-
mately 10% to 15%, and females are more often affected 
than males (Fasmer, Halmoy, Oedegaard, & Haavik, 2011). 
Thus, compared with ADHD, migraine has a very different 
profile regarding its prevalence, gender distribution, and age 
of onset. Both migraine and ADHD have a strong genetic 
basis, and a similar well-established comorbid connection 
with both mood and anxiety disorders is found in clinical 
and epidemiological studies (Fasmer et al., 2012). Cognitive 
dysfunction is not usually thought to be associated with 
migraine, apart from changes occurring during acute attacks.
Two large Norwegian studies showed an association 
between ADHD and migraine. Using data from the 
Norwegian Prescription Database, a positive and significant 
association between prescription of anti-migraine and 
ADHD medication was found for all age groups between 20 
and 50 years and for both genders, with ORs ranging from 
1.8 to 2.8 (Fasmer et al., 2012).
In a cross-sectional study of aADHD patients (n = 572) 
and community controls (n = 675), the prevalence of 
migraine was higher in the patient group compared with the 
controls (28.3% vs. 19.2%, p = .001) (Fasmer, Halmoy, 
Oedegaard, & Haavik, 2011). The difference from controls 
was more marked for men (22.5% vs. 10.7%, OR = 2.43, CI 
= [1.51, 3.90]) than for women (34.4% vs. 24.9%, OR = 
1.58, CI = [1.13, 2.21], although not significanlty so. 
Among the controls, the presence of migraine was associ-
ated with higher scores on both ASRS and WURS.
Sleep Disorders (ICD-10: G47)
ADHD and ADHD symptoms in adults are related to a 
variety of sleep problems and sleep-related disturbances, 
both in clinical and non-clinical samples (Boonstra et al., 
2007; Fargason, Hollar, White, & Gamble, 2013; Gau 
et al., 2007; Kass, Wallace, & Vodanovich, 2003; Oosterloo, 
Lammers, Overeem, de Noord, & Kooij, 2006; Schredl 
et al., 2007; Surman et al., 2009; Vogel et al., 2015; Walters, 
Silvestri, Zucconi, Chandrashekariah, & Konofal, 2008; 
Yoon, Jain, & Shapiro, 2012). Fisher et al. (2014) found 
that 80% of adults with ADHD reported sleep problems, 
regardless of sex and ADHD subtype. Sleep problems were 
more common in aADHD than in controls, also when tak-
ing psychiatric comorbidity and psychotropic medication 
into account (Schredl et al., 2007; Surman et al., 2009). 
Furthermore, persons with sleep problems performed 
worse on neuropsychological testing for attention (Fisher 
et al., 2014). Subjectively, patients with ADHD (without 
current psychiatric comorbidity or ADHD pharmacother-
apy) reported worse sleep quality than controls (Philipsen 
et al., 2005), with more insomnia and problems with the 
sleep–wake pattern (Schredl et al., 2007). In a clinical sam-
ple of ADHD patients without psychiatric comorbidity and 
denying having insomnia symptoms, the ADHD sample 
reported more sleep quality problems compared with con-
trols (Fargason et al., 2013). Measured objectively by poly-
somnography, adults with ADHD showed increased 
nocturnal activity compared with controls (Kooij, 
Middelkoop, van Gils, & Buitelaar, 2001; Middelkoop, 
Van Gils, & Kooij, 1997; Philipsen et al., 2005; Sobanski, 
Schredl, Kettler, & Alm, 2008), although one study found 
no difference between the groups (Boonstra et al., 2007). 
Several studies show that people with ADHD have longer 
sleep latency than controls (Boonstra et al., 2007; Sobanski 
et al., 2008), but the results are conflicting (three studies 
showing no difference between ADHD patients and con-
trols: Kooij et al., 2001; Middelkoop et al., 1997; Philipsen 
et al., 2005).
Excessive daytime sleepiness affects 37% of adults with 
ADHD (Oosterloo et al., 2006), and appears to be a predic-
tor of academic and overall functional impairment among 
students with ADHD (Langberg, Dvorsky, Becker, & 
Molitor, 2014). Furthermore, sleepiness and inattention can 
correlate in ADHD patients (Oosterloo et al., 2006). 
However, a small study by Sangal and Sangal (2004) 
showed no correlation between self-reported sleepiness and 
current inattentive symptoms, concluding that sleepiness is 
not a major contributor to inattention in aADHD individu-
als. It is important to be aware of the possible diagnostic 
confusion between aADHD and hypersomnia or narcolepsy 
using self-report questionnaires, as there is a high degree of 
symptom overlap (Oosterloo et al., 2006).
Sleep and ADHD subtype. Studies investigating the associ-
ation between ADHD and comorbid sleep disorders with 
respect to ADHD subtypes show diverging results. Both 
inattentive and hyperactive-impulsive ADHD symptoms 
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have been associated with delayed sleep timing (Gamble, 
May, Besing, Tankersly, & Fargason, 2013). In a study of 
62 students diagnosed with ADHD, students with the inat-
tentive subtype did not differ from those with combined 
subtype on self-ratings of daytime sleepiness (Langberg 
et al., 2014). However, in two studies with a total of 62 
non-medicated patients with ADHD, sleep problems were 
associated with having the combined ADHD subtype and 
symptoms of hyperactivity/impulsivity (Mahajan, Hong, 
Wigal, & Gehricke, 2010; Van Veen, Kooij, Boonstra, 
Gordijn, & Van Someren, 2010), and hyperactivity alone 
has been associated with decreased sleep duration (Gau 
et al., 2007). No significant associations were found 
between inattention and sleep quality, suggesting that 
sleep problems are connected with hyperactive-impulsive 
but not inattentive symptoms (Mahajan et al., 2010). In 
contrast to these results, which were based on small sam-
ples, other studies found that symptoms of inattention 
were most evidently associated with disturbed sleep, 
delayed circadian rhythm, and greater sleep need (Bae 
et al., 2010; Caci, Bouchez, & Bayle, 2009; Gau et al., 
2007; Rybak, McNeely, Mackenzie, Jain, & Levitan, 
2007; Voinescu, Szentagotai, & David, 2012).
Symptom severity. The severity of sleep problems is posi-
tively correlated with the number of ADHD symptoms, 
both among ADHD patients and in the general population 
(Gau et al., 2007; Mahajan et al., 2010; Schredl et al., 2007), 
also when taking ADHD comorbidity and medication into 
account (Schredl et al., 2007). The severity of daytime 
ADHD symptoms was also associated with the level of 
sleep problems (Schredl et al., 2007). Daytime sleepiness is 
associated with increased ADHD severity (Gamble et al., 
2013), and is a predictor of academic and overall functional 
impairment among students with ADHD (Langberg et al., 
2014).
Insomnia (ICD-10: G47.0). Insomnia implies dissatisfaction 
with sleep quantity or quality due to difficulty initiating 
sleep, maintaining sleep or early-morning awakenings. The 
symptoms impair daily functioning and affect about 6% to 
12% of the adult population when ascertained according to 
formal diagnostic systems (Pallesen, Sivertsen, Nordhus, & 
Bjorvatn, 2014). Insomnia is common in people with 
ADHD; one study showed that 78% of the 40 non-medi-
cated ADHD participants included suffered from sleep-
onset insomnia (Van Veen et al., 2010), another study 
showed that the higher reports of insomnia among ADHD 
patients compared with controls may be related to the pres-
ence of depressive symptoms (Schredl et al., 2007). Sleep-
onset insomnia, defined as difficulty getting to sleep at the 
desired bedtime, is the most problematic sleep problem 
reported in ADHD (Fisher et al., 2014), and is also a promi-
nent initial side effect of stimulant medication.
Circadian rhythm sleep disorder, delayed sleep phase type (ICD-
10: G47.21). Delayed sleep phase syndrome implies a dis-
turbance in the normal circadian rhythm. It is characterized 
by a preference for late sleep and late rising, with sleep-
onset insomnia when trying to get to sleep early and high 
activity in the late evening/night. The prevalence in the 
adult general population is estimated at 0.13% to 3.1% 
(Ando, Kripke, & Ancoli-Israel, 2002; Schrader, Bovim, & 
Sand, 1993). In a Dutch study by Bijlenga et al., including 
202 adults with clinically diagnosed ADHD (18-65 years) 
and 189 controls, delayed sleep phase syndrome was more 
prevalent among aADHD patients (26%) than among con-
trols (2%; Bijlenga, van der Heijden, et al., 2013). Adults 
with comorbid ADHD and insomnia were found to have 
significant circadian rhythm delay, the severity of ADHD 
symptoms and neuropsychological deficits correlating with 
the delay (Gamble et al., 2013; Rybak et al., 2007). In con-
trast to the controls, the patients with aADHD had the same 
prevalence of delayed sleep phase syndrome independent of 
age, the authors suggesting that delayed sleep phase syn-
drome in ADHD is not age related (Bijlenga, Van Someren, 
et al., 2013).
Hypersomnia (ICD-10: G47.1 and G47.4). Central hypersom-
nias such as idiopathic hypersomnia (G47.1) and narco-
lepsy (G47.4) cause excessive daytime sleepiness not 
caused by disturbances in nocturnal sleep or circadian 
rhythm. In a study including 74 patients with narcolepsy 
(G47.4) or idiopathic hypersomnia (G47.1), 19% of the 
affected patients fulfilled the criteria for aADHD when 
using self-report measures (Oosterloo et al., 2006). The 
overlap between symptoms of hypersomnia and ADHD 
might lead to misdiagnosis of both diagnoses (Oosterloo 
et al., 2006). However, both ADHD and hypersomnias are 
treated using psychostimulant medication, indicating a rela-
tion between these disorders (Oosterloo et al., 2006).
Sleep-disordered breathing (ICD-10: G47.3 and G47.8). Sleep-
disordered breathing includes a spectrum of sleep-related 
abnormalities such as upper airway resistance syndrome 
(G47.8) and obstructive sleep hypopnea syndrome (G47.3), 
with symptoms such as snoring, episodes of breathing cessa-
tion during sleep, and excessive daytime sleepiness. Approx-
imately 13% of men and 6% of women suffer from moderate 
to severe sleep-disordered breathing (Peppard et al., 2013). 
Of 78 severely obese adults with ADHD, 56% had sleep 
apnea (Levy et al., 2009). The cognitive and behavioral 
symptoms of obstructive sleep apnea such as inattention, 
poor planning, and restlessness, are similar to symptoms of 
ADHD (Ball, Wooten, & Crowell, 1999), and treatment may 
have a positive effect on ADHD symptoms (Youssef, Ege, 
Angly, Strauss, & Marx, 2011). In a case report of six adults 
with clinically diagnosed ADHD and impaired sleep quality, 
all had polysomnographic evidence of sleep-disordered 
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breathing (Surman, Thomas, Aleardi, Pagano, & Biederman, 
2006). One study indicated that sleep-disordered breathing 
symptoms are mainly associated with increased BMI and 
smoking, and not ADHD symptomatology as such (Schredl 
et al., 2007). In a Turkish study of 81 treatment-naïve 
obstructive sleep apnea patients and 32 controls, the preva-
lence of ADHD symptoms was similar in patients with 
obstructive sleep apnea and controls (Oguzturk, Ekici, 
Cimen, Ekici, & Senturk, 2013). One study found a correla-
tion between low oxygen saturation and hyperactivity in 
patients with sleep-disordered breathing (Sangal & Sangal, 
2004). In two small case studies with a total of nine aADHD 
patients, it was observed that treatment for sleep apnea 
relieved their ADHD symptoms, and some were rediagnosed 
as having sleep apnea instead of ADHD (Ball et al., 1999; 
Naseem, Chaudhary, & Collop, 2001). According to these 
results, sleep apnea may actually be misdiagnosed as ADHD.
Periodic limb movements during sleep (ICD-10: G47.61). In the 
disorder called periodic limb movements during sleep, con-
tractions of muscles during sleep causes periodic episodes 
of repetitive limb movements. Unmedicated patients with 
ADHD show increased periodic limb movements during 
sleep compared with controls (Philipsen et al., 2005; Soban-
ski et al., 2008).
Impact of stimulant medication. Sleep problems are present in 
unmedicated adults with ADHD, but stimulant treatment is 
also associated with dysregulation of sleep. Common initial 
side effect of stimulant medication is insomnia or delayed 
sleep-onset latency (Kirov & Brand, 2014; Kooij & Bijlenga, 
2013). Atomoxetine may also cause insomnia as an adverse 
effect (Adler, Liebowitz, et al., 2009). It varies between indi-
viduals whether stimulants cause insomnia or not, and sleep 
problems such as sleep-onset latency may decrease with time 
as the medication is finished titrated and ADHD symptoms 
improve (Stein, Weiss, & Hlavaty, 2012). If ADHD medica-
tion affects the circadian rhythm, the effect on sleep may be 
less obvious and appear later (Stein et al., 2012).
Subjectively measured, ADHD participants using methyl-
phenidatereported an improvement in sleep quality (Kooij 
et al., 2001). A study of the central stimulant lisdexamphet-
amine including 420 participants showed no difference in 
global sleep quality among aADHD patients receiving lis-
dexamphetamine compared with placebo, and daytime func-
tioning in the stimulant treatment group improved compared 
with the aADHD group receiving placebo (study not included 
in the literature search, as it is not a study primarily on comor-
bidity; Adler, Goodman, Weisler, Hamdani, & Roth, 2009). A 
clinical study including 80 aADHD patients all denying 
insomnia symptoms (treated with stimulants, n = 39; with 
non-stimulants, n = 15 and with no medication, n = 26), 
showed significantly more sleep disturbance and prolonged 
sleep latency compared with controls (n = 25). This result 
indicated that medical treatment, including stimulant treat-
ment, did not account for the sleep quality problems in the 
aADHD group (Fargason et al., 2013).
Objectively measured, sleep-onset latency increased 
(Boonstra et al., 2007) and sleep duration (Gamble et al., 
2013) was reduced in patients treated with stimulant medica-
tion compared with those without such medication, although 
no change (Kooij et al., 2001) and less sleep latency were 
also reported (Sobanski et al., 2008). Objectively measured, 
sleep quality and efficiency improved (Boonstra et al., 2007; 
Sobanski et al., 2008) in ADHD participants using MPH 
compared with placebo (Boonstra et al., 2007) or compared 
with a premedication baseline (Sobanski et al., 2008). Also 
when adjusted for depression and anxiety symptoms, sleep 
was more consolidated with less interrupted sleep (Boonstra 
et al., 2007). Regarding the impact of MPH treatment on 
nocturnal activity, the results are conflicting: Sobanski et al. 
(2008) found unchanged number of periodic limb move-
ments during sleep in contrast to Kooij et al. (2001) who 
found reduced nocturnal activity. Improvements in sleep 
quality may, however, not be directly related to stimulant 
medication, as the same proportion (one third) of a total of 
831 ADHD participants (n = 831) experienced sleep 
improvement independent of receiving stimulant treatment 
or placebo (Surman & Roth, 2011).
Treatment. ADHD is a 24-hr disease, with symptoms 
appearing both at day- and nighttime (Stein et al., 2012). 
Before starting treatment for ADHD, patients should be 
screened for sleep disorders and sleep patterns, to more eas-
ily track changes in sleep associated with stimulant treat-
ment (Stein et al., 2012). Sleep disorders are associated 
with cognitive impairment, thus ADHD symptomatology 
may improve if comorbid sleep disorders are adequately 
treated in addition to specific treatment for ADHD (Schredl 
et al., 2007). If the patient is using medical treatment for 
ADHD and has sleep problems, give advice on sleep 
hygiene and consider reducing the stimulant treatment in 
the late afternoon, add a small dose of stimulant treatment 
earlier in the evening or switch to non-stimulant medication 
(Brown & McMullen, 2001; Hvolby, 2015; Lecendreux & 
Cortese, 2007). Usually, insomnia as a side effect of stimu-
lant treatment attenuates after 1 to 2 months treatment 
(Lecendreux & Cortese, 2007). When treating aADHD with 
delayed sleep phase syndrome, one can combine stimulant 
treatment with exogenous melatonin together with bright 
light therapy and good sleep hygiene; Kooij et al. describe 
this treatment in detail (Kooij & Bijlenga, 2013).
Other Neurological Disorders  
(ICD-10: Chapter XI)
Dementia with Lewy bodies (ICD-10: G31.83). Symptoms of 
dementia with Lewy bodies include mental decline, 
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Parkinson-like motor symptoms, sleep disturbances, and 
hallucinations. In a study from Argentina including patients 
with Lewy body dementia (n = 109), Alzheimer’s disease (n 
= 251), and sex-, age-, and education-matched controls (n = 
149), previous symptoms of aADHD were associated with 
risk of Lewy body dementia (Golimstok et al., 2011). The 
prevalence of previous ADHD symptoms was significantly 
higher than in both the Alzheimer group (OR = 4.9 [2.8, 
8.4]) and the control group (OR = 5.1 [2.7, 9.6]). ADHD 
symptoms were tested according to DSM-IV criteria using 
WURS and ASRS, and in patients with cognitive impair-
ment information was obtained from an informant knowing 
the patient for at least 10 years. Both ADHD and Lewy 
body dementia are related to a hypodopaminergic state; this 
being a possible explanation for the association (Golimstok 
et al., 2011).
Myotonic dystrophy 1 (DM1; ICD-10: G71.1). Douniol and 
coauthors described the psychiatric phenotype of the juve-
nile form of DM1(Douniol et al., 2009), the most common 
inherited neuromuscular disease, with autosomal dominant 
transmission. The study included 28 people with juvenile 
DM1 from 7 to 24 years of age. In the total sample, includ-
ing both children and adults, 28.6% had ADHD, all inatten-
tive subtypes. ADHD was measured by ASRS in the adults. 
A study by Echenne et al. describes adult cases with comor-
bid ADHD and myotonic dystrophy, but it is not known 
how ADHD was diagnosed or if the participants were tested 
for ADHD as adults (Echenne et al., 2008).
Chronic fatigue syndrome (CFS; ICD-10: G93.3). CFS is char-
acterized by a combination of prolonged and severe fatigue 
with non-specific somatic manifestations and cognitive 
symptoms, including difficulties in concentration, short-
term memory and thinking, impaired attention and slow 
processing speed (Valdizán Usón & Idiazábal Alecha, 
2008). These cognitive symptoms may mimic symptoms of 
ADHD and possibly share some underlying pathophysio-
logical mechanisms (Bellanti et al., 2005). Fatigue symp-
toms are also commonly reported in aADHD and may affect 
neuropsychological functioning (Fisher et al., 2014).
We found only one study on prevalence of aADHD in 
CFS patients (Sáez-Francàs et al., 2012). In their clinical 
sample of 158 adults with CFS, 97% women, Sáez-Francàs 
et al. found that 47 patients (29.7%) fulfilled diagnostic cri-
teria for childhood ADHD assessed retrospectively, and 33 
patients (20.9%) were found to still meet criteria for ADHD 
in adulthood. We found no studies on the prevalence of CFS 
in samples of adults with ADHD, nor any population-based 
studies on CFS and aADHD; thus, the possible relationship 
between these conditions and the magnitude of the problem 
is not clear. Young et al. (2013a) described three female 
cases with CFS (38-58 years), who were also found to fulfill 
criteria for ADHD dating back to childhood (Young, 2013a). 
In all three cases, symptoms of chronic fatigue and/or pain, 
and general and occupational functioning, improved after 
treatment with central stimulants.
Despite the limited amount of literature, the suggested 
association between ADHD and CFS is clinically interest-
ing, as central stimulants, the first-line pharmacological 
treatment of ADHD, have shown positive effects on both the 
core symptom of CSF, that is, chronic fatigue (Blockmans, 
Persoons, Van Houdenhove, & Bobbaers, 2006), and the 
associated cognitive symptoms, such as executive dysfunc-
tion (Young, 2013b).
Endocrine Diseases (ICD-10: E00-E35)
Resistance to thyroid hormone (RTH; ICD-10: E07.8). RTH 
usually involves mutations in the thyroid hormone receptor 
β gene and is often transmitted as an autosomal dominant 
trait. Classical features include ADHD, tachycardia, and 
growth delay. Brucker-Davis et al. (1995) described 104 
RTH patients and 114 unaffected participants, both children 
and adults. ADHD was found to be common among the 
RTH patients; more common in males (72%) than in 
females (43%). Among adults, 42% had ADHD in the RTH 
group compared with 4% in the non-RTH group. Full-scale 
IQ was lower among RTH patients than among controls, 
and 38% of the patients had IQ less than 1 standard devia-
tion (SD) below the mean; however, there was no correla-
tion between IQ and ADHD in the RTH patients.
Hypothyroidism (ICD-10: E00-E03). Hypothyroidism is an 
endocrine disorder in which the thyroid gland does not pro-
duce enough thyroid hormone, leading to a large range of 
symptoms, including weight gain, fatigue, and poor ability 
to tolerate cold. In the previously mentioned study by 
Hodgkins et al., investigating U.S. health care claims for 
2006 (aADHD: 31,752; non-ADHD: 95,256), hypothyroid-
ism was significantly more common in adults with ADHD 
compared with those without (p ≤ .0001; Hodgkins et al., 
2011).
Diabetes (ICD-10: E10-E14). Pancreas insulin cells diabetes 
mellitus is a heterogeneous group of metabolic diseases 
characterized by high blood glucose levels over prolonged 
periods of time. Interestingly, diabetes (ICD-10: E10-E14) 
was significantly higher in the non-ADHD group compared 
with the ADHD group in the above-mentioned study inves-
tigating U.S. health care claims (p ≤ .0001; Hodgkins et al., 
2011). However, a Dutch study including older adults with 
ADHD (n = 23) and controls (n = 208) found no difference 
in self-reported diabetes between the individuals with 
ADHD and controls (Semeijn et al., 2013). Furthermore, a 
U.S. study including adult patients with ADHD (n = 98) and 
controls (n = 100) showed no significant differences in the 
number of self-reported diabetes (Spencer et al., 2014).
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Metabolic Disorders (ICD-10: E70-E90)
Bijlenga et al. have reported a significantly increased fre-
quency of self-reported metabolic disorders among adults 
with ADHD compared with controls (Bijlenga, van der 
Heijden, et al., 2013). We also identified studies describing 
the co-occurrence of aADHD or ADHD symptoms with 
several different inborn metabolic diseases:
Albinism (ICD-10: E70.3). Albinism is an inherited disorder 
causing an absence or reduction of melanin in the hair, skin, 
and/or eyes. The prevalence of albinism worldwide is esti-
mated to 1/17,000 (0.006%), although it varies considerably 
over different continents (Gronskov, Ek, & Brondum-Nielsen, 
2007). In their study of albinism and comorbid ADHD, Kutz-
bach et al. found that 17 of 75 children (22.7%) and 3 of 44 
adults (6.8%) met criteria for ADHD, and that the majority of 
these had the hyperactive/impulsive subtype (Kutzbach, Sum-
mers, Holleschau, King, & MacDonald, 2007).
Maple syrup urine disease (MSUD; ICD-10: E71.0). MSUD is 
an inborn error of metabolism, with clinical features includ-
ing neuropsychiatric disturbances and neurologic deteriora-
tion. Muelly et al. (2013) studied neuropsychiatric 
symptoms in 37 patients with MSUD aged 5 to 35 years; 26 
treated with diet and 11 with liver transplantation. They 
found the cumulative lifetime incidence of ADHD to be 
54% among MSUD patients on dietary therapy and 82% 
among patients with liver transplants. They concluded that 
neurochemical deficiencies correlated with neuropsychiat-
ric morbidity (Muelly et al., 2013).
Diseases of the Circulatory System  
(ICD-10: Chapter IX)
Possible increased risk of cardiovascular events due to 
stimulant treatment of ADHD is an important clinical issue. 
Long-term (≥12 months) stimulant treatment is associated 
with increased heart rate and increased blood pressure, but 
no evidence has so far indicated elevated risk of serious car-
diovascular events (Hammerness, Karampahtsis, Babalola, 
& Alexander, 2015). Although this is a debated issue, only a 
few studies have investigated the comorbidity of ADHD 
and cardiovascular disorders per se; none of them focusing 
on cardiovascular disease alone.
The study by Bijlenga et al. on sleep patterns (202 
aADHD patients, 189 controls) reported a significantly 
increased frequency of self-reported cardiovascular disease 
among adults with ADHD compared with controls 
(Bijlenga, van der Heijden, et al., 2013). In contrast to this, 
another Dutch study including older (Mage = 71.6) adults 
with ADHD (n = 23) and controls (n = 208) found no differ-
ence in self-reported hypertension and cardiovascular dis-
ease between the ADHD individuals and controls (Semeijn 
et al., 2013). In line with this result, no significant differ-
ences between adults with ADHD and controls were found 
concerning hypertension and other cardiovascular diseases 
in the previously mentioned study investigating U.S. health 
care claims for 2006 (31,752 aADHD matched with 95,256 
non-ADHD individuals; Hodgkins et al., 2011). 
Furthermore, a U.S. study including adult patients with 
ADHD (n = 98) and controls (n = 100) showed no signifi-
cant difference in the number of self-reported heart attacks 
(Spencer et al., 2014).
Atopic Diseases/Allergic Diseases (Primarily  
ICD-10: Chapter X and Chapter XII)
The results from a systematic review including mainly stud-
ies on children concluded that atopic disease in general was 
not associated with ADHD, but that atopic eczema specifi-
cally appears to be independently associated with ADHD 
(Schmitt, Buske-Kirschbaum, & Roessner, 2010). For fur-
ther information on atopic eczema, we refer to the paragraph 
describing skin disorders. Information on the allergic disor-
ders asthma, allergic rhinitis, atopic dermatitis, and allergic 
conjunctivitis was collected in a study using data from the 
Taiwan National Health Insurance Research Database from 
1996 to 2010. Patients with ADHD (n = 5,811; ICD-9-CM 
diagnosis), patients with tic disorder, patients with comorbid 
ADHD and tic disorder (n = 349), and age/gender-matched 
controls were retrieved (Chen et al., 2013). Most of the 
ADHD patients included were adolescents and young adults. 
Compared with the control group, the ADHD group showed 
a significantly increased risk of having allergic comorbidi-
ties after adjusting for age, gender, and comorbid psychiatric 
disorders. The comorbid ADHD and tic disorders group 
showed the highest prevalence of allergic disease. The 
results pointed to an additive effect of ADHD and tic disor-
der on the association with allergic comorbidities.
Allergic Rhinitis (ICD-10: J 30). A German study focused on 
allergic rhinitis, and by collecting information from the 
German National Health Insurance beneficiaries, 111,394 
patients with allergic rhinitis in 2005/2006 were retrieved 
(Schmitt, Stadler, Kuster, & Wustenberg, 2016). In addi-
tion, information on different comorbid disorders was col-
lected, including hyperkinetic disorder (F 90). The results 
showed that ADHD was more prevalent among those with 
allergic rhinitis compared with those without, RR = 1.21 
[1.13, 1.29]; however, specific information on adults with 
ADHD was not given.
Respiratory Disorders ICD-10: Chapter X
Asthma (ICD-10: J 46). Two studies reported an association 
between unspecific lung diseases and aADHD (Bijlenga, 
van der Heijden, et al., 2013; Semeijn et al., 2013), while 
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there are several studies on aADHD and comorbid asthma 
(Chen et al., 2013; Fasmer, Halmoy, Eagan, Oedegaard, & 
Haavik, 2011; Fasmer, Riise, et al., 2011; Hodgkins et al., 
2011; Karlstad, Nafstad, Tverdal, Skurtveit, & Furu, 2012; 
Secnik et al., 2005; Spencer et al., 2014). Asthma is an 
inflammatory disorder of the airways, following a chronic 
course, but with episodic worsening. Common symptoms 
are wheezing and coughing, caused by reversible airflow 
obstruction and bronchospasm (Handoyo & Rosenwasser, 
2009). As is the case with ADHD, the disorder usually starts 
in childhood, and also similar to ADHD, psychiatric disor-
ders, in particular mood and anxiety disorders, are often 
comorbid problems (Goodwin, Jacobi, & Thefeld, 2003). 
Tobacco smoking may be another factor that is common to 
these conditions (Thomson, Chaudhuri, & Livingston, 
2004). ADHD patients have a higher smoking prevalence 
than the general population. It is uncertain if smoking is a 
cause of asthma, but it aggravates symptoms among people 
prone to asthma, and passive smoking in childhood and pre-
natal exposure are associated with an increased risk of 
asthma (Fasmer, Halmoy, Eagan, et al., 2011).
The relationship between aADHD and asthma has been 
investigated both in clinical samples and using registry data. 
In a U.S. database search, adults with ADHD were signifi-
cantly more likely to have a comorbid diagnosis of asthma 
compared to controls (p < .01 (Secnik et al., 2005). Data 
from the Norwegian Prescription Database showed a higher-
than-expected occurrence of ADHD in 20- to 29-year-olds 
treated for asthma compared with the general population 
(Karlstad et al., 2012). Similarly, another study using the 
Norwegian Prescription Database showed that patients pre-
scribed central stimulants were also prescribed anti-asth-
matic drugs more often than the remaining population 
(Fasmer, Riise, et al., 2011). In this study, a weaker relation-
ship between ADHD and asthma was found in the younger 
age groups (<20 years) than in the older age groups (>20 
years), although the associations were significant across all 
ages. In a cross-sectional questionnaire-based study of 594 
aADHD patients compared with 719 persons from the gen-
eral Norwegian population, the prevalence of self-reported 
asthma was significantly higher in the ADHD group than in 
controls (24.4% vs. 11.3%). In addition, controls with 
asthma had higher scores on ratings of ADHD symptoms 
(Fasmer, Halmoy, Eagan, et al., 2011). These studies point to 
a comorbidity of ADHD and asthma, apparently most pro-
nounced for adult patients, although none of these four stud-
ies adjusted for smoking as a possible confounder.
Diseases of the Digestive System  
(ICD-10: Chapter K)
Irritable bowel syndrome (IBS; ICD-10: K58). IBS causes 
abdominal pain and bloating, and can lead to both diarrhea 
and constipation. In the previously mentioned U.S. database 
search by Secnik et al. (2005), 2,252 adults diagnosed with 
ADHD did not differ significantly from the corresponding 
large control group in the prevalence of IBS (Secnik et al., 
2005). However, the study by Hodgkins et al. (2011), based 
on U.S. health care claims for 2006 (aADHD: 31,752; non-
ADHD: 95,256), found that adults with ADHD reported sig-
nificantly more IBS compared with those without (p ≤ .0001; 
Hodgkins et al., 2011).
Celiac disease (CD; ICD-10: K90.9). CD is an autoimmune 
disease where the ingestion of the wheat protein gluten 
leads to damage and subsequent atrophy of the intestinal 
villi, and thus may compromise nutrient absorption. The 
primary symptoms are diarrhea, abdominal pain, or discom-
fort, with weight loss and anemia being common complica-
tions. CD is estimated to affect 1% to 2% of the population, 
with increasing prevalence in later years due to new screen-
ing methods and the detection of asymptomatic patients.
Zelnik, Pacht, Obeid, and Lerner (2004) studied the 
prevalence of several neurological disorders in a sample of 
111 young patients with CD (Mage = 20 years, 42% men), 
and found that 23 patients (20.7%) had a learning disability 
(LD) and/or ADHD, compared with 10.5% in a control 
group without CD, recruited from the same pediatric gastro-
enterological clinic (Zelnik et al., 2004). Interestingly, the 
gender distribution of LD/ADHD was very even in the CD 
group (20.3% females and 21.2% males), whereas male 
participants were more affected in the control group (12.9% 
vs. 8.7%), as expected in the general population.
Niederhofer & Pittschieler (2006) found an overrepresen-
tation of ADHD symptoms in patients with CD and investi-
gated possible effects of a gluten-free diet on ADHD 
symptoms in a sample of patients with CD consisting of both 
children and adults (n = 78, age = 3-57 years [M = 19.3]; 
(Niederhofer & Pittschieler, 2006). Interestingly, although 
results should be interpreted with caution due to the small 
sample size and open study design, they found a significant 
reduction of ADHD-like symptomatology after at least 6 
months of gluten-free diet. The reduction of ADHD symp-
toms further correlated with pain reduction. The same 
authors also investigated the presence of CD in a primary 
sample of patients with ADHD (n = 67, 52 males, age = 7-42 
years [M = 11.4]), and found that 10 of the 67 patients were 
positive for CD (seven males, 13.5%, and three females, 
20.0%), defined by the presence of CD-specific antibodies 
(antigliadine and antiendomysium) in blood serum. A glu-
ten-free diet of at least 6 months was associated with 
improvement of ADHD symptoms also in this patient sam-
ple (Niederhofer, 2011).
Skin Disorders (ICD-10: Chapter XII)
For unspecific skin disorders, the study by Bijlenga et al. on 
ADHD and sleep patterns showed no differences in 
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self-reported skin disorders between 202 aADHD patients 
and 189 controls (Bijlenga, van der Heijden, et al., 2013).
Atopic dermatitis (ICD-10: L 20). Atopic dermatitis is a 
chronic, pruritic inflammatory skin condition characterized 
by pruritus and red swollen skin. Several studies, mainly on 
children, have shown a positive association between atopic 
dermatitis and ADHD symptoms (Gee & Bigby, 2011). For 
adults, a Turkish study investigating 60 adult patients with 
atopic dermatitis and 50 non-atopic control participants 
found significantly more ADHD symptoms in patients with 
atopic dermatitis than in controls, the association being 
strongest in females (Cicek et al., 2009). A self-report scale 
showed that features of inattention, hyperactivity, and 
impulsivity were all associated with atopic dermatitis, and 
the authors concluded that co-occurrence of ADHD should 
be taken into consideration when treating patients with 
atopic dermatitis.
Alopecia areata (AA; ICD-10: L 63). AA is a likely autoim-
mune disorder causing hair loss. A register-based study 
from Taiwan (n = 5,117 patients with AA and n = 20,468 
controls) investigated psychiatric comorbidity in patients 
with AA and found no association with AA and aADHD 
(Chu et al., 2012).
Acne (ICD-10: L70). Acne is a skin disorder characterized by 
inflammation of the pilo sebaceous follicle. A registry-
based U.S. study including both children and adults showed 
that ADHD was twice as likely to be associated with acne 
relative to all other dermatological disorders (Gupta, Gupta, 
& Vujcic, 2014), also when adjusting for age, sex, atopic 
dermatitis, anxiety, depression, and stimulant medication. 
However, there were few participants >18 years.
Musculoskeletal Disorders  
(ICD-10: Chapter XIII)
Adults with ADHD report chronic musculoskeletal and skel-
etal complaints, including fibromyalgia (FMS), more fre-
quently than controls without ADHD (Bijlenga, van der 
Heijden, et al., 2013; Spencer et al., 2014). Stray and coau-
thors (2013) investigated motor regulation problems and 
reported musculoskeletal pain in 25 adults with ADHD (all 
responders to treatment with MPH) and 23 control individu-
als. The adults with ADHD scored higher on tests indicating 
more motor problems than control individuals. As much as 
80% of the ADHD patients reported widespread pain; pain 
level was more severe and more often widespread than in the 
control individuals. The authors concluded that motor inhi-
bition problems and heightened muscle tone are, as in chil-
dren with ADHD, increased in adults with ADHD, and that 
the more widespread and higher pain levels may represent 
long-term secondary effects of these muscular problems.
Rheumatoid arthritis (ICD-10: M05-M06). In the Dutch study 
including older adults with ADHD (n = 23) and controls 
(n = 208), no difference in self-reported rheumatoid arthritis 
(ICD-10: M05-M06) was found between the ADHD 
patients and controls (Semeijn et al., 2013).
Systemic lupus erythematosus (SLE; ICD-10: M32). SLE (ICD-
10: M32) is an autoimmune connective tissue disorder 
where many internal organs in the body, as well as the ner-
vous system, may be affected. Neuropsychiatric symptoms 
are common, as described in a systematic review by 
Meszaros and coauthors in 2012 (Meszaros, Perl, & Fara-
one, 2012). In a recent Chinese study, Gao and coworkers 
investigated whether SLE patients (n = 117) had more 
ADHD symptoms than healthy age- and sex-matched con-
trols (n = 64; Gao, Lo, & Mok, 2015). ADHD symptoms 
were assessed by the ASRS. Possible ADHD was found in 
7.7% of SLE patients and 6.3% of controls (p = 1.0); how-
ever, SLE patients had more clinically significant items in 
the inattention domain of the ASRS than the controls (p = 
.006), especially if they had previous cerebral involvement 
(p = .004). Anxiety and depressive symptoms correlated 
with ADHD symptoms.
N-acetylcysteine (NAC) has been reported to improve 
psychiatric symptoms in various disorders (Berk et al., 
2008; Bernardo et al., 2009). In a randomized- controlled 
trial, Garcia and coworkers (2013) investigated whether 
ADHD might serve as a marker for neuropsychiatric dis-
ease in SLE patients and as a target for treatment with NAC. 
They included 49 SLE patients and 46 matched healthy 
controls, and randomized 24 of the SLE patients to receive 
placebo or NAC in two dosages. The authors concluded that 
increased scores on the ASRS indicate previously unrecog-
nized and clinically significant ADHD symptoms that 
respond to NAC treatment in SLE patients.
Fibromyalgic syndrome (FMS; ICD-10: M79.7).  Studies focus-
ing on the comorbidity between aADHD and FMS are few, 
small, and still exploratory in nature. In a sample of 201 
women with FMS, 32.3% fulfilled criteria of childhood 
ADHD, compared with 2.5% in an aged-matched control 
group of healthy women (Reyero et al., 2011).
Based on clinical reports of aADHD with co-occurring 
fibromyalgic complaints, who experienced relief of their 
complaints after medication for ADHD, Krause et al. con-
ducted a German pilot study to investigate the comorbidity 
between ADHD and FMS. Twelve patients with FMS were 
compared with 12 patients with pain of other origin. The 
FMS patients had significantly higher symptom scores of 
ADHD (both past and present) than the other pain patients 
(Krause et al., 1998).
In a Dutch study including 44 patients with FMS, 11 (25%) 
of the patients met the criteria for ADHD after being clinically 
interviewed (Derksen, Vreeling, & Tchetverikov, 2015).
 at Universitetsbiblioteket i Bergen on September 28, 2016jad.sagepub.comDownloaded from 
Instanes et al. 15
Legg-Calve-Perthes disease (LCPD; ICD-10: M91.1). LCPD is a 
disease which leads to deformation of the femoral head, is 
diagnosed in children, and is associated with early hip dys-
function and osteoarthritis of the hip. Hailer and coauthors 
studied health-related quality of life, physical activity, and 
behavior patterns in 116 adult patients with LCPD, who had 
been treated at Uppsala University Hospital between 1978 
and 1995 (Hailer, Haag, & Nilsson, 2014). The patients 
answered self-report questionnaires by interview using 
ASRS to assess ADHD symptoms. A total of 28% had 
ASRS scores corresponding to a likely ADHD diagnosis, 
and a higher ASRS score was associated with a lower score 
on quality of life questionnaires.
Congenital Syndromes and Anomalies  
(Mainly ICD-10: Chapter XVII)
This is a heterogeneous disease entity where various organ 
systems are affected, either as isolated anomalies with 
largely unknown etiology occurring sporadically or as mul-
tiple anomalies which may or may not be part of known 
syndromes or associations. The anomalies may be associ-
ated with environmental exposures or have well-defined 
genetic causes. In all instances, ADHD symptoms may be 
an important feature of the condition, for some genetic syn-
dromes even the presenting feature. If all the clinical crite-
ria of ADHD are fulfilled, it is recommended to separately 
diagnose this as ADHD, irrespective of its association with 
other well defined and perhaps underlying illnesses (APA, 
2013). Most of the research on syndromes and associated 
neuropsychiatric disorders such as ADHD and autism is 
based on children, while we focus on studies where adults 
are included.
Tuberous sclerosis (ICD-10: Q85.1) is an autosomal 
dominant genetic syndrome associated with neuropsychiat-
ric manifestations such as mental retardation, autism spec-
trum disorders (ASD), and ADHD (de Vries et al., 2005). 
ADHD is assumed to be associated with brain lesions due to 
this disorder (Hunt, 1998). Muzykewicz et al. (2007) 
reported that 30% of 241 children and adults (average 20 
years, range = 8 months - 63.4 years) with tuberous sclero-
sis had ADHD symptoms (Muzykewicz et al., (2007). A 
similar fraction of patients had anxiety or depression.
Chromosomal aberrations may also be associated with 
ADHD, as well as with other psychiatric disorders. The 
22q11.2 deletion syndrome (ICD-10: D82.1; velo-cardio-
facial [VCFS] or DiGeorge syndrome) is among the most 
studied genetic syndromes in psychiatry. Whereas high 
rates of ADHD have been reported in children, psychotic 
disorders may be the most prominent psychiatric disorders 
in adulthood (Murphy, 2005); however, psychiatric morbid-
ity in adults is not yet adequately documented (Baker & 
Vorstman, 2012). The clinical phenotype of this relatively 
common syndrome (1/2,000-1/4,000 live births) is highly 
variable. In their comprehensive review of 1,402 partici-
pants with VCFS (age = 6-68 years), Schneider et al. (2014) 
reported that ADHD was the most frequent psychiatric dis-
order in children (37.1%) and among the most common in 
adults (15.6%). In contrast to the general population, where 
the combined type of ADHD is the most common, most 
cases of VCFS had the inattentive form of ADHD. A similar 
prevalence of ADHD was found in a smaller study by Tang 
et al. (2014), where 31% of 112 cases with VCFS (age = 
8-45 years, 37% ≥18 years) had ADHD, and 11% had psy-
chosis. There was no significant effect of age on the preva-
lence of ADHD in this group nor in a study by Niklasson 
et al. where in-depth neuropsychiatric assessments were 
done on 100 consecutive patients with VCFS (16% ≥17 
years; Niklasson, Rasmussen, Oskarsdottir, & Gillberg, 
2009). ADHD was diagnosed in 30 individuals; nine of 
these also had ASD. Gothelf et al. assessed 51 consecutive 
patients with VCFS, aged 16 to 30 years (Gothelf et al., 
2004). Twenty-one patients (41.2%) were diagnosed with 
ADHD (Mage [SD] = 11.1 [6.9]), and this group also had a 
significantly greater prevalence of ADHD among their first-
degree relatives. The authors concluded that ADHD in 
VCFS may have a genetic contribution, and that the VCFS-
related developmental factors might play a lesser role.
Both children and adults with trisomy 21 (Down’s syn-
drome; ICD-10: Q 90; Capone, Goyal, Ares, & Lannigan, 
2006; Edvardson et al., 2014) and fragile X syndrome 
(FXS; ICD-10: Q 99.2; Dorn, Mazzocco, & Hagerman, 
1994; Tranfaglia, 2011) have an increased prevalence of 
behavioral problems and comorbid diagnoses, including 
ADHD. FXS is the most common hereditary cause of intel-
lectual disability in men and also affects women. 
Hyperactivity symptoms in FXS usually decline with age 
(Tranfaglia, 2011). Unlike conventional X-linked disor-
ders, men can be carriers of the syndrome. These carriers 
(FXS premutation) may have normal intelligence but differ 
in response inhibition and selective attention, neuropsychi-
atric symptoms also found in ADHD (Cornish et al., 2008; 
Dorn et al., 1994). With age, individuals with FXS premu-
tation may develop more severe problems with inhibitory 
control. A small study from 1994 using a family informant 
method on 24 daughters of FXS carrier fathers and 32 
daughters of control fathers found a significantly higher 
proportion of aADHD as well as other psychopathology 
among FXS carrier fathers (Dorn et al., 1994). It has been 
proposed to screen for FXS carrier status in ADHD indi-
viduals whose male family members have intellectual dis-
ability (Hay, 2008).
As opposed to the mentioned chromosomal aberrations, 
only hyperactivity symptoms associated with ADHD were 
found more frequently in Angelman syndrome (ICD-10: 
Q93.5) when compared with a similar control group of indi-
viduals with intellectual disability (Berry, Leitner, Clarke, 
& Einfeld, 2005). Cornelia de Lange syndrome (CdLS; 
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Table 2. Other Comorbid Disorders With Limited Information on the Association With aADHD.
Comorbid disorder Reference Design Study population Result
STD Hosain, Berenson, 
Tennen, Bauer, & Wu 
(2012)
Cross-sectional 462 females (between 18 and 30 years). ASRS 
to assess ADHD symptoms. Self-reported 
lifetime diagnosis of STD.
aNo significant 
association
Cancer Bijlenga, van der Heijden, 
et al. (2013)
Case control 202 clinically assessed aADHD patients  
(Mage = 34.9), 189 controls (Mage = 33.0).
No significant 
association
Cancer Semeijn et al. (2013) Case control 23 participants with aADHD assessed by 
semistructured diagnostic interview (mean 
age 72.0), 208 controls (mean age 68.0).
No significant 
association
Congenitalesotropia Olson, Louwagie, Diehl, & 
Mohney, (2012)
Case control 42 congenitalesotropia patients, 20 controls.
Age at ADHD diagnosis not specified
No significant 
association
Photophobia Kooij & Bijlenga, (2014) Online survey 231 people with self-reported ADHD 
diagnosis/ADHD symptoms (mean age 36.7), 
263 controls (mean age 38.4).
Significant 
association
Note. aADHD = Adult ADHD; STD = sexually transmitted diseases.
a10% increased risk of being diagnosed with STD when comparing the ADHD symptom group with the control group, no longer statistically significant 
when adjusting for sociodemographic covariates.
ICD-10: Q87.1) is a very rare genetic disorder usually 
caused by de novo mutations. In their study of 69 CdLS 
patients, Kline et al. (2007) have described their physical 
and psychiatric disturbances, among which ADHD is one of 
several psychiatric diagnoses where the symptoms often 
worsen with age.
Regarding ADHD and comorbid anatomical anomalies 
that are not part of a well-known syndrome, there are few 
studies in adults. A large registry-based study from 2012 
found an increased risk of ADHD persisting to adulthood in 
individuals born with oral clefts (ICD-10: Q 35-37; Halmoy, 
Klungsoyr, Skjaerven, & Haavik, 2012). Another study 
describing 447 adults with Fallot’s tetralogy (TOF) found 
an increased prevalence of ADHD among TOF patients 
who had at least two additional “syndromic” features such 
as dysmorphic facies, learning disabilities, or voice abnor-
malities (Piran et al., 2011).
Enuresis (ICD-10: R32)
The previously described study by Bijlenga et al. showed 
no differences in self-reported urinary symptoms in people 
with aADHD and controls (Bijlenga, van der Heijden, et al., 
2013).
The diagnosis of enuresis in aADHD compared with 
controls is reported in two studies using information from 
U.S. claim databases. One study included 2,252 individuals 
diagnosed with ADHD according to ICD-9 during 1999-
2001 matched with a similar number of controls (Secnik 
et al., 2005). Based on ICD-9 codes, there was no signifi-
cant difference in the prevalence of enuresis between the 
groups. In a study investigating U.S. health care claims for 
2006 (aADHD: 31,752; non-ADHD: 95,256), adults with 
ADHD were significantly more often diagnosed with 
enuresis compared with adults without ADHD (p < .05; 
Hodgkins et al., 2011).
In a French study including 1,171 adults, ASRS was 
used to measure aADHD. aADHD was significantly related 
to lifetime self-reported enuresis regardless of sex, OR = 
5.8 [2.4, 14.1] (Caci et al., 2014).
Other Disorders
Our search also identified some papers describing various 
other disorders, summarized in Table 2. For most of these 
disorders, no significant association with aADHD was 
reported. The exception was for photophobia, where 69% of 
the ADHD participants reported photophobia compared 
with 28% in the control group (p = .001; Kooij & Bijlenga, 
2014).
Discussion
In our systematic review, we have included 126 papers over 
the past 20 years mentioning aADHD in connection with 
somatic disease. We found a consistent association between 
aADHD and increased risk of obesity, sleep disorders, and 
asthma. Associations were also consistent for migraine and 
celiac disease. Less robust associations have been reported for 
a number of different disorders such as enuresis, irritable 
bowel syndrome, restless legs, epilepsy, chronic fatigue syn-
drome, , fibromyalgic syndrome, systemic lupus erythemato-
sus and atopic dermatitis. One large population-based study 
(aADHD: n = 31,752) and two smaller studies showed no 
association between aADHD and diseases of the circulatory 
system (Hodgkins et al., 2011; Semeijn et al., 2013; Spencer 
et al., 2014). In contrast, a small study by Bijlenga et al. showed 
an increased risk of self-reported cardiovascular disorder in 
 at Universitetsbiblioteket i Bergen on September 28, 2016jad.sagepub.comDownloaded from 
Instanes et al. 17
aADHD. Many rare congenital syndromes/malformations, 
including tuberous sclerosis and FXS, are reported to increase 
the risk of ADHD. However, under such conditions the ADHD 
symptoms may also be considered part of the syndrome itself 
and not a proper comorbid disorder.
We noticed several methodological limitations in the 
evaluated studies. Most studies were small. Many studies 
compared a case group with a control/comparison group. 
However, while the case group might be well defined and 
characterized, the control group was often less well defined, 
often based on self-selection and from a different source 
population than the cases. Information on recruitment and 
participation rates was sparse, and selection bias was diffi-
cult to assess. While the diagnosis of ADHD was often 
based on clinical interviews or validated self-report ques-
tionnaires, the comorbid conditions were sometimes based 
entirely on a single question to the individual about the con-
dition being present or not. An example is the study by 
Bijlenga et al., which includes 202 clinically diagnosed 
ADHD patients and 189 controls non-randomly recruited 
from students and their acquaintances, and self-selected by 
posters in libraries and municipal buildings (Bijlenga, van 
der Heijden, et al., 2013). The numerous somatic diseases 
described were based solely on self-report from a general 
health questionnaire.
The larger studies were often based entirely on self-
report questionnaires or on registries and databases. Large 
population-based disease registries may be more suitable to 
study comorbidity across many different diagnoses, in par-
ticular for less prevalent conditions. However, such regis-
tries can also be subject to systematic bias, depending on 
the diagnostic traditions in different countries (Polanczyk 
et al., 2007) and the covered population.
For details on characteristics of the individual studies 
with their associated sources of bias, see table in 
Supplementary 2.
Many studies on psychiatric comorbidity in somatic con-
ditions have explicitly excluded “childhood” psychiatric 
conditions such as ADHD, as they are not included in com-
monly used structured psychiatric diagnostic interviews, 
such as The Structured Clinical Interview for DSM-IV Axis 
I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 
2002) or The Mini-International Neuropsychiatric Interview 
(MINI; Sheehan et al., 1998). This systematic bias could 
give the false impression that ADHD is not a relevant psy-
chiatric comorbidity in somatic disease among adults.
As mentioned in many of the cited articles, there are 
many reasons to systematically search for psychiatric disor-
ders in somatic conditions and to screen for somatic dis-
eases among psychiatric patients. For the individual patient, 
it is important to detect potentially treatable somatic dis-
eases masking as a psychiatric disorder. The utility of this 
approach was illustrated in a recent report, showing that 
metabolic screening of individuals with psychosis revealed 
treatable metabolic disorders in a significant number of 
cases (Demily & Sedel, 2014).
ADHD is a prevalent condition, and patients with many 
different somatic conditions may exhibit ADHD symptoms 
either as a comorbid condition or as part of the somatic dis-
ease. Likewise, the lifestyle of ADHD patients may make 
them more vulnerable to certain somatic diseases. Thus, the 
identification of other treatable and possibly underlying 
conditions should be addressed in every diagnostic workup.
The presence of a known co-occurring somatic condition 
has important implications for ADHD treatment. For 
instance, stimulant therapy may be contraindicated or need 
careful monitoring in the presence of cardiac disease, 
hypertension, glaucoma, or liver failure (Kooij, 2012). 
However, stimulant therapy may have positive effects on 
the treatment of obesity, sleep disorders, CFS, and restless 
legs.
Pathophysiology
Conditions classically thought to be disorders of the ner-
vous system may also include alterations in other physio-
logical systems, for example, involving immunological or 
endocrine signaling mechanisms (Qureshi & Mehler, 2013). 
Classical quantitative genetic studies, such as twin studies, 
and more recently genome-wide association studies with 
polygenic analyses have revealed genetic correlations 
between many different psychiatric and somatic disorders 
and traits. Elucidation of such shared genetic mechanism 
could lead to new therapies or diagnostic procedures. There 
is increasing evidence for inflammatory and autoimmune 
mechanisms in psychiatric disorders, including ADHD. In a 
recent epidemiological study of 48,000 Norwegian ADHD 
patients, a strong connection between immunological dis-
eases in the mothers and ADHD in the offspring was 
observed (Instanes et al., 2015).
Different hypotheses regarding underlying pathophysio-
logical mechanisms are further elaborated for some of the 
most commonly associated diseases.
Several mechanisms may account for the reported asso-
ciation between ADHD and obesity. Shared neurobiological 
or genetic mechanisms may be common to both ADHD and 
obesity (Nigg, 2013); ADHD and obesity being facets of the 
same underlying condition (Odent, 2010). Both ADHD and 
obesity are related to the dopamine system, and dopamine-
related genes may affect body weight, eating patterns, and 
ADHD (Davis, 2009). It has been hypothesized that the 
urge for food intake can share the same mechanisms as 
ADHD-drug abuse (Cortese et al., 2007; Davis, 2010). Low 
tonic dopamine levels in the prefrontal cortex may lead to 
overeating as a kind of self-medication to increase the dopa-
mine levels (Campbell & Eisenberg, 2007). Hypersensitivity 
to reward contributes to overeating because of an increased 
motivation in engaging in pleasurable activities (Davis, 
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2009). Other possible mechanisms involve the Brain 
Derived Neurotrophic Factor (Cortese & Morcillo-Peñalver, 
2010), immune or inflammatory response (Nigg, 2013), and 
the melatonin system (Cortese & Morcillo-Peñalver, 2010; 
Kirov & Brand, 2014). A mediation analysis conducted in a 
clinical sample including 114 obese people, 202 aADHD 
patients, and 154 controls showed that both sleep duration 
and unstable eating patterns mediated the association 
between BMI and ADHD after controlling for current anxi-
ety/depression and sociodemographics (Vogel et al., 2015).
Obesity and disorders related to obesity could also create 
symptoms resembling ADHD symptoms, such as sleep-
disordered breathing, which can lead to inattentive symp-
toms during the day (Cortese & Morcillo-Peñalver, 2010). 
ADHD itself can lead to obesity rather than the other way 
around (Cortese, Ramos-Olazagasti, et al., 2013). The 
behavior associated with ADHD can lead to bad eating hab-
its due to poor planning of the meals (Davis, 2009), or defi-
cient inhibitory control or aversion to delay leading to 
increased consumption of palatable fast food (Cortese, 
Angriman, et al., 2008; Davis et al., 2006). Impulsivity 
associated with binge eating may contribute to impulsivity 
as a symptom of ADHD in obese patients, and abnormal 
eating behaviors may lead to symptoms of inattention and 
hyperactivity (Cortese, Angriman, et al., 2008). ADHD may 
also be characterized by motor clumsiness and poor energy 
regulation, resulting in periods of overactivity interspersed 
with underactivity, making it difficult for persons with 
ADHD to be a part of activities promoting fitness and 
weight loss that requires planning and sustained effort 
(Nigg, 2013). Positive correlations between symptoms of 
aADHD measured by ASRS, depression, anxiety, and dis-
ordered eating pattern have been shown (Alfonsson et al., 
2012).
The cause of sleep problems in ADHD appears to be mul-
tifactorial and complex (Kirov & Brand, 2014), and the 
association between ADHD and sleep problems may be 
caused by different underlying pathways. It is not fully 
understood how obstructive sleep apnea, periodic limb 
movements during sleep, and RLS are connected to ADHD 
pathophysiology, or whether they can be viewed as comor-
bid sleep disorders in ADHD (Kirov & Brand, 2014). RLS 
share features with ADHD, and RLS and ADHD may be a 
part of the same symptom complex and share a central ner-
vous dopaminergic dysfunction (Philipsen, Hornyak, & 
Riemann, 2006). As for ADHD, altered dopaminergic sig-
naling and iron deficiency have been hypothesized to con-
tribute to the pathophysiology of RLS (Cortese et al., 2005; 
Cortese, Lecendreux, et al., 2008). Hyperactive symptoms 
may directly cause sleep problems (Hvolby, 2015), and per-
sons with ADHD can be more vulnerable to the effects of 
sleep disturbances (Hvolby, 2015). In itself, sleep problems 
may mimic ADHD symptomatology (Hvolby, 2015) and 
may also exacerbate underlying ADHD symptoms (Owens, 
2005). Insomnia may cause inattention, a core symptom of 
ADHD (Voinescu et al., 2012). Without a thorough assess-
ment, persons with sleep problems could be misdiagnosed as 
having ADHD (Gau et al., 2007). Furthermore, the stimulant 
treatment used for ADHD may result in sleep problems as a 
side effect (Owens, 2005). Common pathophysiology can 
lead to both ADHD and sleep disturbance (Brown & 
McMullen, 2001; Hvolby, 2015). Furthermore, a person 
with a delayed circadian rhythm may compensate being 
tired by binge eating during the day, which again leads to 
obesity (. Kooij & Bijlenga, 2013). A delayed sleep phase 
and sleep deficit can be risk factors for several disorders 
such as obesity, diabetes, and cardiovascular disorders 
(Kooij & Bijlenga, 2013).
As for ADHD, the dopaminergic system has also been 
suggested as a possible factor involved in the pathophysiol-
ogy of asthma, as dopaminergic receptors are present in 
sensory nerves in the airways, and inhaled dopamine may 
induce bronchodilation during asthma attacks (Birrell et al., 
2002; Cabezas, Lezama, & Velasco, 2001). Other common 
pathophysiological factors for these disorders may be 
inflammatory mechanisms (Barrios, Kheradmand, Batts, & 
Corry, 2006) and obesity (Cortese, Angriman, et al., 2008; 
Delgado, Barranco, & Quirce, 2008), as obesity leads to a 
proinflammatory state (Bazar, Yun, Lee, Daniel, & Doux, 
2006).
There is substantial evidence that dopaminergic mecha-
nisms are involved in migraine. It is therefore possible that 
changes in dopaminergic systems may represent common 
etiological factors for ADHD and migraine (Fasmer, 
Akiskal, Kelsoe, & Oedegaard, 2009).
Suggestions for Further Research
A number of shortcomings have been identified in the lit-
erature cited in this review.
1. Different research designs have been utilized to 
explore the relationship between ADHD and somatic 
health. As each of these designs has their inherent 
limitations, there is a need to establish the preva-
lence of somatic diseases in representative samples 
of ADHD.
2. In many studies, the patients were simply screened 
for ADHD symptoms. We need to know what pro-
portion of these patients has the full clinical syn-
drome, including impairment criteria. Harmonization 
of diagnostic protocols should increase reliability of 
such data.
3. It is suspected that many of the reported associated 
conditions are due to recognized or previously 
unknown confounders. Future research should 
investigate how much of the comorbidities are actu-
ally due to confounding factors, for example, that 
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headache or sleep disorders may be confounding 
factors for the association between obesity and 
ADHD (Cortese & Angriman, 2014; Gau et al., 
2007), or that iron deficiency in ADHD is explained 
by, at least partly, the elevated presence of obesity 
(Cortese & Angriman, 2014).
4. Many of the existing studies are small. To be able to 
reveal a true association between ADHD and comor-
bid somatic diseases with adequate control for 
potential confounders, large studies are needed. The 
possibilities of combining the use of population-
based registries and common diagnostic protocols 
should be investigated.
5. From a practical perspective, we need to know how 
current diagnostic and treatment algorithms should 
be optimized to account for coexisting conditions.
6. Access to biomarkers from large samples of ADHD 
cases and its comorbid conditions will allow sys-
tematic studies of their shared pathophysiology. 
This information should also inform future deci-
sions regarding diagnoses and treatment.
7. Even for the best documented conditions, the litera-
ture was dominated by a few authors, research 
groups, and study populations. More research 
should be conducted in different geographical areas 
and ethnic groups.
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Search Strategy MEDLINE 8.12.2014: 
1     Attention Deficit Disorder with Hyperactivity/ (21710) 
2     (adhd or addh or attention deficit disorder or hyperkinetic disorder).tw. (17126) 
3     1 or 2 (25533) 
4     exp "diseases (non mesh)"/ (12226658) 
5     Epidemiologic studies/ or exp case control studies/ or exp cohort studies/ (1604084) 
6     Case control.tw. (85883) 
7     (cohort adj (study or studies)).tw. (100884) 
8     Cohort analy$.tw. (4268) 
9     ((follow up or follow-up or followup) adj (study or studies)).tw. (40272) 
10     (observational adj (study or studies)).tw. (51544) 
11     (Longitudinal or retrospective or cross sectional).tw. (626298) 
12     Cross-sectional studies/ (193902) 
13     5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (2045054) 
14     3 and 4 and 13 (2566) 
15     limit 14 to "all adult (19 plus years)" (834) 
16     limit 14 to "all child (0 to 18 years)" (2263) 
17     15 and 16 (603) 
18     16 not 17 (1660) 
19     14 not 18 (906) 
20     "review"/ (1985863) 
21     review.tw. (994783) 
22     20 or 21 (2395613) 
23     19 and 22 (120) 
24     3 and 4 and 22 (1922) 
25     limit 24 to "all adult (19 plus years)" (356) 
26     limit 24 to "all child (0 to 18 years)" (1210) 
27     25 and 26 (280) 
28     26 not 27 (930) 
29     24 not 28 (992) 
 
Search Strategy PsycINFO 8.12.2014: 
1     exp attention deficit disorder/ (19335) 
2     (adhd or addh or attention deficit disorder or hyperkinetic disorder).tw. (20785) 
3     1 or 2 (23135) 
4     exp congenital disorders/ or exp feeding disorders/ or exp physical disorders/ (404949) 
5     exp symptoms/ (173417) 
6     4 or 5 (507138) 
7     3 and 6 (7838) 
8     limit 7 to "300  adulthood <age 18 yrs and older>" (2144) 
9     limit 7 to (100 childhood <birth to age 12 yrs> or 200 adolescence <age 13 to 17 yrs>) (5309) 
10     8 and 9 (1112) 
11     9 not 10 (4197) 
12     7 not 11 (3641) 
13     limit 12 to ("0430 followup study" or "0450 longitudinal study" or "0451 prospective study" or "0453 
retrospective study") (238) 
14     clinical trials/ (8138) 
15     longitudinal studies/ (14979) 
16     retrospective studies/ (347) 
17     cohort analysis/ (1061) 
18     Prospective Studies/ (438) 
19     (Cohort adj (study or studies)).mp. (10998) 
20     (Case control adj (study or studies)).mp. (4806) 
21     followup studies/ (12314) 
22     ((follow up or follow-up or followup) adj (study or studies)).tw. (11745) 
23     (Family adj (study or studies)).mp. (2806) 
24     (observational adj (study or studies)).tw. (5761) 
25     (epidemiologic$ adj (study or studies)).tw. (10301) 
26     (cross sectional adj (study or studies)).tw. (13481) 
27     14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 (90626) 
28     12 and 27 (166) 
29     13 or 28 (343) 
30     limit 29 to ("0200 book" or "0240 authored book" or "0280 edited book" or "0300 encyclopedia" or "0400 
dissertation abstract") (35) 
31     29 not 30 (308) 
32     review.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
(303998) 
33     12 and 32 (420) 
34     33 not 30 (418) 
35     limit 34 to yr="1994 -Current" (366) 
 
Search Strategy EMBASE 26.01.2015: 
1     attention deficit disorder/ (38493) 
2     (adhd or addh or attention deficit disorder or hyperkinetic disorder).tw. (21522) 
3     1 or 2 (40160) 
4     exp physical disease/ (15651306) 
5     3 and 4 (24757) 
6     limit 5 to (adult <18 to 64 years> or aged <65+ years>) (5041) 
7     limit 5 to (embryo <first trimester> or infant <to one year> or child <unspecified age> or preschool child <1 to 6 
years> or school child <7 to 12 years> or adolescent <13 to 17 years>) (12157) 
8     6 and 7 (2191) 
9     7 not 8 (9966) 
10     5 not 9 (14791) 
11     Clinical study/ or Case control study/ or Family study/ or Longitudinal study/ or Retrospective study/ (633963) 
12     Prospective study/ (271121) 
13     Randomized controlled trials/ (63501) 
14     12 not 13 (269332) 
15     Cohort analysis/ (186105) 
16     (Cohort adj (study or studies)).mp. (127928) 
17     (Case control adj (study or studies)).tw. (79630) 
18     ((follow up or follow-up or followup) adj (study or studies)).tw. (48562) 
19     (observational adj (study or studies)).tw. (70739) 
20     (epidemiologic$ adj (study or studies)).tw. (77107) 
21     (cross sectional adj (study or studies)).tw. (93580) 
22     cross-sectional study/ (128813) 
23     11 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 (1346755) 
24     10 and 23 (1274) 
25     limit 24 to (book or book series or conference abstract) (187) 
26     24 not 25 (1087) 
27     review.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] (2770704) 
28     10 and 27 (5006) 
29     limit 28 to (book or book series or conference abstract) (228) 
30     28 not 29 (4778) 
31     limit 30 to yr="1994 -Current" (4668) 
32     *attention deficit disorder/ (21353) 
33     (th or dt).fs. (3887116) 
34     31 and 32 (1384) 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary 3.  
Different diagnostic tools used to evaluate ADHD, other psychiatric disorders, and tools used to assess specific somatic disorder described in several articles in this 
review. Due to the large number of comorbid somatic disorders, only the most frequently used evaluating tools are described. We refer to each specific article for more 
information. 
Type Name Abbreviation Use 
ADHD    
Self-report    
questionnaire 
   
 Adult ADHD clinical 
diagnostic scale 
ACDS Clinician-based, semi-structured interview consisting of 18 items investigating current adult symptoms of 
ADHD. Version 1.2 includes a retrospective assessment of all symptoms of childhood ADHD and 
assessment of recent (past 6 months) symptoms of adult ADHD (aADHD) covering both DSM-IV symptoms 
and 14 non- DSM symptoms believed to be relevant to aADHD such as mood lability (Adler & Cohen, 
2004). 
 ADHD self-rating 
behaviour questionnaire 
ADHD-SR German self-rating behavior questionnaire covering aADHD symptoms according to DSM-IV and ICD-10 
research criteria (Rosler et al., 2004). 
 Adult Behavior Checklist ABC An 18-item checklist divided in two subscales, Attention and Hyperactivity, assessing ADHD symptoms 
according to DSM-IV criteria based on self-report data (Kass, Wallace, & Vodanovich, 2003). 
 ADHD Rating Scale ADHDRS–IV  Check list for parents and teachers covering ADHD symptoms to closely approximate the DSM-IV diagnostic 
criteria in children and adolescence from 4-20 years. The purpose is to provide clinicians information on 
ADHD (DuPaul, 1998). 
 Adult ADHD Self-Report 
Scale /  
Adult ADHD 




Developed in conjunction with the World Health Organization and is designed to measure current ADHD 
symptoms. Consists of 18 items covering the DSM-IV-TR criteria for ADHD and the core symptoms of 
ADHD: inattention, impulsivity and hyperactivity. A high symptom score on ASRS is not sufficient to 
clinically diagnose ADHD in adults, but is frequently used both clinically and in research to define study 
populations with possible ADHD (Kessler et al., 2005). 
 The Assessment of Adult 
Attention Deficit 
Hyperactivity Disorder 
 In longitudinal studies, a questionnaire designed to follow-up ADHD symptoms in adults diagnosed with 
childhood ADHD (Mannuzza et al., 2011)  
 Barkley Adult ADHD 
Rating Scale-IV 
BAARS-IV Based on the DSM diagnostic ADHD criteria, it covers both childhood and adult ADHD symptoms (Barkley, 
2011) 
 Barrat Impulsivity Scale BIS Self-report measure designed to evaluate impulsivity at the time of assessment (Patton, Stanford, & Barratt, 
1995). 
 Brown Attention Deficit 
Disorder Scale 
BADDS Covers a wide range of symptoms focusing on inattention (Thomas E Brown, 1996). Hyperactivity and 
impulsivity are not sufficiently addressed (Kooij et al., 2008).  
 Conners’ Adult ADHD 
Rating Scale 
CAARS Covers inattention, hyperactivity, impulsivity, as well as emotional lability (Conners, Erhardt, & Sparrow, 
1999). 
 Wender Utah Rating Scale WURS Retrospectively assesses symptoms of ADHD in childhood (Ward, Wender, & Reimherr, 1993). 
Interviews    
 Adult Attention Deficit 
Disorders Evaluation Scale 
A-ADDES Provides clinicians information on aADHD symptoms. It is available in three versions, one self-report, one 
reporting from close relation/friend, and one from co-workers (McCarney S., 1996). 
 Hyperactivity disorder 
(ADHD) Screening List 
 A short questionnaire developed to distinguish adults with ADHD from community controls and people with 
clinical disorders other than ADHD. It has shown good validity when used in older individuals  > 60 years 
(Semeijn et al., 2013).  
 The Diagnostic Interview 
for ADHD in adults 
DIVA A semi-structured interviewed shown to be reliable in diagnosing ADHD in adults (Ramos-Quiroga et al., 
2016). 
 Structured interview 
Conners' adult ADHD 
diagnostic interview for the 
DSM-IV 
CAADID Assesses current and childhood symptoms, impairment and pervasiveness of symptoms over time (Conners, 
Epstein, & Johnson, 2001). 
 The QUEST method QUEST A semi structured clinical interview assessing adult ADHD symptoms according to DSM-IV, providing age-
appropriate probes. Queries about current problems, symptoms and comorbidities are included (Wigal et al., 
2007). 
 The Schedule for Affective 
Disorders and 
Schizophrenia for School-
Age Children  
Kiddie-SADS A semi structured diagnostic interview used to assess current and lifetime psychiatric history, and can be 
adapted to be used in adults. One module assesses ADHD symptoms (Kaufman et al., 1997). 




   
 Beck Depression Inventory BDI Measuring severity of depressive symptoms, consisting of 21 questions assessing depressive symptoms the 




The Hospital Anxiety and 
Depression scale. 
HAD The Hospital Anxiety- Depression Scale (HAD) is designed to recognize symptoms of anxiety and 
depression in patients with physical illness. It also measures the severity of emotional disorder (Zigmond & 
Snaith, 1983). 
 Hamilton Anxiety Rating 
Scale  
HAM-A Rating scale used by clinicians to rate the severity of anxiety symptoms (Hamilton, 1959) 
 Hamilton Depression 
Rating Scale  
HAM-D Rating scale used by clinicians to rate the severity of depression symptoms (Hamilton, 1980)  
 Mood Disorder 
Questionnaire 
MDQ Short screening questionnaire for bipolar spectrum disorders validated for use in the general population and 
in 
psychiatric patient populations (Hirschfeld et al., 2003; Hirschfeld et al., 2000). 
 The Symptom Checklist-90 
(-R) 
(SCL-90-R) A multidimensional inventory assessing psychiatric symptoms and psychological distress the preceding 
seven days. It can be used in both clinical and community samples and gives a severity index of general 
mental distress as well as assessing nine psychiatric symptoms dimensions (Derogatis, 1996). 
Interview.    
 The World Health 
Organization World 
Mental Health Composite 
International Diagnostic 
Interview 
CIDI A comprehensive, fully-structured standardized interview designed to be used by trained lay interviewers for 
the assessment of mental disorders consistent with DSM-IV and ICD-10 (Robins et al., 1988).  
 Diagnostic Interview 
Schedule for DSM-IV 
DIS-IV A fully-structured interview designed to diagnose major psychiatric disorders according to DSM-IV that can 
be used by non-clinican interviewers (Segal, 2010). 
 The Mini-International 
Neuropsychiatric Interview 
M.I.N.I A short structured diagnostic interview developed to investigate major psychiatric disorders as described in 
DSM-IV (Axis 1) and ICD-10. It was designed to capture routine and repetitive information to be used in 
clinical trials and epidemiology studies, and as a first step in a clinical evaluation of a patient (Sheehan et al., 
1998). 
 Mini International 
Neuropsychiatric Interview 
Plus 
M.I.N.I. Plus Similar to M.I.N.I., but with a more extensive interview, also including a module for ADHD (Sheehan et al., 
1998). 
 Psychiatric Research 
Interview for Substance 
and Mental Disorders  
PRISM A diagnostic interview to assess affective disorders, anxiety disorders, psychotic symptoms, eating disorders 
and personality disorders in individuals who drink heavily or use drugs. (Hasin et al., 1996) 
 The Structured Clinical 
Interview for the 
Diagnostic and Statistical 
SCID I A diagnostic semi-structured interview assessing major DSM-IV Axis I (clinical) diagnoses (First, Spitzer, 
Gibbon, & Williams, 1997) 
Manual of Mental 
Disorders-IV (DSM-IV) 
Axis I disorders   
Somatic 
comorbidity 
   
Nutritional 
disorder, Obesity 
   




Body mass index  BMI Used to identify overweight and obesity, and is defined as weight in kilograms divided by height in meters 
squared. In adults, < 18.5 kg/m2 is defined as underweight, 18.5 to <25 kg/m2  defined as normal,  25.0 to 
<30 kg/m2  is defined as overweight and a BMI of ≥30 kg/m2 is defined as obese (World Health 
Organization, 1992).  BMI is a simple and easy way to evaluate obesity and is useful to evaluate obesity 
trends in the general population. However, BMI does not provide an accurate measurement of body fat on 
the individual level, nor does it take sex, age and ethnicity into account (Bhurosy & Jeewon, 2013). 
Self-reported 
questionnaire 
   
 The Dutch Eating 
Behaviour Questionnaire  
DEBQ Self-reported questionnaire measuring emotional, external and restrained eating, eating styles likely to be 
associated with the development of overweight (van Strien, Frijters, Bergers, & Defares, 1986). 
Sleep disorders    
Self-report 
questionnaire 
   
 The Composite Scale of 
Morningness  
CMQ Determines circardian typology (morning activities, morning affect, and eveningness) (Smith, Reilly, & 
Midkiff, 1989). It is developed from  a combination of some items from the MEQ (Horne & Ostberg, 1976) 
and a diurnal scale by Torsvall and Akerstedt (Torsvall & Akerstedt, 1980). 
 Epworth Sleepiness Scale ESS Measures daytime sleepiness and can be used to differentiate between different sleep disorders, such as 






MEQ Suited to measure circadian sleep-phase, and is an indicator of natural sleep cycle (Horne & Ostberg, 1976) 
 The Landecker Inventar 
sur Erfassung von 
Schlafstörungen  
LISST A screening instrument to detect different sleep disorders, like insomnia, nocturnal breathing disorders, 
restless legs, parasomnias and sleep/wake rhythm disorders (Weeß, Schürmann, & Steinberg, 2002).  
 Pittsburgh sleep quality 
index 
PSQI Subjectively measures sleep quality and disturbances over a 1-month time. It is a screening tool identifying 
patients that may require further sleep testing and is accurate in distinguishing good versus bad sleep patterns 
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). It is not designed to define the presence of insomnia, 
but has been useful to differentiate people with and without insomnia (Backhaus, Junghanns, Broocks, 
Riemann, & Hohagen, 2002). 
 The Schlaffragebogen A   German sleep questionnaire measuring sleep quality the preceding night (Görtelmeyer, 1985, 2011).  
 The Schlaffragebogen B  German sleep questionnaire measuring sleep quality and the feeling of being refreshed in the morning the 
previous 2 weeks (Görtelmeyer, 2011). 
 The Sleep Disorders 
Questionnaire 
SDQ  Self-report questionnaire evaluating the presence of insomnia according to the DSM-IV and International 
Classification of Sleep Disorders-Revised (Violani, Devoto, Lucidi, Lombardo, & Russo, 2004).  
 The Dutch Sleep Disorder 
Questionnaire 
SDQ (Dutch)  (SDQ) is a questionnaire used to evaluate symptoms of common  sleep disorders including insomnia, sleep 
apnea and restless legs syndrome (Sweere et al., 1998). 
 Sleep log/sleep diary  A simple and convenient way to self- report sleep patterns at a daily basis, and is used to diagnose sleep 
disorders such as insomnia, delayed sleep phase syndrome and narcolepsy (Ramar & Olson, 2013). The 
information provided can also be used to assess the effect of the treatment of sleep disorder. 
Objective 
measurement 
   
 Actigraphy  
  
 Used to assess sleep patterns and circadian rhytms. Actigraphy is a non-invasive objective method performed 
by an actigraph, traditionally records motor activity and sleep parameters.  It as an electronic device worn on 
the body, often like a small watch-like device.  Later year actigraphs have developed and can include 
features such as light- and temperature measurement and pulse recording. The sleep patterns are derived 
from nightly activity scores (De Crescenzo et al., 2016). Compared to PSG, actigraphy can assess sleep in a 
natural environment and can easily record sleep patterns over week’s duration. Compared to sleep logs, it is 
more reliable as it does not depend on the patient´s recall.  On the other hand, polysomnography collects 
more comprehensive information from different data sources (Ancoli-Israel et al., 2003). 
 Polysomnography (PSG).  Used to record several physiologic parameters relevant to sleep, such as electroencephalography (EEG), 
electrooculography (EOG), electrocardiography (ECG),  chin- and anterio tibilais electromyography (EMG), 
respiratory effort, airflow and oximetry (Chesson et al., 1997). Polysomnography is used assessing a number 
of different sleep related disorders, such as restless legs syndrome, periodic limb movements during sleep, 
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